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Summary 
 
1.  Previous research in the bovine intraocular long posterior ciliary artery (LPCA) has 
suggested that its response to electrical field stimulation (EFS) is a uniphasic 
vasodilatation, mediated jointly by the neurotransmitters nitric oxide (NO) and 
calcitonin gene related-peptide (CGRP). 
2.  This study of the bovine intraocular LPCA, where a short period of EFS (10 s) was 
employed, demonstrated that the vasodilator response to EFS was in fact biphasic. 
The first and second components of the response peaked separately at 10 s and 50 s 
following the onset of stimulation. 
3.  Both components of vasodilatation to EFS were abolished by tetrodotoxin (TTX), 
confirming their neurogenic origin.  
4.  Inhibition of the first component of the vasodilatation to EFS by the nitric oxide 
synthase (NOS) inhibitor, L-NAME, and the inhibitor of soluble guanylate cyclase, 
ODQ, confirmed the involvement of NO from nitrergic nerves. Experiments 
involving treatment with capsaicin and the CGRP antagonist, CGRP8-37, failed to 
produce any evidence of involvement of CGRP in the second component of 
neurogenic vasodilatation. 
5.  A number of other potential neurotransmitter candidates including substance P, 
vasoactive intestinal polypeptide (VIP) and adenosine triphosphate (ATP) were 
investigated, but there was no convincing evidence to suggest that they play a role 
in mediating the second component of neurogenic vasodilatation. 
6.  As the transmitter responsible for mediating the second component of neurogenic 
vasodilatation could not be identified, the mechanism by which it operated was also 
investigated. 
7.  Although the first component of neurogenic vasodilatation was clearly mediated by 
NO, inhibitors of PDE5, PKG and the soluble guanylate cyclase/cGMP/NO 
pathway had no effect on the second component of vasodilatation.  
8.  Furthermore, various K
+ channel blockers, or inhibitors of the PKA/cAMP pathway 
did not inhibit the second component of neurogenic vasodilatation. Therefore, 
neither the identity of the neurotransmitter responsible for the second component, 
nor its mechanism of action could be determined. 
9.  N
G-substituted analogues of L-arginine are routinely used to inhibit the NOS family 
of enzymes. The first of these to be introduced, N
G-methyl-L-arginine (L-NMMA), 
is generally reported to inhibit all three isoforms of NOS. Despite this, however, L-   Summary 
  iv
NMMA does not inhibit nitrergic nerve-mediated relaxation in other bovine tissues 
including the retractor penis muscle or penile artery.  
10. In this study of the bovine intraocular LPCA, L-NMMA was found to inhibit the 
endothelium-dependent dilatation mediated by eNOS, but not the nitrergic 
vasodilatation by nNOS. Indeed, the ability of L-NMMA to protect nitrergic 
dilatation against blockade by L-NAME in a manner similar to L-arginine, suggests 
it might act as an alternative substrate for nNOS in this tissue.  
11. Isoform-selective inhibitors of NOS are of great interest, both as investigational 
tools and potential therapeutic agents. Two nNOS-specific inhibitors have recently 
been identified: N-[(4S)-4-amino-5-[(2-aminoethyl)amino]pentyl]-N'-
nitroguanidine tris (trifluoroacetate) salt (AAAN) and N
G-propyl-L-arginine. 
12. AAAN failed to affect vasodilatation induced either by nitrergic nerves or by 
bradykinin-induced, endothelium-derived NO in the bovine intraocular LPCA. 
13. Although N
G-propyl-L-arginine did inhibit nitrergic vasodilatation, it also blocked 
the bradykinin-induced, endothelium-dependent vasodilatation mediated by NO. It 
thus failed to exhibit the expected selectivity for nNOS over eNOS in the bovine 
intraocular LPCA. 
14. These findings with AAAN and N
G-propyl-L-arginine are a reminder that it is not 
always possible to extrapolate findings in biochemical assays to functional 
responses in intact tissues. 
15. In conclusion, these findings show that neurogenic vasodilatation in the bovine 
LPCA involves two components: a fast, transient component mediated by NO from 
nitrergic nerves, and a second slower, more sustained component mediated by an as 
yet unidentified second neurotransmitter. 
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1  Introduction 
1.1  The Eye 
The eye is the organ of vision and operates by detecting light. Only the anterior portion of 
the eye is visible (Figure 1.1a), the remainder sits within a bony fossa of the skull, which 
separates the eye from the cranial cavity. This fossa protects the delicate structures of the 
eye and provides a pathway for ocular nerves and blood vessels. The anatomy of the eye is 
dedicated to focusing light onto the photosensitive cells of the retina. The wall of the 
eyeball can be divided into three layers: the fibrous tunic, the vascular tunic and the 
nervous tunic.  
1.1.1  Fibrous Tunic 
The fibrous tunic is the outermost layer and provides the eyeball with shape, whilst 
protecting the delicate inner structures of the eye. It consists of the anterior cornea, which 
covers one-sixth of the surface area, and the posterior sclera, which covers the remaining 
five-sixths. The cornea is an avascular, curved, transparent coat that covers the iris and 
helps to focus light entering the eye. In the bovine eye, the cornea is roughly pear shaped 
(Prince  et al., 1960). The sclera is better known as the “white” of the eye and is a 
protective coat of dense connective tissue. This makes the eye more rigid and also serves 
as an attachment for extraocular muscles that move the eye (Figure 1.1b). 
1.1.2  Vascular Tunic 
The vascular tunic or uvea is the middle layer of the eyeball and is made up of the choroid, 
the ciliary body and the iris. The choroid is a vascular layer that lines the sclera and 
nourishes the retina. It is highly pigmented and the bovine choroid appears almost black in 
colour. The ciliary body connects the choroid with the iris and is located just behind the 
iris. Attached to the ciliary body are tiny fibres called zonules and these fibres hold the 
large, crystalline lens of the eye in place. The ciliary body produces a fluid known as 
aqueous humor, which nourishes both the cornea and lens and gives shape to the eye. 
Another function of the ciliary body is to change the shape of the lens (accommodation) to 
enable the eye to focus on both near and distant objects. However, in the bovine eye there 
is no real evidence of functional activity of the ciliary body, with respect to the 
accommodation process (Prince et al., 1960). 
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Figure 1.1 Schematic diagrams showing (a) the external and (b) the internal structures of 
the mammalian eye. Taken from www.99main.com/~charlief/Blindness.htm 
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The iris is a circular, pigmented diaphragm that divides the space between the cornea and 
the lens into two chambers, the anterior and posterior, both of which are filled with 
aqueous humor. A third chamber exists between the lens and the retina and this is filled by 
a more viscous liquid, vitreous humor. The opening in the middle of the iris is known as 
the pupil. In the bovine eye, this is oval in shape and becomes almost circular upon dilation 
(Prince et al., 1960). The size of the pupil determines the amount of light that enters the 
eye, with pupil size controlled by the dilator and sphincter muscles of the iris (Figure 1.1b). 
1.1.3  Nervous Tunic  
The innermost layer of the eye, or nervous tunic, is more commonly known as the retina. 
The retina itself is comprised of many layers, made up of two types of photoreceptor cells, 
known as rods and cones. As these are neural cells it is essential that they, like the brain, 
receive a constant oxygen supply. Cones are situated in a central area of the retina, known 
as the macula. More specifically, they are densely packed within the central area of the 
macula, the fovea. Cones operate best in bright light and allow us to detect colour. The 
rods are spread throughout the retina and operate best in dim light, giving us “night 
vision”.  Nerve impulses are carried by the optic nerve from the cells of the retina to the 
brain. The outer layers of the retina receive nutrients and oxygen from the choroid, while 
the retinal blood vessels nourish the inner layers (Figure 1.1b). 
1.2  Structure and Function of Arteries 
Arteries are the vessels of the vascular system responsible for transporting blood from the 
heart to all of the tissues in the body. However, they are not passive “tubes” that simply 
allow blood to flow through the body. The largest artery is the aorta, which progressively 
divides into smaller elastic arteries, conduit or muscular arteries, terminal arteries, 
arterioles and then capillaries. Together the terminal arteries and arterioles are known as 
the resistance vessels or small arteries and have a diameter of 100 – 500 μm (Bloom & 
Fawcett, 1968). All blood vessels, apart from capillaries, have a wall comprising of three 
morphologically distinct layers.  
1.2.1  Tunica Intima 
The tunica intima is the innermost layer, which surrounds the lumen. It consists of a flat 
layer of endothelial cells, which rest on a bed of collagen and proteoglycans, and is bound  Chapter 1    Introduction 
  5
 
 
 
 
 
Figure 1.2 Schematic diagram of (a) the structure of a typical artery, showing the three 
distinct layers, the tunica intima, the tunica media and the tunica adventitia (adapted from 
Bryan et al., 2005), and (b) arterial structure in more detail (taken from Lusis, 2000). 
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by a sheet of elastic fibres called the internal elastic lamina (Figure 1.2a and 1.2b). Until 
quite recently, the endothelium was considered merely to be a barrier between the blood 
and vascular smooth muscle (VSM). The discovery by Furchgott & Zawadzki (1980) that 
the endothelium influences the underlying vascular smooth muscle by synthesising and 
secreting endothelium-derived relaxing factor (EDRF), now regarded as nitric oxide (NO; 
Palmer et al., 1987), was a catalyst for further, intense study of the endothelium. The 
discovery that it releases not only NO, but a number of other vasoactive substances, such 
as endothelium-derived hyperpolarising factor (EDHF; Chen et al., 1988) and prostacyclin 
(PGI2; Moncada et al., 1976), which cause smooth muscle relaxation, and endothelin (De 
May & Vanhoutte, 1981), a potent vasoconstrictor, has meant that the endothelium is now 
recognised as a vital regulatory component of the cardiovascular system. As well as local 
vascular control, the endothelium is also involved in transport of metabolites and signalling 
molecules between blood and tissues (Baldwin & Thurston, 2001) and inhibition and 
activation of platelet aggregation (Wu & Thiagarajan, 1996). The loss of endothelial 
function is implicated in pathophysiological states, such as atherosclerosis (Lusis, 2000). 
1.2.2  Tunica Media 
The tunica media, or middle layer, consists of spindle-shaped smooth muscles cells (SMC) 
arranged in a helical pattern, surrounded by a matrix of collagen and elastin and bound by 
the external elastic lamina (Figure 1.2a and 1.2b). The degree of contraction of this VSM 
controls the diameter of the lumen and therefore the blood flow through it. The contractile 
unit within the cell is composed of actin and myosin filaments. Agents that elicit 
contraction of VSM increase intracellular calcium (Ca
2+) concentration ([Ca
2+]i) and those 
that elicit vasodilatation reduce [Ca
2+]i or desensitise the contractile apparatus to Ca
2+. In 
SMC, Ca
2+ and calmodulin regulate the activity of the enzyme myosin-light chain kinase 
(MLCK), which phosphorylates the regulatory light chains of myosin (MLC). 
Phosphorylation of MLC allows the myosin ATPase to be activated by actin and the 
muscle to contract (Levick, 2000). The enzyme MLC phosphatase (MLCP) is responsible 
for dephosphorylation of MLC. Dephosphorylation of MLC promotes relaxation (Pfitzer, 
2001). 
1.2.3  Tunica Adventitia 
The outer layer, or tunica adventitia, is less structured than the other two layers and is a 
sheath of connective tissue interspersed with collagen bundles, elastin fibres and 
fibroblasts, which loosely tethers the artery in place (Figure 1.2a and 1.2b). In larger Chapter 1    Introduction 
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vessels, the adventitia also contains smaller blood vessels known as the vasa vasorum, 
which penetrate into the media and nourish the SMC. Recent evidence suggests that the 
adventitia is also much more physiologically relevant than perhaps was first thought. It 
may act as a biological processing centre for retrieval, integration, storage and release of 
key regulators of vessel wall function. In particular, the adventitial fibroblast seems to have 
an important role in the response to vascular stress such as hypoxia or over-distension of 
the vessel. Once activated, the fibroblast may undergo phenotypic changes such as 
proliferation, differentiation and release factors that affect neighbouring smooth muscle 
tone and growth. They also stimulate recruitment of inflammatory and progenitor cells to 
the vessel wall (Stenmark et al., 2006). 
1.3  Regulation of Vascular Tone 
The active tension exerted by VSM in a segment of wall is called vascular tone. Arteries 
and arterioles have a degree of tone (i.e. are partially constricted) at all times, known as 
basal tone. In order to undergo vasodilatation, a vessel must initially have some degree of 
basal tone. Vessel tone can be influenced by a number of mechanisms. As mentioned in 
section 1.2.1, the endothelium releases the vasodilators NO,  PGI2 and EDHF and 
endothelin, which causes vasoconstriction. In addition to this, nerves that innervate arteries 
release a variety of vasoactive transmitters capable of causing vasodilatation or 
vasoconstriction.  
Furthermore, in tissues such as skeletal muscle, the heart and the brain, an increase in 
metabolic activity results in metabolic hyperaemia. This is an increase in blood flow to the 
tissue caused by vasodilatation of the arteries and arterioles in response to the products of 
metabolism. Metabolic activity results in the accumulation of carbon dioxide (CO2), 
lactate, potassium (K
+) and adenosine, which results in vasodilatation (Madden, 1993; 
Clifford & Hellsten, 2004). 
Circulating hormones also play a role in vascular tone, For example, catecholamines 
released from the adrenal gland (Wong, 2003), vasopressin from the pituitary gland 
(Treschan & Peters, 2006) and the renin-angiotensin-aldosterone system (Seravalle et al., 
1993) promote vasoconstriction in the vast majority of tissues, while natriuretic peptides 
(atrial natriuretic peptide; ANP, brain natriuretic peptide; BNP and cardiac natriuretic 
peptide; CNP) released from atrial and ventricular myocytes and the endothelium, 
respectively, promote vasodilatation (Ahluwalia et al., 2004). Chapter 1    Introduction 
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Finally, myogenic tone, a contributing factor to basal tone, is the result of the contraction 
of VSM in response to the mechanical distension caused by an increase in pressure within 
the vessel. This mechanism, discovered by Sir William Bayliss, is important in stabilising 
blood flow in response to changes in blood pressure (Levick, 2000). 
1.4  Neurogenic Control of Vascular Tone 
Blood vessels are innervated by a variety of different types of nerves. These nerves are 
capable of mediating vasoconstriction, and in a small number of vessels vasodilatation, 
depending on the neurotransmitter released. They run along the adventitial-medial border 
of the blood vessel and do not directly innervate the inner part of the media. The 
neurotransmitter is released from the nerve terminal into a cleft between the nerve and 
VSM, known as the neuroeffector junction. This cleft can be as small as 60 nm in some 
arterioles or as great as 2 μm in some large elastic arteries (Burnstock, 1993). 
 
1.4.1  Sympathetic Constrictor Nerves 
1.4.1.1 Anatomy of Sympathetic Constrictor Nerves 
Sympathetic nerves are part of the autonomic nervous system (ANS). The main difference 
between somatic and autonomic nervous systems is that the ANS consists of a chain of two 
neurons, while in the somatic system, one neuron connects the central nervous system 
(CNS) to the skeletal muscle. The two neurons in the autonomic pathway are known as the 
preganglionic and the postganglionic fibres and they synapse in an autonomic ganglion. 
This lies outwith the CNS and contains the nerve endings of the preganglionic fibre and the 
cell body of the postganglionic fibre (Tortora, 1999). Sympathetic preganglionic neurons 
have their cell bodies in the lateral horn of the grey matter of the thoracic and lumbar 
segments of the spinal cord. The fibres leave the spinal cord in spinal nerves as the 
thoracolumbar sympathetic outflow. They leave the spinal cord as filaments that run to the 
paravertebral chain of sympathetic ganglia (bilaterally on either side of spinal cord). These 
ganglia contain the cell bodies of the postganglionic sympathetic neurons, the axons of 
which rejoin the spinal nerve (Tortora, 1999). Many of the postganglionic sympathetic 
fibres reach their destination via branches of the spinal nerve. The nerve terminals of 
sympathetic fibres, which innervate all blood vessels, end in nodules known as varicosities. 
Each varicosity is filled with many synaptic vesicles, which are the site of synthesis and 
release of the main sympathetic neurotransmitter, noradrenaline (NA; Tortora, 1999). Chapter 1    Introduction 
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1.4.1.2 Pharmacology of Sympathetic Constrictor Nerves 
NA released from sympathetic varicosities binds to various adrenoceptors on VSM. 
Ahlquist (1948) identified two classes of adrenoceptors, which he named α and β based 
upon differential responses to various catecholamines such as adrenaline, NA and 
isoprenaline. Some years later, Langer (1974) suggested subclassification of α-receptors 
into α1 and α2 subtypes. Cloning of adrenergic receptors, has subsequently revealed at least 
9 subtypes of adrenoceptors (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2 and β3; Insel, 1996). On the 
whole, vasoconstriction is mediated by activation of α1-adrenoceptors on the membrane of 
VSM, via activation of the inositol trisphosphate (IP3) pathway and release of Ca
2+ stored 
within the sarcoplasmic reticulum. Although α2-adrenoceptors mediate vasoconstriction in 
cutaneous arterioles, they more commonly occur on nerve fibres, as prejunctional receptors 
(also known as autoreceptors). Activation of these prejunctional receptors by NA inhibits 
further NA release from the nerve terminal. Until the 1970s, the theory that nerves released 
a single transmitter, commonly known as Dale’s Principle, was widely accepted. The 
suggestion by Burnstock (1976) that adenosine 5’ triphosphate (ATP) may be released 
from adrenergic nerves, along with NA, has since been confirmed, initially with evidence 
from the guinea-pig vas deferens (Fedan et  al., 1981; Sneddon & Burnstock, 1984b). 
Purinergic cotransmission was later described in the rat tail artery (Sneddon & Burnstock, 
1984a) and in the rabbit saphenous artery (Burnstock & Warland, 1987a). ATP mediates 
vasoconstriction by activating postjunctional P2X purinergic receptors. Another co-
transmitter released with NA, especially at high stimulation frequencies, is neuropeptide Y 
(NPY; Lundberg et al., 1986). Neuropeptide Y actives the Y1 receptor on VSM to initiate 
vasoconstriction. 
 
1.4.2  Sympathetic Vasodilator Nerves 
In some species, such as cats and dogs (Bulbring & Burn, 1935; Uvnäs, 1966), small 
arteries that serve the skeletal muscle are innervated by sympathetic vasodilator nerves, as 
well as sympathetic vasoconstrictor nerves. These nerves utilise acetylcholine (ACh) as 
their neurotransmitter and excitation of sympathetic cholinergic nerves causes relaxation of 
VSM and increased muscle blood flow, as part of the defence response (Abrahams et al.,  
1964). The presence of these nerves in the arteries of human skeletal muscle is highly 
contentious. Proponents of the theory have suggested that these nerves are activated at 
times of emotional or physical stress, akin to the defence mechanism in animals. Much of 
the evidence has arisen from an observation that there is marked skeletal muscle Chapter 1    Introduction 
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vasodilatation in the forearm, when the subject is under mental stress or at the time of 
fainting, which is absent following surgical sympathectomy (Barcroft & Edholm, 1945; 
Blair  et  al., 1959). However, there is no histochemical evidence to demonstrate 
sympathetic cholinergic vasodilator nerves in the human forearm and most researchers 
believe that the vasodilatation is a result of circulating catecholamines and locally released 
NO (Reed et al.,  2000). 
1.4.3  Parasympathetic Vasodilator Nerves 
Most blood vessels lack parasympathetic vasodilator nerves. However, they can be found 
in a small number of tissues, most commonly in the brain (Biesold et  al., 1989), 
reproductive system (Toda et al., 2005), eye (Toda et al., 1997) and coronary circulation 
(Broten et al., 1992; Feigl, 1969). 
1.4.3.1 Anatomy of Parasympathetic Vasodilator Nerves 
Parasympathetic nerves arise from two separate regions of the CNS. The cranial outflow 
consists of preganglionic fibres in certain cranial nerves (e.g. vagus, glossopharyngeal, 
oculomotor and facial nerves; Tortora, 1999). Ganglia lie close to the target organ, with 
short postganglionic fibres compared to the sympathetic system. Parasympathetic fibres 
destined for pelvic and abdominal viscera emerge from the sacral outflow from the spinal 
cord (nervi erigentes). They synapse in pelvic ganglia, with short postganglionic fibres that 
run to the bladder, genitalia, etc. Although the parasympathetic branch of the ANS utilises 
ACh as its primary postganglionic neurotransmitter (Tortora, 1999), this does not appear to 
be the case with parasympathetic vasodilator nerves.  
1.4.3.2 Pharmacology of Parasympathetic Vasodilator Nerves 
Early studies suggested parasympathetic vasodilator nerves did exist in the cerebral 
circulation, utilising ACh as a neurotransmitter (Biesold et al., 1989; Busija & Heistad, 
1984).  Indeed there was anatomical and physiological evidence to support this theory, 
including a dense network of choline acetyltransferase (ChAT)-immunoreactive fibres 
(Saito et al., 1985; Yu et al., 1992) and measurable ChAT activity in the cerebral vessels 
(Florence & Bevan, 1979). However, in the early 1980s, Lee (Lee 1980; 1982) suggested 
that nerve-derived ACh did not induce vasodilatation in the cat cerebral artery. In fact, he 
provided evidence that ACh was a vasoconstrictor neurotransmitter in this vessel. It is now 
widely accepted that although exogenously applied ACh can initiate vasodilatation by Chapter 1    Introduction 
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activating muscarinic receptors on endothelial cells, ACh released from parasympathetic 
nerves does not induce vasodilatation. Instead, NO released from nitrergic nerves is 
responsible for the vasodilatory effects of parasympathetic nerve stimulation (Lee et al., 
2001). However, ACh either co-released from these nerves or from separate cholinergic 
nerves does have a role to play in the regulation of vascular tone in monkey, porcine and 
canine ciliary arteries through presynaptic inhibition of release of NO and noradrenaline 
from nitrergic and adrenergic nerves, respectively (Toda et al., 1997; 1998; 1999).  
1.4.4  Non-Adrenergic Non-Cholinergic (NANC) Nerves 
For many years it was thought that only adrenergic and cholinergic systems of autonomic 
nerve transmission existed and this became known as the autonomic paradigm. However, 
from the end of the 19
th century until the discovery of adrenergic neuron blocking agents, 
nerve mediated responses that did not easily fit the autonomic paradigm were reported, but 
their significance not fully understood. For example, the research group led by Burnstock 
(Burnstock et al., 1963; Burnstock et al., 1964)  reported that transmural stimulation of 
guinea pig taenia coeli produced inhibitory junction potentials in smooth muscle cells, 
which were associated with relaxation and persisted in the presence of atropine and 
guanethidine. As the number of specific adrenergic blocking agents grew, it became 
apparent that NANC nerves did indeed exist and played an important role in the relaxation 
of smooth muscle in the gastrointestinal (Hata et al.,  2000), respiratory (Linden, 1996) and 
urogenital tracts (Andersson & Holmquist, 1994). The theory of NANC transmission is 
now widely accepted and a number of NANC transmitters have been identified: NO, 
calcitonin gene related peptide (CGRP), substance P, vasoactive intestinal polypeptide 
(VIP), NPY and ATP. 
1.4.5  Nitrergic Nerves 
Much of the research that suggested NO was a putative NANC transmitter was carried out 
in the anococcygeus and retractor penis (RP) muscles of various species, as these muscles 
receive dual innervation consisting of a motor adrenergic component from the lumbar 
sympathetic output and an inhibitory NANC component from the sacral parasympathetic 
output (Gillespie, 1971; Klinge & Sjostrand, 1974). A labile compound, termed inhibitory 
factor (IF) was extracted from the bovine RP (BRP) and rat anococcygeus muscle 
(Gillespie  et  al., 1981; Gillespie & Martin, 1980), which was able to replicate the 
relaxation witnessed upon stimulation of NANC nerves. At around this time it was also Chapter 1    Introduction 
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noted that IF (now identified as an NO-releasing s-nitrosothiol) bore a striking resemblance 
to the newly identified vasodilator, EDRF (Furchgott & Zawadzki, 1980). The discovery 
that oxyhaemoglobin blocked both relaxation to electrical field stimulation (EFS) in the 
BRP and rat anococcygeus muscle (Bowman & Gillespie, 1982) and also EDRF in the 
rabbit aorta (Martin et al.,  1985), further suggested involvement of a common substance. 
In addition to this, the relaxant effects of EDRF, IF and NANC nerves in the BRP were all 
associated with an increase in cyclic guanosine 3’,5’-monophosphate (cGMP; Rapoport & 
Murad, 1983), were blocked by the inhibitor of soluble guanylate cyclase, methylene blue 
(Martin  et  al., 1985), and potentiated by the selective phosphodiesterase 5 (PDE5) 
inhibitor, zaprinast (Bowman & Drummond, 1984). The identification of EDRF as NO, the 
elucidation of the NO synthesis pathway and subsequent development of NOS inhibitors, 
such as N
G-monomethyl-L-arginine (L-NMMA), eventually resulted in the inhibition of 
NANC relaxation in the rat (Gillespie et  al., 1989) and mouse (Gibson et  al., 1990) 
anococcygeus muscle. Furthermore, although L-NMMA did not block NANC relaxation in 
the BRP, it was blocked by another NOS inhibitor, N
G-nitro-L-arginine (L-NOARG), 
confirming the role of the L-arginine-NO pathway in NANC transmission in this tissue 
also (Liu et al., 1991). Moreover, Gillespie & Sheng (1990) continued to investigate the 
hypothesis that NANC nerves released NO in these tissues and utilised drugs capable of 
disabling NO by generating superoxide anions. They examined the effects of pyrogallol 
and hydroquinone on the BRP and rat anococcygeus muscle response to NANC nerve 
stimulation. Both drugs significantly reduced the NANC response to stimulation in the rat 
anococcygeus muscle but not the BRP muscle. In rat anococcygeus, the action of 
pyrogallol was reversed by superoxide dismutase, suggesting the inhibition by pyrogallol 
was due to the generation of superoxide anions. This was taken as further evidence that NO 
may have a neurotransmitter function, at least in some tissues. 
Parasympathetic, NANC vasodilator nerves were first discovered in dog cerebral arteries 
(Toda, 1975). He suggested that nicotine caused a transient relaxation in strips of isolated 
canine cerebral arteries by activating a specific nicotinic receptor and that β-adrenergic and 
cholinergic mechanisms did not have a large role to play in this process. Fifteen years later 
Toda & Okamura (1990) suggested that NO could act as a neurotransmitter in VSM, 
following further experimentation with dog cerebral artery strips. EFS of such strips 
resulted in relaxation, which was abolished by tetrodotoxin (TTX). The NOS inhibitor L-
NMMA inhibited relaxation in a concentration-dependent manner. The actions of L-
NMMA were reversed by L-arginine, but not D-arginine. In endothelium-denuded tissue, 
responses to EFS and L-NMMA were not significantly different from tissues with intact Chapter 1    Introduction 
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endothelium. Toda & Okamura also measured what they termed as NOx, this being NO or 
its breakdown products (NO2
- and NO3
-) and found that the level of NOx in the perfusate of 
tissues increased significantly following EFS. From this evidence they hypothesized that 
NO or an NO related compound had a role in transmitting information from nerve to VSM 
in this tissue. 
It is now widely recognised that NO transmission is an important control mechanism in 
many autonomically innervated tissues. In the literature nerves that operate via the release 
of NO as a neurotransmitter have been called both nitroxidergic (Toda & Okamura, 1991) 
and nitrergic (Rand, 1992). The issue was resolved by the NO Nomenclature Committee of 
the International Union of Pharmacology, which chose “nitrergic” as the official term 
(Moncada et al., 1997). 
1.4.5.1 NO Synthesis  
NO is synthesised by the NO synthase (NOS) family of enzymes, from the amino acid L-
arginine (Palmer et al., 1988). This two-step process, which also utilises O2, results in the 
formation of L-citrulline and NO via the intermediate product N
G-hydroxy-L-arginine 
(Figure 1.3). L-arginine is obtained from the extracellular space via a cation amino acid 
transporter system (Closs et al., 2006) or by synthesis from L-citrulline inside the cell via 
argininosuccinate synthetase and argininosuccinate lysase (Mori & Gotoh, 2000). 
Three distinct forms of NOS exist and all three have been purified, characterised and 
cloned: 
1.  Neuronal NOS, also known as nNOS, ncNOS, bNOS or NOS I (referred to as 
nNOS in the present study). nNOS was the first member of the NOS family to be 
purified, from the rat cerebellum (Bredt & Snyder, 1990). However, nNOS has also 
been identified in a number of other tissues, including skeletal muscle (Nakane et 
al., 1993) and epithelial cells of rat lungs, uterus and stomach (Schmidt et al., 
1992). Human nNOS is 161 kDa in size (Nakane et al., 1993). 
2.  Inducible NOS, also known as iNOS, mNOS and NOS II (referred to as iNOS in 
the present study). iNOS was first identified in murine macrophages (Hevel et al., 
1991; Stuehr et al., 1991) and has since been identified in murine and human lung 
epithelial cells (Asano et al., 1994; Robbins et al., 1994) and the pancreatic islets of Chapter 1    Introduction 
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diabetic rats (Kleemann et al., 1993). iNOS is slightly smaller than nNOS and is 
131 kDa in size (Charles et al., 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Schematic diagram showing the synthesis of NO from the amino acid L-
arginine. NO is synthesised by the nitric oxide synthase (NOS) family of enzymes, in a 
two-step process, which also utilises O2 and results in the formation of L-citrulline and NO 
via the intermediate product N
G-hydroxy-L-arginine.  
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3.  Endothelial NOS, also known as eNOS, ecNOS and NOS III (referred to as eNOS 
in the present study). The third member of the NOS family was initially discovered 
in endothelial cells of the bovine aorta (Pollock et al., 1991). eNOS has also been 
identified in syncytiotrophoblasts of human placenta (Myatt et  al., 1993) and 
kidney tubular epithelial cells (Tracey et al., 1994). eNOS is similar in size to iNOS 
and has been characterised as 133 kDa (Marsden et al., 1992). 
All three isoforms require the cofactors nicotinamide-adenine-dinucleotide phosphate 
(NADPH), (6R)-5,6,7,8-tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN) and contain an iron protoporphorin IX (haem) prosthetic 
group. eNOS and nNOS are constitutively expressed in cells (Bredt & Snyder, 1990) and 
synthesise NO in response to an increase in intracellular Ca
2+ concentration (Busse & 
Mülsch, 1990) and other Ca
2+-independent processes, such as shear stress (Fleming et al., 
1998). In contrast, iNOS is not constitutively expressed and is induced by inflammatory 
cytokines (interleukin-1, tumor necrosis factor-α, interferon-γ) and bacterial endotoxins 
(Hierholzer et al., 1998). However, Dweik et al. (1998) reported that iNOS is expressed 
constitutively in lung epithelial cells, where it controls generation of NO in proportion to 
the inspired oxygen concentration. 
1.4.5.2 Inhibitors of NOS 
Inhibition of NOS, especially of specific NOS isoforms, is of great pharmacological and 
therapeutic interest. For example nNOS has been implicated in the pathophysiology of 
many neurodegenerative diseases, such as Parkinsons disease (Hantraye et al., 1996) and 
iNOS has been implicated in autoimmune and inflammatory disorders such as rheumatoid 
arthritis (Evans et al., 1995). Specific and non-specific NOS inhibitors have already been 
identified and these are usually classified by their mechanism of action. 
The discovery that L-arginine was the substrate for NOS led to the identification of a 
number of L-arginine analogues, which occupy the substrate binding site on NOS and 
prevent NO formation. The first L-arginine analogue identified was L-NMMA (Hibbs et 
al., 1987), which inhibits all NOS isoforms. Another commonly used L-arginine analogue, 
L-NOARG (Moore et al., 1990) is commonly administered in prodrug form as N
G-nitro-L-
arginine methyl ester (L-NAME; Hobbs & Gibson, 1990). L-arginine analogues are 
generally reported as being non-specific NOS inhibitors (Rees et al., 1990). N
G-propyl-L-Chapter 1    Introduction 
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arginine (Zhang et al., 1997a) is a putative nNOS-specific inhibitor, that is reported to 
exhibit ~150-fold selectivity for bovine nNOS over eNOS in enzyme assays (Zhang et al., 
1997b). 
Another putative nNOS-selective inhibitor is N-[(4S)-4-amino-5-[(2-
aminoethyl)amino]pentyl]-N'-nitroguanidine tris(trifluoroacetate) (AAAN), a 
nitroarginine-containing dipeptide amide, which has a ~2,500-fold greater selectivity for 
rat nNOS over bovine eNOS (Hah et al., 2001). Other NOS inhibitors do not bind to the 
substrate-binding site, but instead attach to another part of the NOS molecule. For 
example, imidazole and compounds that contain this structure, bind to the haem site and 
are weak NOS inhibitors, which are relatively iNOS selective (Chabin et al., 1996). The 
indazole family are also NOS inhibitors. The best-studied member of this group is 7-
nitroindazole (7-NI). In isolated enzyme studies 7-NI is an equipotent inhibitor of all three 
enzymes (Alderton et al., 2001), however, when administered in vivo, it has also been 
described as an nNOS specific inhibitor (Southan & Szabo, 1996). 
1.4.5.3 Mechanism of NO-Mediated Vasodilatation 
NO-induced vasodilatation is mediated via the second messenger, cGMP, which plays an 
important role in many cellular signal transduction pathways. The level of cGMP within a 
cell is determined by the rate of synthesis, by guanylate cyclase, and the rate of hydrolysis 
by cyclic nucleotide phosphodiesterases (PDEs). 
1.4.5.3.1  cGMP Synthesis 
cGMP can be synthesised by two different forms of guanylate cyclase, particulate 
guanylate cyclase and soluble guanylate cyclase. Particulate guanylate cyclase is a 
membrane bound enzyme and is activated by the binding of peptide ligands, such as ANP 
and BNP, to membrane bound receptors that have transmembrane domains coupled with 
guanylate cyclase. Soluble guanylate cyclase is located within the cytoplasm of the cell and 
is an intracellular target of NO (Figure 1.4). NO activates soluble guanylate cyclase by 
binding to a haem moiety in the structure of the enzyme and inducing a conformational 
change. This, in turn, activates the catalytic site of the enzyme to produce cGMP (Ignarro 
et al., 1984). 
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1.4.5.3.2  Activation of cGMP-Dependent Protein Kinase 
An increase in intracellular cGMP serves to activate cGMP-dependent protein kinase 
(PKG). A number of forms of PKG exist, mainly a soluble form (type I, α and β) and a 
membrane-bound form (type II). Both type Iα and Iβ have been identified in VSM 
(Keilbach et al., 1992). As discussed earlier, VSM contracts when [Ca
2+]i is increased and 
dilates when  [Ca
2+]i is decreased. PKG activation has been reported to mediate 
vasodilatation by reducing cytosolic Ca
2+ in a number of ways: 
1.  Inhibition of Ca
2+ influx through voltage-gated (L-type) Ca
2+ channels and by 
promotion of Ca
2+ uptake into the sarcoplasmic reticulum (Clapp & Gurney, 1991) 
via phosphorylation of phospholamban (Cornwell et al., 2006). 
2.  Activation of the Na
+/Ca
2+ exchanger (Furukawa et al., 1991). 
3.  Activation of the plasma membrane Ca
2+-ATPase (Yoshida et al., 1991). 
4.  Inhibition of inositol phosphate formation, which is important for Ca
2+  release 
(Hirata et al., 1990). 
PKG activation is reported to induce vasodilatation by triggering phosphorylation of 
MLCK, which leads to decreased Ca
2+ sensitivity (Himpens et al., 1989) and also by 
activating KCa channels, leading to hyperpolarisation of the SMC (Robertson et al., 1993). 
However, NO can also directly activate KCa
 channels in the absence of cGMP (Bolotina et 
al., 1994). 
1.4.5.3.3  The PDE Family 
The PDE group is a large family of enzymes that catalyse hydrolysis of the 3’-
phosphoester bond of both cGMP and cyclic adenosine 3’, 5’-monophosphate (cAMP). 
Currently, at least 11 distinct PDE families have been identified (Soderling & Beavo, 
2000). Several genes encode each family and there are over 50 different PDE enzymes. 
Although each family differs in structure, distribution, regulation and function, all PDEs 
have a core of ~ 270 highly conserved amino acids, which make up the catalytic domain 
(Charbonneau, 1990). PDEs within each family are at least 65% homologous but between 
families this homology drops to 40%, with most of the similarity in the catalytic domain 
(Beavo, 1995). Each PDE family hydrolyses cGMP (PDE5, PDE6 and PDE9), cAMP Chapter 1    Introduction 
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(PDE4, PDE7 and PDE8) or both cyclic monophosphates (PDE1, PDE2, PDE3, PDE10 
and PDE11). 
Not all of the PDE isoforms have been reported in smooth muscle and to date it is 
unknown whether PDE6, PDE8, PDE9, PDE10 and PDE11 are expressed in the vascular 
system. PDE1 has been identified in a number of VSM sources, including bovine (Lugnier 
et al., 1986), canine (Pagani et al., 1992) and human (Lugnier et al., 1986) aorta. Low 
PDE2 activity has been detected in extracts of porcine aorta (Saeki & Saito, 1993). PDE3 
has a high affinity for both cAMP and cGMP and has been identified in cultured rat (Liu & 
Maurice, 1998) and human (Palmer & Maurice, 2000) VSM cells. cAMP-specific PDE4, 
has been identified in the bovine (Prigent et al., 1988) and porcine (Saeki & Saito, 1993) 
aorta and the human pulmonary artery (Rabe et al., 1994). PDE5 is cGMP specific and is 
abundant in VSM (Corbin & Francis, 1999). PDE5 is perhaps the most familiar member of 
the PDE family, thanks to the development of the PDE5 inhibitor, sildenafil (Viagra; 
Boolell et al., 1996), which is used to treat male erectile dysfunction. PDE7 has been 
identified in VSM, but not endothelial cells, of the human pulmonary artery (Smith et al., 
2003). Meanwhile, PDE8 - 11 are fairly recent discoveries (Soderling & Beavo, 2000) and 
consequently much less is known about their distribution and function. 
1.4.5.4 Mechanism of Nitrergic Neurotransmission 
The gaseous nature of NO has led to fierce debate over the actual mechanism of nitrergic 
transmission. NO must be synthesised as required and is not stored in vesicles, like 
traditional transmitters. Toda & Okamura (2003) proposed a mechanism of nitrergic 
transmission to cerebral arteries, which is illustrated in Figure 1.4. As has already been 
discussed, NO is synthesized from L-arginine by nNOS, which is activated
 by Ca
2+ in the 
presence of calmodulin and other cofactors (Bredt & Snyder, 1990). The response to 
electrical stimulation
 is abolished by removal of extracellular Ca
2+ and also by
 ω-conotoxin 
GVIA, an N-type Ca
2+ channel blocker (Toda et  al., 1995), but not by nicardipine, a 
blocker of L-type Ca
2+ channels (Toda & Okamura, 1992). They suggest that Ca
2+ entry 
into nerve terminals via N-type Ca
2+ channels, upon arrival
 of generated action potentials, 
is responsible
 for activation of nNOS and NO synthesis (Toda et al., 1995).
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Figure 1.4 Schematic diagram summarising a proposed mechanism of neurotransmission 
from nitrergic nerves to smooth muscle (adapted from Toda & Okamura, 2003). A solid 
line indicates stimulation and a dotted line indicates inhibition. ω-CT, ω-conotoxin GVIA; 
N, nicotinic receptor; X, unknown protein that contributes to nNOS activation upon 
phosphorylation (X-P); O2
-, superoxide anion; MB, methylene blue; Hb, haemoglobin; C6, 
hexamethonium; CaM, calmodulin; ODQ, 1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; 
GTP, guanosine triphosphate; ADMA, asymmetric dimethylarginine; L-NA, L-
nitroarginine; W-7, a calmodulin antagonist. 
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1.4.6  VIP-Containing Nerves 
VIP was first isolated in the porcine duodenum in 1970 (Said & Mutt, 1970) and contains 
28 amino acid residues (Mutt & Said, 1974). The human VIP amino acid sequence is 
identical to the bovine, ovine, canine, porcine, goat, rat and rabbit peptide (Nussdorfer & 
Malendowicz, 1998). VIP-like immunoreactivity was quickly described within nerve cell 
bodies and axons, particularly in the cerebral circulation of a number of species (Edvinsson 
et al., 1980). 
1.4.6.1  Synthesis of VIP 
VIP is derived from prepro-VIP, cleavage of which yields not only VIP, but also peptide 
histidine isoleucine/methionine (PHI/PHM). PHI /PHM are structurally related to VIP and 
can mimic many of the actions of VIP but are less potent (Nussdorfer & Malendowicz, 
1998). VIP is synthesised in the neuronal cell body and transported to the axon terminal 
(Gilbert et al., 1980). 
1.4.6.2  VIP Receptors  
The VIP receptor belongs to a family of G-protein coupled receptors (GPCR), which are 
also activated by pituitary adenylate cyclase activating polypeptide (PACAP), PHI and 
PHM (Harmar et al., 1998). Two subtypes of VIP receptor, VPAC1 and VPAC2 have been 
cloned (Adamou et al., 1995; Sreedharan et al., 1993). In the porcine basilar artery, both 
VPAC1 (endothelium) and VPAC2 (smooth muscle) can mediate vasodilatation, via 
different mechanisms. Another VIP-activated receptor, the natriuretic peptide clearance 
receptor (NPR-C), can also mediate vasodilatation in this vessel (Grant et al., 2006). 
1.4.6.3  VIP Inhibition 
The VIP fragments, VIP6-28 and VIP10-28, the VIP derivative [4-Cl-D-Phe
6, Leu
17]VIP and a 
growth hormone releasing factor derivative are effective, non-specific, antagonists  against 
VIP-mediated relaxation of the gut in a preparation of mouse stomach (Mulè & Serio, 
2003) and guinea-pig taenia coli (Grider & Rivier, 1990). However other mechanisms of 
VIP inhibition have also been reported. The protease α-chymotrypsin (Mulè & Serio, 
2003) and VIP antiserum (Matthew et al., 1997) have also been used successfully to inhibit 
neurally-mediated vasodilatation. Chapter 1    Introduction 
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1.4.6.4  Mechanism of VIP-Mediated Vasodilatation 
VIP is known to mediate vasodilatation via a number of mechanisms. In rat cerebral 
vessels and the rabbit mesenteric artery (Huang & Rorstadt, 1983; Itoh et al., 1985), VIP-
mediated neurogenic vasodilatation is mediated by activation of adenylate cyclase (AC) 
and cAMP.  
There are nine recognised isoforms of AC to date (AC-I to AC-IX; Houslay & Milligan, 
1997). However, only AC-III has been identified in VSM (Zhang et al., 1997c). All AC 
isoforms are coupled to GPCR and differ from each other in their activation or inhibition 
by Ca
2+/calmodulin, phosphorylation by cAMP-dependent protein kinase (PKA) and   
protein kinase C (PKC) and differences in the structure of the G-protein (Hurley, 1998). 
An increase in intracellular cAMP serves to activate PKA, which promotes vasodilatation 
in a number of ways: 
1.  Phosphorylation of MLCK, decreasing the sensitivity of the contractile apparatus to 
Ca
2+ (de Lanerolle et al., 1984). 
2.  Stimulation of Ca
2+-ATPase in the plasma membrane and sarcoplasmic reticulum, 
resulting in decreased [Ca
2+]i (Kimura et al., 1982). 
3.  Phosphorylation of KCa
 channels, resulting in hyperpolarisation and vasodilatation 
(Price et al., 1996; Taguchi et al., 1995). 
However, in the human uterine artery (Jovanovic et al., 1998), VIP mediated vasodilatation 
is endothelium-dependent and is produced by NO, leading to stimulation of guanylate 
cyclase and an increase in intracellular cGMP. Furthermore, VIP is reported to produce 
smooth muscle hyperpolarisation via activation of ATP-sensitive K
+ (KATP) channels, 
which in turn leads to vasodilatation (Standen et al., 1989).  
1.4.6.5 Breakdown of VIP 
VIP is hydrolysed by a number of enzymes including neutral endopeptidase (Goetzl et al., 
1989) and mast cell chymase and tryptase (Caughey et  al., 1988). As previously 
mentioned, degradation of VIP by protease enzymes, is often used as an investigational 
tool. Chapter 1    Introduction 
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1.4.7  Vascular Sensory Nerves 
Release of the neuropeptide transmitters calcitonin gene-related peptide (CGRP) and 
substance P from the terminals of sensory nerves can result in vasodilatation. In addition to 
release by nerve stimulation, the irritant capsaicin, extracted from chilli peppers, induces 
the release of CGRP and substance P from sensory neurons. This results in a profound 
depletion of CGRP and substance P within the nerves (Wharton et al., 1986).  
1.4.7.1 CGRP 
CGRP is a single chain 37 amino acid peptide, which is highly conserved in different 
mammalian species (Collyear et al., 1991). There are two forms of CGRP in humans: α-
CGRP (Morris et al., 1984) and β-CGRP (Alevizaki et al., 1986), which differ by 3 amino 
acids. Immunoreactivity to CGRP has been demonstrated in many tissues but is 
concentrated in unmyelinated C-fibres and Aδ fibres of the peripheral nervous system and 
the dorsal horn of the spinal cord (Rosenfeld et al., 1983).  
1.4.7.1.1  CGRP Receptors  
Two CGRP receptor subtypes have been described, CGRP1 and CGRP2. Classification is 
based upon the antagonist properties of the CGRP inhibitor CGRP8-37 (Chiba et al., 1989). 
Receptors that can be inhibited by CGRP8-37 have been designated CGRP1 receptors, and 
those unaffected are known as CGRP2 receptors (Dennis et al., 1990). CGRP8-37 is an 
effective CGRP antagonist, both in vivo (Gardiner et al., 1990) and in response to EFS in 
vitro in the canine lingual artery (Kobayashi et al., 1995).  
1.4.7.1.2  Mechanism of CGRP-Mediated Vasodilatation 
CGRP is a potent vasodilator (Brain et al., 1986) and mediates neurogenic vasodilatation 
in the rat mesentery (Kawasaki et al., 1988), the canine lingual artery (Kobayashi et al., 
1995) and small mesenteric artery of the rabbit (Kakuyama et al., 1998). CGRP-induced 
vasodilatation can be both endothelium-dependent and in some cases endothelium-
independent. In rat aorta, dilatation in response to CGRP is endothelium-dependent and 
can be inhibited by both NOS inhibitors and CGRP8-37. This suggests that dilatation to 
CGRP is mediated via NO in this tissue (Gray & Marshall, 1992). However in cat cerebral 
arteries, human skeletal muscle arteries and rabbit mesenteric arteries (Nelson et al., 1990), Chapter 1    Introduction 
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CGRP-induced vasodilatation is endothelium-independent and may be the result of 
activation of KATP channels. 
1.4.7.2 Substance P  
Substance P is part of the tachykinin family of peptides, along with neurokinin A, 
neurokinin B, neurokinin K and neuropeptide γ. Although substance P was initially 
isolated from equine brain and intestine in the 1930s (Von Euler & Gaddum, 1931), the 
structure was not determined until the 1970s (Chang et al., 1971) when it was discovered 
that substance P was an undecapeptide. It was demonstrated by Hökfelt et al. (1975) that 
substance P is present in sensory neurons.  
1.4.7.2.1  Substance P Receptors 
Three receptor types mediate the effects of the tachykinins: neurokinin 1 (NK1), neurokinin 
2 (NK2) and neurokinin 3 (NK3; Buck et al., 1984; Lee et al., 1982). Each peptide can act 
as a full agonist at all 3 receptors, but substance P is more selective for NK1 receptors (Bell 
& McDermott, 1996). Substance P-induced vasodilatation is mediated via NK1 receptors. 
NK1 antagonists such as L-733,060 (Seabrook et  al., 1996) are available to inhibit 
responses mediated by this receptor. 
1.4.7.2.2  Mechanism of Substance P-Mediated Vasodilatation 
In a number of vascular beds, substance P-induced vasodilatation is mediated via NO 
(Persson et al., 1991; Whittle et al., 1989). However, in other tissues substance P can 
evoke vasodilatation in the presence of NOS inhibitors (Kerezoudis et al., 1993). In some 
blood vessels, such as the rabbit jugular vein (Nantel et al., 1990), substance P evokes a 
vasoconstrictor response. 
1.4.8  Purinergic Nerves 
  ATP, first identified by Fiske & Subbarow (1929) from muscle extract, is a purine 
nucleotide, which can be found in every cell of the body, as a source of energy. In addition 
to this critical role in cellular metabolism, extracellular ATP exerts pronounced effects in a 
variety of biological processes including neurotransmission, muscle contraction, cardiac 
function and vasodilatation. The first to propose ATP as a neurotransmitter was the 
research group led by Burnstock (Burnstock et al., 1970). Although the concept met with Chapter 1    Introduction 
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resistance for many years, purinergic transmission and co-transmission involving ATP 
(Burnstock, 1971) are now widely accepted. 
1.4.8.1  Synthesis of ATP 
The ATP molecule is comprised of three different chemical structures: an adenine ring 
formed through purine biosynthesis, a ribose molecule formed in the pentose phosphate 
pathway and a triphosphate chain. Nerve terminals take up glucose from the extracellular 
surroundings and some ATP is generated from glycolysis and the citric acid cycle. 
However, the majority of ATP is formed by oxidative phosphorylation in the mitochondria 
of the nerve terminal (Sperlagh & Vizi, 1996). ATP utilised in neurotransmission, as 
opposed to cellular metabolism, is stored in a variety of synaptic vesicles. ATP has been 
identified within cholinergic synaptic vesicles (Dowdall et  al., 1974) and in those 
containing catecholamines (Douglas & Poisner, 1966). 
1.4.8.2  ATP Receptors  
ATP receptors are members of the purinoceptor family. Initially two isoforms of 
purinoceptor were identified, P1 (the adenosine receptor) and P2 (ATP and ADP receptor; 
Burnstock, 1978). The nomenclature of these receptors has been adapted, with the 
discovery of new receptor isoforms. The current system for P2 receptors was suggested by 
Abbracchio & Burnstock (1994), who proposed that receptors be classified as either P2X 
(ligand-gated ion channel receptors) or P2Y (G-protein-coupled receptors). Currently 
seven P2X and eight P2Y receptor subtypes exist (Burnstock, 2006). P2Y receptors 
mediate vasodilatation in the rabbit portal vein (Brizzolara et al., 1993) and lamb coronary 
arteries (Simonsen et al., 1997). 
1.4.8.3  ATP Inhibition 
The large number of purinoceptor subtypes has led to a vast array of specific and non-
specific purinoceptor antagonists being developed. Previous research has reported that the 
non-specific inhibitors, suramin and reactive blue 2 (RB2), inhibit neurogenic, ATP-
mediated vasodilatation in lamb coronary arteries (Simonsen et al., 1997). Another novel 
inhibitor, 4-[[4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-
1,3 benzenedisulfonic acid tetrasodium salt (PPADS), effectively inhibits neurogenic ATP 
in the rabbit vas deferens (Lambrecht et al., 1992). Chapter 1    Introduction 
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1.4.8.4  Mechanism of ATP-Mediated Vasodilatation 
ATP can mediate vasodilatation by activation of P2Y receptors on the endothelium or 
VSM and is believed to mediate neurogenic vasodilatation in the rabbit portal vein and 
mesenteric artery (Brizzolara et  al., 1993; Kakuyama et  al., 1998) and lamb coronary 
arteries (Simonsen et  al., 1997). Activation of P2Y1 and P2Y2 receptors on the 
endothelium, results in activation of NOS and production of NO. PGI2 production can also 
be stimulated in this way but plays a minimal role in vasodilatation (Ralevic & Burnstock, 
1998). Activation of P2Y1 receptors on VSM is also reported in rabbit mesenteric and 
hepatic arteries (Brizzolara & Burnstock, 1991; Mathieson & Burnstock, 1985). 
1.4.8.5  Breakdown of ATP 
ATP released from neurons and non-neuronal cells can be broken down by a number of 
enzyme families, known collectively as the ectonucleotidases. ATP is broken down to 
adenosine, which is then capable of activating P1 receptors. Ecto-nucleoside triphosphate 
diphosphohydrolases (E-NTPDases), ectonucleotide pyrophosphatases (E-NPPases), 
alkaline phosphatases, ecto-5’-nucleotidase and ecto-nucleoside diphosphokinase (E-
NDPK) are all capable of breaking down extracellular ATP (Zimmerman, 2001). 
1.4.9  Other Potential Vasodilator Neurotransmitters 
NO, although now firmly established, challenged the traditional definition of a 
neurotransmitter. Recently another two gases, carbon monoxide (CO) and hydrogen 
sulphide (H2S), have been proposed as putative neurotransmitters. 
1.4.9.1  CO 
CO is generated by the enzyme haem oxygenase (HO) and is able to stimulate soluble 
guanylate cyclase (Stone & Marletta, 1994). Three isoforms of HO have been identified, 
one highly inducible (HO1; Shibahara et al., 1985) and two constitutive forms (HO2 and 
HO3; McCoubrey et al., 1997; Rotenberg & Maines, 1990). 
Evidence that CO plays a role in neurotransmission is based upon studies of NANC 
transmission in the enteric nervous system. In the gut, HO2 is co-localised with nNOS and 
NANC transmission is reduced by 50% in nNOS-deficient mice and also in HO2-deficient 
mice (Battish et al., 2000; Ny et al., 1997; Zakhary et al., 1997). In mice lacking both Chapter 1    Introduction 
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nNOS and HO2, very little NANC transmission is observed (Xue et al., 2000). cGMP 
levels are depleted in a similar manner in both knockout mice (Zakhary et al., 1997). 
CO also has guanylate cyclase-independent effects. In rat-tail arteries, a combination of 
cGMP inhibitors and inhibitors of large conductance calcium-activated K
+ channel are 
needed to fully inhibit CO-induced vasodilatation (Wang et al., 1997). 
1.4.9.2 H2S 
H2S, a potent SMC relaxant, is formed from cysteine by the enzymes cystathionine β-
synthase (CBS) and cystathionine γ-lysase (CSE; Stipanuk & Beck, 1982). CBS is the 
dominant enzyme in the brain (Abe & Kimura, 1996), but both isoforms are present in 
SMC (Hosoki et al., 1997). 
The mechanism of H2S-mediated SMC relaxation is unknown at the present time. In the rat 
aorta it is not blocked by inhibitors of the cGMP pathway and seems to be partly mediated 
by the endothelium and partly by the VSM (Zhao & Wang, 2002). Additional studies in the 
rat aorta suggest that H2S may activate KATP channels in the VSM, resulting in 
hyperpolarisation and vasodilatation (Zhao et  al., 2001). However, H2S-mediated 
relaxation of the guinea-pig ileum is not blocked by inhibitors of NOS, cyclo-oxygenase 
(COX) or KATP channels (Teague et al., 2002).    
1.5  Endothelial Control of Vascular Tone 
1.5.1  NO 
1.5.1.1 Identification of Endothelium Derived-Relaxing Factor as NO 
As has already been discussed, until the early 1980s the common belief was that the 
endothelium of blood vessels acted merely as a barrier and did not contribute to vascular 
tone. However, Furchgott & Zawadzki (1980) demonstrated that vasodilatation in response 
to ACh was endothelium-dependent and that the endothelium did contribute to vascular 
tone by releasing a vasodilator substance. The term EDRF was coined to describe this 
labile compound released from the endothelium. A number of groups investigated EDRF, 
in order to identify it. Bioassays were utilised to show that EDRF had a very short half-life 
(Griffith et al., 1984) and that it was released under basal conditions and after stimulation 
with ACh (Griffith et al., 1984; Martin et al., 1985). EDRF was also inhibited by Hb, Chapter 1    Introduction 
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methylene blue (Martin et al., 1985) and hydroquinone (Griffith et al., 1984). The effects 
of EDRF appeared to be mediated by stimulation of soluble guanylate cyclase and an 
increase in intracellular cGMP concentration (Rapoport & Murad, 1983). 
EDRF was identified in 1987 (Ignarro et al., 1987; Palmer et al., 1987), when evidence 
from different groups supported the proposal that EDRF was NO. NO can be measured 
using chemiluminesence and using this technique it was shown that the concentration of 
bradykinin that induced EDRF release in cultured porcine aortic endothelial cells also 
caused a concentration-dependent release of NO (Palmer et al., 1987). Comparison of the 
physiological actions of EDRF and NO on vascular strips (Hutchinson et al., 1987; Palmer 
et al., 1987) and platelets (Radomski et al., 1987) showed that they were indistinguishable 
from each other. The actions of NO and EDRF on vascular strips and platelets were 
potentiated by superoxide dismutase (SOD) and cytochrome c and inhibited by iron (Fe
2+; 
Hutchinson et al., 1987; Palmer et al., 1987). As EDRF and NO appeared to have identical 
chemical properties and biological actions it was widely accepted, although not by all 
groups (Dusting et al., 1988), that EDRF was indeed NO.  
1.5.1.2 Mechanism of Endothelium-Dependent, NO-Mediated Vasodilatation  
Shear stress and activation of membrane bound receptors on the vascular endothelium, by 
mediators such as bradykinin or ACh, results in an influx of Ca
2+ into the endothelial cell. 
The resulting increase in intracellular Ca
2+ stimulates eNOS to generate NO, which 
diffuses into surrounding SMC (Moncada & Higgs, 1993). This stimulates the soluble 
guanylate cyclase pathway described earlier (Figure 1.5). However, it has also been 
suggested that in the rabbit aorta and rat middle cerebral arteries, NO may mediate 
vasodilatation via activation of KCa
 channels (Bolotina et al.,  1994; Sun et al., 2000). 
1.5.2  PGI2 
PGI2, a member of the prostanoid family, was the first EDRF to be discovered, when 
Moncada et al. (1976) described an agent that had platelet anti-aggregating properties and 
was also capable of relaxing VSM.  
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Figure 1.5 Schematic diagram showing the mechanisms of smooth muscle relaxation 
employed by the endothelium-derived vasodilators NO, PGI2 and EDHF. R, receptor; SR, 
sarcoplasmic reticulum; AA, arachidonic acid; P-450, cytochrome P-450. Adapted from 
Momboulil & Vanhoutte, 1999. 
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1.5.2.1 PGI2 Synthesis 
PGI2 is synthesised, like a number of other vasoactive products, from arachidonic acid 
released from membrane bound phospholipids by phospholipases. The COX family of 
enzymes converts arachidonic acid into prostaglandins G2 and H2 and these are, in turn, 
converted into various vasoactive prostanoids such as PGI2, prostaglandins D2, E2 and F2α 
and thromboxane A2. The endothelium synthesises mainly PGI2 and platelets synthesise 
thromboxane A2 (Moncada & Vane, 1979). 
 
1.5.2.2 Receptors for PGI2 
Five isoforms of prostanoid receptor have been classified. These are DP, EP, FP, IP and TP 
and are specific for prostaglandins D2, E2 and F2α, PGI2 and thromboxane, respectively 
(Coleman et al., 1994). As expected, IP receptors have been localised in the VSM and on 
platelets (Oliva & Nicosia, 1987). 
1.5.2.3 Mechanism of PGI2-Mediated Vasodilatation 
Activation of IP receptors, which are coupled to AC, increases the cAMP level within the 
VSM cell and initiates vasdilatation (Kukovetz et al., 1979). However, PGI2 can also elicit 
hyperpolarisation in VSM, leading to vasodilatation (Parkington et al., 1995). Furthermore, 
PGI2 can also stimulate release of NO from endothelial cells, which in turn, results in 
vasodilatation (Shimokawa et al., 1988). 
1.5.2.4 Inhibitors of PGI2 
Non-steroidal anti-inflammatory drugs (NSAID), such as aspirin, commonly prescribed for 
acute and chronic pain, inhibit the COX family of enzymes (Vane, 1971). There are two 
recognised COX isoforms, COX-1 and COX-2. COX-1 is constitutively expressed in most 
cells of the body and is known as the “housekeeping” isoform as it regulates the synthesis 
of prostaglandins used for homeostatic purposes, such as vasodilatation and blood clotting. 
In contrast, COX-2 is an inflammatory, inducible enzyme (Dubois et  al., 1998). The 
discovery of the role of COX-2 in inflammatory diseases led to a surge in research into a 
specific COX-2 inhibitor, which could be used as an anti-inflammatory, without affecting 
the activity of COX-1. A number of COX-2 inhibitors such as celecoxib and rofecobix 
have been introduced in recent years (Wallace, 1999). Chapter 1    Introduction 
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1.5.3   EDHF 
In the late 1980s it became apparent that there was a third endothelium-dependent mediator 
of vasodilatation, unaffected by inhibitors of NO and PGI2. This became known as EDHF. 
The identity of EDHF is still under investigation, as there are a number of mechanisms by 
which hyperpolarisation of VSM can occur and a number of candidate molecules that can 
initiate the hyperpolarisation process. Therefore, Félétou & Vanhoutte (2006) proposed 
that “once an endothelial mediator has been identified properly, it should be adequately 
named (i.e., epoxyeicosatrienoic acid [EET], H2O2) and no longer denominated with the 
acronym EDHF”.  
The characteristics of an EDHF-mediated vasodilatation have been described as (Campbell 
& Harder, 2001):  
1.  Endothelium-dependent 
2.  Distinct from a vasodilatation mediated by endothelium-derived NO or COX 
metabolites 
3.  Results in hyperpolarisation of VSM 
4.  Involves activation of K
+ channels and may be inhibited by the K
+ channel 
blockers, charybdotoxin and apamin (Waldron & Garland, 1994) 
1.5.3.1 Hyperpolarisation and K
+ Channels 
The membrane potential of arterial smooth muscle has an important role to play in arterial 
tone. K
+ channels are important regulators of membrane potential; the opening of K
+ 
channels leads to K
+ efflux, causing membrane potential hyperpolarisation, which in turn 
closes voltage-dependent Ca
2+ channels, decreasing Ca
2+ entry, resulting in vasodilatation 
(Nelson & Quayle, 1995). Four types of K
+ channel have been reported in VSM, voltage-
dependent K
+ (KV) channels, Ca
2+-activated K
+ (KCa) channels, inward rectifier K
+ (KIR) 
channels and KATP channels. 
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1.5.3.1.1  KV Channels 
KV channels are activated by membrane depolarisation and can be inhibited by 4-
aminopyridine (4-AP; Okabe et al., 1987) and also charybdotoxin (Zygmunt et al., 1997). 
1.5.3.1.2  KCa Channels 
Three categories of KCa channels have been identified and classified according to their 
conductance: large-conductance, 100–300 pS (BKCa; Marty, 1981), intermediate-
conductance, 25–100 pS (IKCa; Ishii et al., 1997), and small-conductance, 2–25 pS (SKCa; 
Blatz & Magleby, 1986) Ca
2+-activated potassium channels. These channels can be 
activated by membrane depolarisation and intracellular Ca
2+. BKCa channels are inhibited 
by iberiotoxin (Latorre et  al., 1992) and charybdotoxin (Miller et  al.,  1985). 
Charybdotoxin also inhibits IKCa and KV channels, as mentioned previously, while apamin 
is reported to inhibit SKCa (Blatz & Magleby, 1986). 
1.5.3.1.3  KIR Channels  
The KIR channel conducts inward current at membrane potential negative to the K
+ 
equilibrium potential (EK; ~-85 mV) and smaller outward currents at membrane potentials 
positive to EK. KIR channels are sensitive to blockade by BaCl2 (Quayle et al., 1993). 
1.5.3.1.4  KATP Channels 
KATP channels were initially discovered in cardiac muscle, but have also been described in 
VSM (Standen et al., 1989). They are closed by intracellular ATP and have been reported 
to react to a number of endogenous vasodilators, such as CGRP (Nelson et al., 1990) and 
VIP (Standen et  al., 1989). KATP channels are blocked by sulfonylurea drugs such as 
glibenclamide (Schmid-Antomarchi et al., 1987). 
 Some of the putative EDHF candidates include K
+ ions, gap junctions, arachidonic acid 
metabolites and CNP.  
1.5.3.2 K
+ Ions 
K
+ ions were described as EDHF by Edwards et al. (1998) in the rat hepatic and mesenteric 
arteries. They hypothesised that the activation of KCa
  channels in the membrane of Chapter 1    Introduction 
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endothelial cells led to efflux of K
+ from the cell. This, in turn, led to an increase in 
extracellular K
+ and activated VSM Na
+/K
+ATPase and KIR channels, leading to a net loss 
of positive charge and hyperpolarisation of the cell.  
However, a number of studies, also in the rat mesenteric artery, have refuted the claims of 
Edwards et al. (1998). Both Doughty et al. (2000) and Lacy et al. (2000) report that the 
response to K
+ does not mimic the response to EDHF in this vessel. 
1.5.3.3 Arachidonic Acid Metabolites 
One product of arachidonic acid metabolism, EETs, has also been described as an EDHF. 
The mechanism of EETs-mediated vasodilatation is dependent on activation of endothelial 
receptors. This gives rise to an increase in cytoplasmic free Ca
2+, which in turn releases 
arachidonic acid from membrane phospholipids. The arachidonic acid is converted to EETs 
by an epoxygenase enzyme. EETs then diffuse from the endothelium to VSM cells where 
it activates and opens BKCa channels. The resulting K
+ flux from the SMC leads to 
hyperpolarisation and dilatation (Bryan et al., 2005). 
A number of separate observations have led to EETs being described as an EDHF. 
Selective inhibition of epoxygenases by antisense oligonucleotide
  transfection blocked 
EDHF-mediated dilatation in resistance arteries from the hamster gracilis muscle (Bolz et 
al., 2000), as did an EETs antagonist in bovine coronary arteries (Gauthier et al., 2002). 
EETs also increased the open state probability of BKCa channels and hyperpolarised VSM 
in bovine coronary arteries (Campbell et  al., 1996). Furthermore, agents that increase 
expression of cytochrome P450 epoxygenase, also increased EDHF-mediated dilatation in 
the porcine coronary arteries (Fisslthaler et al., 1999). 
However, those who oppose the EETs theory argue that the specific BKCa blocker, 
iberiotoxin, does not inhibit EDHF-mediated vasodilatation in the rat hepatic (Zygmunt & 
Högestätt, 1996) and mesenteric (Vanheel & Voorde, 1997) and guinea-pig basilar arteries 
(Petersson et al., 2006). 
1.5.3.4 Gap Junctions 
Gap junctions are intracellular channels that allow small water-soluble molecules, but not 
proteins, to pass between cells. Gap junctions are comprised of protein subunits called 
connexins and six connexins are required to form a connexon or hemichannel. A gap Chapter 1    Introduction 
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junction is formed when the hemichannels of two adjacent cells dock (Christ et al., 1996). 
Gap junctions between endothelial cells and smooth muscle cells are called myoendothelial 
gap junctions (Sandow & Hill, 2000). These myoendothelial gap junctions may be 
involved in the EDHF response, by relaying the dilator signal from the endothelium to 
SMC. 
Gap junctions can be blocked by peptide inhibitors, known as gap peptides and the EDHF-
mediated response in the rabbit superior mesenteric artery can be inhibited in this way. 
Further evidence for the involvement of gap junctions in the EDHF response was provided 
by Sandow et al. (2002) who compared the structure of arteries that did and did not have 
an EDHF-mediated dilatation. The rat mesenteric artery, which does undergo EDHF-
mediated dilatation was found to contain myoendothelial gap junctions and had tight 
electrical coupling between the endothelium and smooth muscle cells. However, in the rat 
femoral artery, which does not have an EDHF-mediated dilatation, myoendothelial gap 
junctions were absent and there was no electrical coupling between the endothelium and 
smooth muscle cells. 
Although there is much evidence for the involvement of gap junctions in the EDHF-
mediated response, the identity of the substance conducted between the endothelium and 
the smooth muscle remains unknown.  
1.5.3.5  CNP 
CNP is a member of the natriuretic peptide family, homologous to both ANP and BNP, 
originally isolated in the porcine brain (Sudoh et al., 1990). CNP contains 22 amino acids, 
17 of which form a ring structure that is highly conserved in all 3 natriuretic peptides 
(Sudoh et al., 1990). CNP is also highly conserved between species with almost 100% 
homology between the human and porcine form (Ogawa et al., 1992). 
CNP binds to the natriuretic peptide receptors (NPR) and is a potent vasodilator. Evidence 
that CNP is EDHF is provided by the observation that CNP-induced vasodilatation is 
inhibited by a variety of K
+ channel blockers (Honing et al., 2001; Wei et al., 1994). 
Furthermore, in the rat mesenteric artery, EDHF and CNP-induced hyperpolarisation and 
relaxation of the VSM are both attenuated in the presence of high [K
+] and a combination 
of Ba
2+ and ouabain. The responses were also mimicked by the NPR-C agonist cANF
4-23, 
indicating that the effects of CNP were mediated by NPR-C (Chauhan et al., 2003). Chapter 1    Introduction 
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However, in the porcine coronary artery, the characteristics of the hyperpolarisation 
evoked by CNP were not comparable to EDHF-mediate hyperpolarisation (Barton et al., 
1998). In addition to this, the mechanism of hyperpolarisation suggested by Chauhan et al. 
(2003) relies upon activation of GIRK channels and to date there is no evidence that CNP 
can activate GIRK in any cell type (Félétou & Vanhoutte, 2006). 
1.5.4  Endothelin 
In addition to the vasodilators NO, PGI2 and EDHF, the endothelium also releases a 
vasoconstrictor substance, endothelin. De May & Vanhoutte, (1981) initially reported that 
in canine femoral arteries, the endothelium was essential for vascular contraction. 
Endothelin (known today as ET-1) was eventually characterised by Yanagisawa et  al. 
(1988) from the endothelial cells of pig aorta. Another two endothelins, ET-2 and ET-3, 
have since been discovered.  
 
ET-1 is a 21 amino acid peptide and has been localised in non-vascular tissues, such as the 
brain and kidney, in addition to the endothelium (Sakurai et al., 1991). ET-2 and ET-3 can 
also be detected in other tissues, but not the vascular endothelium. The endothelins are 
synthesised from precursors known as preproendothelins (preproET). PreproET undergo 
cleavage by endopeptidases to form intermediate products, proendothelins (proET), also 
known as big endothelins (big ET). Big ET is then processed by a specific endothelin 
converting enzyme (ECE) to form active endothelin (Ortega Mateo & de Artinano, 1997). 
 
ET receptors exist in both the endothelium and VSM. Two isoforms of ET receptors, ETA 
and ETB, exist, with ETA showing affinity for ET-1 over ET-2 and ET-3 and ETB showing 
no selectivity for any form of ET (Hosoda et al., 1991). The vasoconstrictor response of 
ET is usually mediated by ETA receptors on the VSM, however in the rabbit jugular vein, 
ETB also plays a role (Sumner et al., 1992). In addition to this, activation of endothelial 
ETB receptors can sometimes also mediate vasodilatation, via the NO-cGMP and COX 
pathways (Iwasaki et al., 1999; Tirapelli et al., 2005).  Activation of both ET-receptor 
subtypes is thought to be coupled to an activation of phospholipase C and this in turn leads 
to production of phosphoinositol and diacylglycerol and an increase in free cytosolic Ca
2+ 
and therefore contraction of the VSM (Takuwa et al., 1989; 1990). 
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1.6  Vasculature of the Bovine Eye 
The blood vessels that supply the bovine eye stem from the carotid artery (Prince et al., 
1960), with the external carotid artery continuing on to become the internal maxillary 
artery. The largest branch of the internal maxillary artery is the external ophthalmic artery 
and this supplies the orbit of the eye. The external ophthalmic artery generates many 
branches such as the lateral rectus muscle artery and the lacrimal artery, which nourish 
distinct parts of the eye. It eventually branches into the ethmoidal and supraorbital arteries, 
with some branches of the supraorbital artery becoming some of the dorsal anterior arteries 
(Figure 1.6). 
Importantly, some of the branches of the external ophthalmic artery form a network of 
vessels known as the external rete and this is the origin of the ciliary artery. The ciliary 
artery bifurcates into the large medial and smaller lateral ciliary artery, which run parallel 
to each other and are loosely tethered to the optic nerve. Both arteries branch before 
reaching the globe of the eye and then each further subdivides into many short posterior 
ciliary arteries. Two branches of the large medial ciliary artery each form a long posterior 
ciliary artery (LPCA), one of which travels along the medial side of the globe and the other 
travels along the lateral side. The LPCA enter the sclera superficially at first but penetrate 
fully before the equator is reached. These vessels anastamose with anterior ciliary arteries 
and form the major arterial circle of the iris, which supplies both the iris and the ciliary 
body and is well developed in the bovine eye (Prince et al., 1960). 
Within the bovine eye there are three main venous chains that allow blood to be carried 
away from the eye: the supraorbital vein, which is the largest intraorbital vein, the lateral 
orbital vein and the inferior orbital vein (Prince et al., 1960). 
1.6.1  The Bovine Intraocular LPCA 
Figure 1.7 shows a transverse section of the bovine intraocular LPCA, which was used 
throughout this study. It was dissected out and then fixed, processed and stained for light 
microscopy by Dr Ian Montgomery, a histologist in this department. Sections were then 
stained with haematoxylin and eosin (H&E), staining the cell nuclei blue and other 
structures, such as smooth muscle and endothelial cells, deep pink. Images of the vessel, at 
a magnification of x12, were then captured. The internal diameter of the vessel is 
approximately 400 μm and some erythrocytes (stained cherry red) are present in the lumen. 
A thin layer of endothelial cells can be observed surrounding the lumen, resting on a bed of Chapter 1    Introduction 
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SMC. These SMC are long, thin cells with elongated nuclei and the tunica media appears 
to consist of 5-6 layers of spindle-shaped cells, arranged concentrically. It is clear from this 
image that the tunica adventitia is much less structured than both the tunica intima and the 
tunica media. The fibroblasts and elastin fibres of the adventitia appear to be interspersed 
with darkly pigmented areas, which may be cells from the choroid, as this structure lies 
adjacent to the intraocular LPCA. 
1.7  Regulation of Ocular Vascular Tone 
1.7.1  Neural Mechanisms Regulating Ocular Vascular Tone 
1.7.1.1  Adrenergic Innervation of the Ocular Vasculature  
Adrenergic nerves have a role to play in regulating the ocular circulation. It has been 
reported that blood flow to the retina and the choroid is increased by approximately 30% 
after superior cervical ganglionectomy and is decreased by approximately 50% after 
stimulation of sympathetic nerve fibres in the cat (Weiter et al., 1973). The central retinal 
artery of the rat (Bergua et al., 2003) and the bovine ophthalmic artery (Yoshitomi & Ito, 
1994) both contain adrenergic nerve fibres.  In the bovine ophthalmic artery, neurogenic 
contractions are sensitive to guanethidine but not α- or β-adrenergic blocking agents, 
leaving the authors to speculate that ATP or NPY released as a cotransmitter may mediate 
contraction (Yoshitomi & Ito, 1994).  
1.7.1.2 Cholinergic Innervation of the Ocular Vasculature 
Histochemical studies have demonstrated the presence of nerves containing 
acetylcholinesterase in the adventitia of porcine, monkey and dog ciliary arteries (Toda et 
al., 1997, 1998, 1999). Functional studies in porcine and monkey ciliary arteries have 
suggested that ACh released from cholinergic nerves acts prejunctionally to inhibit 
vasodilatation mediated by nitrergic nerves (Toda et  al., 1997; Toda et  al., 1998). 
However, in the dog ciliary artery, ACh interferes with release of NA from sympathetic 
nerves by acting on prejunctional muscarinic receptors (Toda et al., 1999). 
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Figure 1.6  Schematic diagram of the vascular system of the bovine eye. The bovine 
intraocular long posterior ciliary artery (LPCA) originally stems from the internal 
maxillary artery, which branches to form external ophthalmic artery and then in turn forms 
the ciliary arteries. Two LPCAs run towards either pole of the globe of the eye but 
penetrate the sclera before reaching the equator to form the intraocular LPCA (adapted 
from Prince et al., 1960). Chapter 1    Introduction 
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Figure 1.7 An image of the bovine intraocular LPCA histochemically stained with H&E. 
Cell nuclei are stained blue and other structures, such as smooth muscle and endothelial 
cells, deep pink. The internal diameter (i.d.) of the vessel is approximately 400 μm. 
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1.7.1.3 Nitrergic Innervation of the Ocular Vasculature 
Prior to the development of specific antibodies for the each of the NOS subtypes, NADPH 
diaphorase was used to localise nerve tracts containing NOS enzymes histochemically. 
Positive NADPH reactions have been seen in dog ophthalmic and retinal arteries (Toda et 
al., 1993) and the posterior ciliary arteries of pigs and monkeys (Toda et al., 1997; Toda et 
al., 1998). 
Evidence from canine retinal (Toda et al., 1993) and monkey ophthalmic (Ayajiki et al., 
2000) arteries, suggests that these nitrergic nerves are likely to stem from the 
pterygopalatine ganglion. Ethanol was injected into the vicinity of the unilateral 
pterygopalatine ganglion, to determine if damage to the ganglion would impair the 
response to nitrergic nerve stimulation in the canine cerebral and retinal arteries. One week 
after treatment with ethanol, NADPH diaphorase activity was examined in the ganglia and 
in the arteries. In the ganglia, NADPH diaphorase staining in the cell bodies and nerve 
fibres was markedly decreased, compared to control tissues, and in the arteries there was 
no positive staining at all. In functional tests of the retinal artery, control tissues responded 
to nicotine with a transient contraction, followed by a dilatation. This vasodilatation was 
abolished by inhibition of NOS and restored by L-arginine. In ethanol treated tissues, a 
number of vessels did not respond to nicotine and the remainder showed a contraction. In 
birds, however, it seems that the source of nitrergic nerves innervating the ocular 
vasculature may be the ciliary ganglion (Bergua et al., 1996; Sun et al., 1994). 
1.7.1.4 Other Innervation of the Ocular Vasculature 
Gaspar et al. (2004) reported the presence of CGRP, NK1 and NK2 receptors in rabbit 
retinal arteries, which mediated CGPR and substance P-induced vasodilatation, 
respectively, although it is not clear if these have functional relevance. Nerve fibres 
showing VIP-like immunoreactivity have been described in human (Flügel et al., 1994) 
and duck choroid (Bergua et al., 1996) and monkey (Ye et al., 1990) and rat central retinal 
arteries (Bergua et al., 2003), however, again, the presence of these immunoreactive fibres 
is not indicative of a functional role in neurogenic vasodilatation.  Chapter 1    Introduction 
  40
1.7.2  Endothelial Mechanisms Regulating Ocular Vascular Tone 
1.7.2.1 NO 
Immunohistochemical and functional studies have both indicated that in a number of 
species, basal production and release of NO provides tonic vasodilator tone in the ocular 
vasculature. NADPH diaphorase staining in rat, rabbit pig and cat choroidal vessels 
suggests the presence of NOS (Flügel et al., 1994; Yamamoto et al., 1993). Furthermore, 
NOS inhibition in isolated segments of the porcine and human ophthalmic arteries leads to 
contraction of the vessel (Haefliger et al., 1993; Yao et al., 1991).  
 
1.7.2.2 PGI2 
Indomethacin inhibits a NO-independent vasodilatation in the porcine ciliary artery (Quinn 
et al., 2003), suggesting that a product of COX is responsible for this response. In the 
porcine ophthalmic microcirculation (Meyer et al., 1993) and the retinal and choroidal 
circulation of the newborn pig (Hardy et al., 1998), there is evidence that prostaglandins 
may be involved in endothelin and NO-mediated vasodilatation, respectively. However, 
Benedito et al. (1991) reported that there was no role for PGI2 in vasodilatation in the 
bovine small retinal arteries. 
1.7.2.3 EDHF 
Little work has been carried out to identify the significance of EDHF–mediated 
vasodilatation in the eye. However, the majority of current research has been in the bovine 
eye, where EDHF is an important vasodilator mechanism (McNeish et al., 2001). In the 
bovine ciliary vascular bed it mediates the endothelium-dependent vasodilator response 
induced by ACh and bradykinin. In these vessels NO mediates only a small tonic 
vasodilator action. EDHF-mediated vasodilatation in this vascular bed is blocked in a time 
and concentration-dependent manner by ascorbate (McNeish et al., 2002). In addition, an 
EDHF-mediated vasodilatation has recently been described in the porcine ciliary artery 
(Cleary et al., 2005). 
1.8  Neurogenic Control of the Ciliary Artery 
Neurogenic vasodilatation has been specifically investigated in the ciliary artery of a 
number of species. Chapter 1    Introduction 
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1.8.1  Bovine LPCA 
Wiencke et al. (1994) have previously described a uniphasic neurogenic vasodilatation in 
the bovine intraocular LPCA. In this tissue, neurogenic vasodilatation was inhibited by the 
NOS inhibitor L-NOARG which was partly reversed by addition of surplus L-arginine. 
However, the authors also reported that part of the response persisted in the presence of L-
NOARG. This was sensitive to incubation with capsaicin and the CGRP1 receptor 
antagonist, CGRP8-37. The authors suggested that CGRP released from trigeminal sensory 
fibres was responsible for the capsaicin-sensitive component of the response and that NO 
released from nitrergic nerves mediated the L-NOARG-sensitive component. 
1.8.2  Porcine LPCA 
Su  et  al. (1994) reported on neurogenic vasodilatation in the porcine LPCA. Nerve 
stimulation resulted in a frequency-dependent contraction, which was abolished by TTX. 
Addition of guanethidine abolished the contractile response to EFS and uncovered a 
relaxant response. Incubation of the vessel with L-NAME reduced the magnitude of the 
relaxation by 52%. Relaxation was restored on addition of excess L-arginine. The authors 
concluded that two neurotransmitters mediated relaxation, one of which was probably NO. 
They hypothesised that the other transmitter might be a neuropeptide such as VIP or 
CGRP.  However, although Toda and colleagues (Toda et al., 1997) described VIP-like 
immunoreactive fibres in the porcine ciliary artery, they concluded that only nitrergic 
nerves were responsible for neurogenic vasodilatation in this vessel.  
1.8.3  Canine Ciliary Artery 
Toda et al. (1999) investigated neurogenic vasodilatation in the canine ciliary artery. In 
this vessel the response to EFS was abolished by the NOS inhibitor, L-NA, and the 
inhibitor of soluble guanylate cyclase, ODQ, and could be restored by L-arginine. They 
concluded that neurogenic relaxation was mediated solely by NO in this vessel. 
1.8.4  Monkey Ciliary Artery 
Toda and co-workers (Toda et al., 1998) also investigated neurogenic vasodilatation in 
ciliary arteries from monkeys. They observed slight contractions in response to EFS in a 
small number of tissues, but relaxation in the majority. These responses were inhibited by 
TTX. The NOS inhibitor, L-NA, either abolished the relaxation, or in some cases reversed Chapter 1    Introduction 
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the relaxation to a contraction. They concluded that a nitrergic vasodilator nerve was 
heavily involved in the regulation of vascular tone in this vessel. 
1.9  Aims 
The main aims of this investigation were as follows: 
1.  To confirm the presence of vasodilator and vasoconstrictor nerves in the bovine 
intraocular LPCA. 
2.  To identify the neurotransmitters responsible for vasodilatation in this vessel and 
therefore confirm or dispute the findings of Wiencke et al. (1994). 
3.  To identify the mechanisms by which the neurotransmitters induce vasodilatation in 
the bovine intraocular LPCA. 
4.  To establish whether the NOS inhibitor, L-NMMA, inhibits both endothelium-
dependent and nitrergic nerve-mediated vasodilatation in the bovine intraocular 
LPCA. 
5.  To investigate whether the putative nNOS-specific inhibitors, AAAN and N
G-
propyl-L-arginine, specifically block the neuronal but not the endothelial isoform of 
NOS in the bovine intraocular LPCA. 
 
 
 
 
 
 
 Chapter 3   Results: Identification of Neurotransmitters 
  43
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2. 
METHODS & MATERIALS 
 
 
 
 
 
 
 
 Chapter 3   Results: Identification of Neurotransmitters 
  44
2  Methods and Materials 
2.1  Myography 
2.1.1  Historical Background of Myography 
The mechanical, morphological and pharmacological properties of small arteries are of 
great interest, as they are implicated in the physiological control of blood pressure and 
blood flow as well as the pathophysiology of hypertension. Small arteries are prearteriolar 
vessels with a diameter of <500 μm (Bloom & Fawcett, 1968). Depending on the vascular 
bed examined, at least 50% of peripheral resistance lies proximal to vessels with diameters 
of 100 μm (Mulvany & Aalkjaer, 1990). 
However, until Mulvany & Halpern (1976) adapted a technique suggested by Bevan & 
Osher (1972), information about small arteries was restricted to that obtained from 
perfusion experiments and histological examination, as traditional organ bath techniques 
were too traumatic to be successfully applied to vessels of this size. This technique, known 
as wire myography, was further developed in subsequent years (Mulvany et al., 1978; 
Mulvany & Halpern, 1977) and allows ring preparations of small arteries with an internal 
diameter of 100 – 400 μm to be investigated. 
 
Technological advances in recent years, have allowed the technique to be adapted for EFS 
experiments, with platinum electrodes embedded in the mounting jaws of the myograph 
(Angus et al., 1988).    
 
2.1.2  The Myograph 
The model of myograph used in the present study was the multi myograph model 610 M 
(Danish Myo Technology, Aarhaus, Denmark). This system has four separate chambers, 
which allows four vessels to be studied simultaneously. Each chamber can be detached 
from the myograph to allow the vessel to be mounted under a microscope. Each myograph 
unit consists of a round, acid-resistant, stainless steel bath, which holds a maximum 
volume of 8 ml (Figure 2.1). Inside the bath, two plastic mounting jaws are positioned on 
opposite sides of the chamber. One of the mounting jaws is fixed in place and connected 
via a pin to an isometric force transducer. The other jaw is moveable and is connected to a  
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Figure 2.1 Colour photographs showing (a) an individual myograph unit and (b) a view of 
the mounting jaws. The main features of the myograph, such as: the bath, the micrometer, 
the force transducer unit and the connections to the Grass 88 stimulator are highlighted in 
photograph (a). Photograph (b) displays a close-up view of the bath, containing the 
mounting jaws and the platinum electrodes. 
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micrometer, which allows the distance between jaws to be adjusted and the internal 
diameter of the vessel determined (Figure 2.1). Embedded within each of the plastic jaws is 
a small platinum electrode, which was connected to an S88 stimulator (Grass, Quincy, 
U.S.A.). These jaws, although specifically adapted for EFS experiments, can also be used 
for experiments that do not require nerve stimulation. Each unit also has a gas supply and 
suction facility mounted on a swivelling arm, which allows the bathing medium to be 
gassed with an appropriate gas mix and washed out when necessary. Both of these 
functions are controlled by a system of valves, which allows each bath to be monitored 
individually. However, bath temperature is controlled centrally and all baths are 
maintained at a pre-determined temperature (37 
oC in all experiments in this study). The 
system also contains an external thermometer, which can be inserted into the baths to 
verify the temperature. Chamber covers were used to keep the temperature and conditions 
of the mounted rings as stable as possible. There are holes in the covers to accommodate 
gassing and suction apparatus, and to allow the addition of fresh bathing medium and 
drugs. Each myograph unit was connected to a separate input port of a Powerlab 4/20 data 
acquisition system (ADInstruments, Hastings, U.K.) and this was linked to a PC. Data was 
displayed on the PC using Chart v5 software (ADInstruments, Hastings, UK). 
 
2.1.3  Calibration of the Myograph 
The myograph was calibrated regularly, especially after non-routine maintenance, as per 
the owner’s manual supplied by Danish Myo Technology (Aarhaus, Denmark). In 
summary, a 40 μm wire was mounted on the jaw connected to the force transducer, in the 
usual manner. The bath was filled with 5 ml of Krebs solution and the temperature set to 
37 
oC. The calibration bridge, balance and weight were placed on the myograph, to be 
warmed up, together with the myograph unit, for a period of 30 min. The balance was then 
placed over the bath, resting upon the bridge. The tip of the transducer arm on the balance 
was placed in the gap between  the mounting wire and the jaw. The bridge was then 
adjusted carefully so that the tip of the transducer arm was hanging freely in the gap and 
was not touching either the mounting wire or the jaw. The balance was left in this position 
for a further 30 min. The 2 g weight was then placed on the balance, in order that the force 
applied on the transducer mimicked the stretch created by the contraction of a mounted 
ring preparation. This calibrated the force transducer to an output of 9.81 mN. This process 
was then repeated for the other three myograph units. 
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2.1.4  Maintenance of the Myograph 
2.1.4.1 General Cleaning 
The myograph chamber and surroundings were cleaned after each experiment. The 
myograph bath was filled with a 10 % acetic acid solution. The acid was left for a few 
minutes to dissolve salt build-up.  A cotton swab was then used to clean all chamber 
surfaces. The acetic acid was drained away and the myograph bath and supports were 
rinsed 10 times with distilled water. 
 
2.1.4.2 Myograph Chamber Pipes 
To prevent the pipes from being blocked by salt deposits after an experiment, the chamber 
covers were removed and the vacuum pump turned on for approximately 10 seconds. Gas 
flow was not turned off until the vacuum pump was switched off. Sometimes, however, a 
blockage due to salt accumulation did occur in the gas inlet pipe. On such occasions, the 
rubber tubing section of the gas inlet pipe was disconnected and a thin piece of wire 
entered into the lumen of the metal section of the pipe. The wire was gently rotated within 
the pipe and this was enough to dislodge the blockage. The rubber tubing was then 
reconnected. 
 
2.1.4.3 Force Transducer 
As it is the most fragile component of the myograph, the force transducer must be handled 
with great care. Particular attention was taken to ensure that buffer from the bath did not 
enter the transducer housing. Consequently, the area where the force transducer arm enters 
the housing unit was sealed with high vacuum grease (Danish Myo Technology, Aarhus, 
Denmark). The seal was checked on a daily basis and replaced at least once a week 
 
2.2  Dissection of the Bovine Intraocular LPCA 
Bovine eyes were obtained from a local abattoir and transported to the laboratory within 60 
minutes of killing. Eyes were stored in Krebs solution containing (mM): NaCl, 118; KCl, 
4.7; CaCl2, 2.5; KH2PO4, 1.2; NaHCO3, 25; glucose, 11.5; which had been gassed with O2 
containing 5 % CO2, at 4
oC until required. 
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To dissect the intraocular LPCA, all excess fat and skeletal muscle was removed from the 
globe of the eye. An incision was made with a scalpel at the equator of the globe and 
scissors were used to cut around the equator. The posterior segment of the eye was 
discarded, along with the vitreous humour and lens. The choroid of the anterior portion of 
the eye was separated from the sclera and the intraocular LPCA located, running along the 
surface of the sclera. The area of sclera surrounding the vessel was cut away from the rest 
of the eye and carefully pinned to a dissecting dish (a large petrie dish with a Sylguard-
covered base, suitable for securing tissue samples) containing cold, gassed Krebs solution. 
Dissection was carried out under a microscope (Vickers, York, UK) with an external light 
source (Leica, Wetzlar, Germany) at x10 magnification. To avoid damage to the vessel, the 
artery was manoeuvred by gripping the surrounding connective tissue gently with fine 
forceps (Dumont #5, Interfocus, Haverhill, UK). The vessel was cut at the proximal 
(closest to the cornea) end using fine, spring-mounted dissection scissors, with a straight, 
sharp edge (FST, Interfocus, Haverhill, UK). The cut end of the vessel was lifted gently 
and the underlying connective tissue, tethering the vessel to the sclera, was cut away. By 
progressively cutting away the underlying tissue, whilst lifting the freed section of the 
vessel without stretching it, removal of the vessel from the sclera was fairly simple. The 
distal end of the vessel was cut, just as it entered into the sclera. The whole vessel was 
carefully removed and stored in gassed Krebs solution at 4
oC until required.  
 
2.3  Mounting Procedure 
The bovine intraocular LPCA was placed in a dissecting dish containing Krebs solution. A 
2 mm segment was cut using spring-mounted dissection scissors, for mounting on the 
myograph. The vessel was held in position using fine forceps, grasped in the left hand. To 
avoid damage to the vessel during the mounting procedure, the artery was held in place by 
gripping the surrounding connective tissue and never the vessel itself.  A 5 cm length of 40 
μm tungsten wire (Danish Myo Technology, Aarhaus, Denmark) was held by another pair 
of fine forceps in the right hand. The tip of the wire was inserted into the proximal end of 
the artery lumen and gently guided through the lumen until the tip exited the distal end. 
The wire was fed through the lumen, until the vessel sat approximately half way along the 
wire. Care was taken to ensure that the wire remained in the centre of the lumen at all 
times, so that the endothelium remained intact. In some vessels, access to the lumen was 
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wire was used to gently tease apart the vessel walls. An individual myograph chamber was 
placed under the microscope with the micrometer on the left hand side and 5 ml of Krebs 
solution was added to the bath.  
 
The stages of mounting the vessel are shown in Figure 2.2 and are described as follows: (a) 
The wire skewering the lumen was carefully lifted from the dissection dish using forceps 
and placed between the jaws of the myograph, ensuring that the segment of intraocular 
LPCA sat in the gap between the prongs of the jaws. (b) The jaws were brought together 
until the wire was held securely without additional help from the forceps. (c) The distal 
section of the wire was then bent to the left, towards the micrometer and wrapped in an 
anti-clockwise manner around the distal fixing screw. The screw was then tightened. (d) 
The proximal section of wire was bent to the left and wrapped in a clockwise manner 
around the proximal fixing screw, which was then tightened. (e) The jaws were opened 
slightly and a second 5 cm length of tungsten wire was carefully passed through the lumen, 
in parallel to the existing wire. Care was taken not to stretch the vessel wall, damage the 
endothelium or cross the wires. The jaws were then closed again, holding the second wire 
in place. (f) The distal section of the wire was bent to the right, towards the force 
transducer and wrapped in a clockwise fashion around the fixing screw. The screw was 
then tightened. (g) The proximal section of the wire was bent to the right and wrapped 
around the fixing screw in an anti-clockwise manner and the screw tightened. All 
superfluous lengths of tungsten wire were trimmed and removed from the bath. The jaws 
were then adjusted so a small but distinct space was visible between the intralumenal wires 
(Figure 2.3).  
 
The chamber was then returned to the myograph unit and plugged into the appropriate myo 
interface. A chamber cover was placed over the bath and the gas supply/suction unit placed 
into the bath. This process was repeated with the three remaining chambers. Prior to 
mounting the vessels, the temperature of the unit was set to 37 
oC. The tissues were then 
left for 30 minutes to equilibrate. 
 
2.4  Setting Transmural Stretch 
All experiments were conducted at a level of stretch equivalent to a transmural pressure of 
100 mmHg, as this is equivalent to the pressure experienced by the bovine intraocular 
LPCA in vivo. The degree of stretch was determined for each vessel prior to the beginning 
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Figure 2.2 Schematic visualising the stages of mounting a 2 mm section of bovine 
intraocular LPCA on a wire myograph, as described in the text. Adapted from the multi 
myograph 610 owners manual (Danish Myo Technology, Aarhaus, Denmark). 
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Figure 2.3 Schematic showing final stage of the mounting process (stage g in Figure 2.2). 
At this time, all superfluous lengths of tungsten wire had been trimmed and removed. The 
jaws were adjusted so a small but distinct space was visible between the intralumenal wires 
(adapted from Wang et al., 2000). 
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LaPlace’s law states that the pressure (P) within a sphere is proportional to wall tension (T) 
and is inversely proportional to the internal radius (r): 
 
P = 
r
T 2
 
 
 
T is defined as stress (S) multiplied by wall thickness (w). Stress is the force per unit cross 
sectional area of wall. Consequently, LaPlace’s law can also be written as: 
 
P = 
r
Sw 2
 
 
Therefore, LaPlace’s law states that as the radius of a sphere decreases, the magnitude of 
the inward component of the wall stress increases. This, in turn, increases pressure 
generated within the sphere. 
 
An expanded version of this equation was used to determine the degree of stretch to apply 
in order to obtain the required pressure equivalent (Pi). The Pi is an estimate of the force 
needed to extend the vessel to the internal circumference (IC) and set pressure, as seen in 
vivo:  
 
Pi = wall tension/IC/(2xπ) 
 
To determine the IC of each vessel, the IC of the vessel at point X0 (the point when the 
intralumenal wires are touching) was first established. As each wire had a diameter of 40 
μm, the following calculation was employed: 
 
(2 + π) x 40 
 
Therefore, at X0 the IC was 205.6 μm. A note of the micrometer reading at X0 was also 
made. The IC was further dependent on point Xi, which is the point where the wires are 
apart and initial tension has been applied to the vessel. The micrometer reading at Xi was 
noted. IC was finally calculated using the following equation: 
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The IC value was then converted from μm into mm in order to calculate Pi. Wall tension 
(T) can be described as force (F) divided by wall length (L). In this situation wall length is 
doubled to account for the upper and lower wall, so: 
 
T = 
L
F
2
 
 
Pi = wall tension/IC/(2xπ) 
 
Pi = 
IC
xT x ) 2 ( π
 
 
Pi = 
LxIC
xF x
2
) 2 ( π
 
 
The Pi was calculated in KPa and given that the pressure exerted by 1 mm column of 
mercury (1 mmHg) is 133 Pa, the Pi was divided by 0.1333 to calculate the pressure in 
mmHg. If the tension was too low, more tension was applied by moving the jaws further 
apart. The Pi value was then recalculated, until a value of approximately 100 mmHg was 
obtained. An excel spreadsheet was established based on these principles, to automatically 
calculate the Pi for a given set of X0 and Xi values.  
 
2.5  Experimental Protocols  
2.5.1  Stimulation  
Rings of bovine intraocular LPCA were mounted, as previously described, on myograph 
jaws containing a pair of parallel platinum electrodes for EFS. EFS, consisting of square 
wave pulses (10 - 15 V, 0.3 ms pulse width, 10 s train length, 0.5 - 32 Hz), was delivered 
from an S88 stimulator (Grass, Quincy, U.S.A.). Stimulation parameters were designed to 
evoke maximal neurogenic and minimal myogenic response. TTX; (Narahashi et al., 1964; 
0.1 μM) was used to confirm the neurogenic origin of responses obtained. All experiments 
were carried out in the presence of tone induced by the thromboxane A2 mimetic, U46619 
(0.1 – 1 μM), and adrenergic neurone blockade using guanethidine (Page & Dustan, 1959; 
30 μM).  The concentration of U46619 used was chosen to give a submaximal level of tone 
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voltage-response curve (10 – 15 V) was constructed for each ring of bovine intraocular 
LPCA, to determine the optimal stimulation strength for that tissue. 
 
2.5.2  Stimulation in the Absence of Tone 
Early in the project, frequency-response curves were generated in a small number of rings, 
in the absence of U46619-induced tone, to investigate if a contractile response to EFS 
could be obtained in the bovine intraocular LPCA. A control frequency-response curve 
was obtained, followed by a curve generated in the presence of the NOS inhibitor, L-
NAME (Hobbs & Gibson, 1990; 100 μM), to determine if NO released spontaneously 
from endothelial cells or from nerves by EFS suppressed neurogenic constriction. A final 
curve was then obtained in the presence of the adrenergic neurone blocker, guanethidine 
(30 μM), and L-NAME (100 μM) to determine if neurogenic contraction was adrenergic. 
 
2.5.3  Endothelium-Denudation  
The role of the endothelium in both, bradykinin-mediated vasodilatation and neurogenic 
vasodilatation was investigated. To remove the endothelium, a human hair was passed 
through the lumen of the isolated vessel and rotated gently for 2 minutes. The vessel was 
then mounted on the myograph jaws as normal. As the endothelium had to be removed 
prior to mounting, a different set of bovine intraocular LPCA rings had to serve as control 
tissues. These endothelium-denuded rings then followed the normal protocol for generating 
frequency-response curves (as described below), or in the presence of U46619-induced 
tone, were subjected to bradykinin (1 μM). 
 
2.5.4  Frequency-Response Curves 
A control frequency-response curve (0.5 – 32 Hz) was obtained for each vessel before a 
second curve was generated in the presence of the appropriate blocking agent. A period of 
at least 5 minutes, or until the vessel had regained a stable level of tone, was observed 
between each stimulation. In time-matched controls, where the second curve was also 
generated under control conditions, there was no statistically significant difference 
between the first and second curves. 
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2.5.5  Stimulation at a Single Frequency of 16 Hz 
In some groups of experiments, a full frequency-response curve (0.5 – 32 Hz) was not 
performed and instead tissues were stimulated at a single frequency of 16 Hz only. This 
allowed a large number of potential blocking agents to be screened, without being a time-
consuming process. Stimulation was carried out at 16 Hz and not the optimal stimulation 
value of 32 Hz, as repeated stimulation at the higher value often led to a loss in vessel tone 
because the level of tone did not return to pre-stimulation level following EFS induced- 
vasodilatation. As before, all experiments were carried out in the presence of tone induced 
by the thromboxane A2 mimetic, U46619 (0.1 – 1 μM), and adrenergic neurone blockade 
using guanethidine (30 μM). The same stimulation parameters were also used (10 - 15 V, 
0.3 ms pulse width, 10 s train length). In these experiments, EFS was delivered at the 
single frequency of 16 Hz at 15 min intervals. When reproducible neurogenic 
vasodilatation had been obtained the appropriate blocking agent was then added and 
subsequent effects on neurogenic vasodilatation noted. 
2.5.6   Concentration-Response Curves and Desensitisation of Receptors 
In experiments where concentration-response curves were produced, they were generated 
in cumulative fashion. Protocols involving desensitisation of receptors were used to 
investigate the involvement of various putative neurotransmitter substances in the response 
to EFS. This was carried out in a number of ways. In order to investigate the potential role 
of VIP in neurogenic vasodilatation, 0.3 μM VIP was introduced to the myograph bath to 
promote vasodilatation and the tone was allowed to stabilise following loss of the dilator 
response. The same concentration of the peptide was added again and lack of response was 
taken as an indication that receptors had become desensitised (Toda, 1982). In contrast, 
desensitisation to substance P (Fukuhara et al., 1998) was established by constructing a 
concentration response curve (0.1 nM – 0.1 μM) to the peptide, during which complete 
desensitisation occurred. The P2X agonist, α-β-methyleneATP, was used to desensitise 
P2X receptors and therefore determine if they were involved in ATP-mediated dilatation of 
the bovine intraocular LPCA (Corr & Burnstock, 1994). 10 μM α-β-methyleneATP was 
introduced to the myograph bath, which promoted vasoconstriction. Following this, the 
tone was allowed to stabilise and this process was repeated until a lack of constrictor 
response was taken as an indication that receptors had become desensitised. This usually 
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2.6  Role of NO in Neurogenic Vasodilatation 
Initially, frequency-response curves were carried out in the presence of L-NAME (100 
μM) and ODQ (Garthwaite et al., 1995; 0.3 μM), to determine the role of NO and soluble 
guanylate cyclase, respectively, in neurogenic vasodilatation. To investigate the 
mechanism of EFS-induced vasodilatation, frequency-response curves were also 
performed in the presence of the PDE5 inhibitors, zaprinast (Bowman & Drummond, 
1984; 10 μM) and sildenafil (Boolell et al., 1996; 1 μM), to determine if cGMP played a 
role. In addition to this, single stimulation experiments were carried out using the PKG 
inhibitors, Rp-8-Br-PET-cGMPS (Butt et al., 1995; 30 μM) and KT5823 (Wyatt et al., 
1991; 10 μM), and the PKA inhibitors, Rp-8-Br-cAMPS (Gjertsen et al., 1995; 50 – 100 
μM) and H89 (Combest et al.,  1988; 10 μM), to determine the role of PKG and PKA, 
respectively.  
 
Additionally, in a separate series of experiments to assess the ability of various NOS 
inhibitors to block nitrergic nerve-mediated vasodilatation in the bovine intraocular LPCA, 
frequency-response curves were generated in the presence of the non-specific NOS 
inhibitor, L-NMMA (Hibbs et al., 1987), and the putative nNOS inhibitors, AAAN (Hah et 
al., 2001) and N
G-propyl-L-arginine (Zhang et  al., 1997a). In some experiments, the 
concentration dependence of the ability of NOS inhibitors to inhibit neurogenic 
vasodilatation was examined. In such experiments, EFS was delivered at a single 
frequency of 16 Hz (as previously described in section 2.5.5). When reproducible 
neurogenic vasodilatation had been obtained, the effects of increasing concentrations of L-
NAME (0.1 – 100 μM), L-NMMA (10 μM – 1 mM) or N
G-propyl-L-arginine (0.1 – 100 
μM) were examined. Other experiments were conducted to determine if L-arginine or L-
NMMA could inhibit the blockade of neurogenic vasodilatation induced by L-NAME. In 
these experiments, reproducible neurogenic vasodilatation at 16 Hz, was first obtained in 
the presence of either L-arginine or L-NMMA (both 1 mM) before examining the effects 
of increasing concentrations of L-NAME (0.1 μM – 1 mM). 
 
2.7  Role of CGRP in Neurogenic Vasodilatation 
A frequency-response curve, following incubation of the vessels for approximately 20 min 
with the sensory nerve excitotoxin, capsaicin (Jancsó et al., 1967; 1 μM), which causes the 
release and depletion of both CGRP and substance P from nerve terminals was utilised to 
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this a concentration-response curve to CGRP (0.1 – 300 nM) was performed in the 
presence of the CGRP1 receptor antagonist CGRP8-37 (Chiba et al., 1989; 1 and 5 μM) to 
determine if CGRP8-37  could successfully inhibit CGRP-induced vasodilatation in the 
bovine intraocular LPCA. Following this, frequency-response curves were generated in the 
presence of CGRP8-37 (1 and 5 μM), to explore the involvement of CGRP in neurogenic 
vasodilatation. 
2.8  Role of Substance P in Neurogenic Vasodilatation 
Following the experiments carried out in the presence of capsaicin, a frequency-response 
curve was generated in the presence of receptors desensitised to substance P (as described 
in section 2.5.6) to further determine the role of this neuropeptide in neurogenic 
vasodilatation. Additionally, a frequency-response curve was obtained in the presence of 
the NK1 receptor antagonist, L-733,060 (Seabrook et al., 1996; 0.3 μM). 
2.9  Role of VIP in Neurogenic Vasodilatation 
A number of strategies were employed to examine the role of VIP in neurogenic 
vasodilatation. Initially a frequency-response curve was generated in the presence of 
receptors desensitised to VIP (as described in section 2.5.6), to determine whether 
neurogenic vasodilatation was still possible, when dilatation in response to exogenous VIP 
was inhibited. A separate group of vessels were incubated with the protease, α-
chymotrypsin (Morris, 1993; 10 U ml
-1), in order to break down VIP present in the nerve 
terminals, and then a frequency-response curve generated. Furthermore, concentration-
response curves to VIP (0.1 – 300 nM) in the presence of the KATP channel blocker, 
glibenclamide (Schmid-Antomarchi et al., 1987; 10 μM), and VIP antiserum (raised in 
rabbit; active against rat, cat, porcine, bovine, monkey and human VIP; Matthew et al., 
1997; dilution 1:250) were performed, to determine if either inhibited VIP-mediated 
dilatation in the bovine intraocular LPCA. Following this, frequency-response curves were 
also obtained in the presence of VIP antiserum (dilution 1:250, incubated for 2 hr) and 
glibenclamide (10 μM) to investigate the involvement of VIP in neurogenic vasodilatation. 
2.10  Role of ATP in Neurogenic Vasodilatation 
Concentration-response curves to ATP (10 nM - 30 μM) were carried out in the presence 
of the P2Y receptor antagonists, suramin (Dunn & Blakeley, 1998), PPADS (Lambrecht et 
al., 1992), and reactive blue 2 (Burnstock & Warland, 1987b) in order to determine if they Chapter 3   Results: Identification of Neurotransmitters 
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blocked ATP-induced vasodilatation in the bovine intraocular LPCA. A concentration-
response curve to ATP was also carried out in the presence of receptors desensitised to α-
β-methyleneATP (as described in section 2.5.6) to establish if P2X receptors mediated 
ATP-induced vasodilatation in this vessel. A frequency response curve was also 
constructed in the presence of suramin (500 μM), to explore the involvement of ATP in 
neurogenic vasodilatation. 
2.11  Role of K
+ Channels in Neurogenic Vasodilatation 
A number of specific and non-specific K
+ channel inhibitors were utilised to determine if 
K
+ channels were involved in the mechanism of neurogenic vasodilatation in the bovine 
intraocular LPCA. Frequency-response curves were generated in the presence of the 
inhibitor of large conductance KCa channels, iberiotoxin (Latorre et al., 1992; 0.1 μM), the 
inhibitor of large and intermediate KCa channels and KV channels, charybdotoxin (Grissmer 
et al., 1994; Miller et al., 1985; 0.1 μM), the inhibitor of small conductance KCa channels, 
apamin (Blatz & Magleby, 1986; 0.1 μM), and the KATP channel inhibitor, glibenclamide 
(Schmid-Antomarchi et al., 1987; 10 μM). Single stimulations at 16 Hz were carried out in 
the presence of the non-specific K
+ channel blocker, TEA (Nelson & Quayle, 1995; 10 
μM) and the inhibitor of KIR channels, BaCl2 (Quayle et al., 1993; 30 μM), to determine if 
the aforementioned K
+ channels played a role in neurogenic vasodilatation. 
2.12  Ability of NOS Inhibitors to Block Endothelium-Dependent, NO-Mediated 
Vasodilatation 
In order to assess the ability of the non-specific NOS inhibitiors, L-NAME and L-NMMA, 
and the putative nNOS inhibitors, N
G-propyl-L-arginine and AAAN to inhibit eNOS, in 
addition to nNOS, in the bovine intraocular LPCA, endothelium-dependent dilatation was 
evoked using bradykinin (1 μM) in tissues with U46619 (0.1 μM)-induced tone. To ensure 
that only the nitric oxide-mediated vasodilatation was investigated, the tissues were treated 
with apamin (0.1 μM) and charybdotoxin (0.1 μM) to block EDHF and indomethacin (10 
μM) to inhibit cyclo-oxygenase. The effects of NOS inhibitors L-NAME, L-NMMA, 
AAAN and N
G-propyl-L-arginine (all 100 μM) were then examined on bradykinin-
induced, NO-mediated dilatation. 
 
In a further group of experiments, the concentration dependence of the ability of N
G-
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was examined. In the presence of U46619 (0.1 μM)-induced tone, endothelium-dependent 
dilatation was induced using bradykinin (1 μM). To ensure that only the NO-mediated 
vasodilatation was investigated, the tissues were treated with apamin (0.1 μM) and 
charybdotoxin (0.1 μM) to block EDHF and indomethacin (10 μM) to inhibit cyclo-
oxygenase. The effects of increasing concentrations of N
G-propyl-L-arginine (0.1 – 100 
μM) were then examined on bradykinin-induced, NO-mediated dilatation. 
 
2.13  Use of Papaverine 
At the end of all experimental protocols, papaverine (500 μM) was added to determine the 
level of tone that had been present and all relaxations were expressed as a percentage of 
this active tone. 
2.14  Histological Staining 
Samples of bovine intraocular LPCA were dissected out as described previously (section 
2.2) and then fixed, processed and stained for light microscopy using the following 
schedule. Sections were stained with H&E. This stained cell nuclei blue and other 
structures, such as smooth muscle and endothelial cells, deep pink. 
2.14.1  Fixation of Bovine Intraocular LPCA Samples 
Vessels were bathed in 10% formalin for 18 hours at room temperature and then washed in 
running tap water for a few minutes. The vessels were then placed in 70% ethanol for two 
thirty-minute periods, 90% ethanol for four thirty-minute periods and 100% ethanol for a 
further four thirty-minute periods. The next stage was to incubate the vessels in Tissue-
Clear (Sakura Finetek, Zoeterwoude, Netherlands) for two fifteen-minute periods. The 
tissues were then placed in liquid paraffin wax for two periods of two hours duration. The 
tissues were then embedded in cassettes using fresh paraffin wax. 
 
2.14.2  Sectioning of Bovine Intraocular LPCA Samples 
Embedded specimens were trimmed and then cooled on ice before sectioning at 5 µm 
using a Leica RM2035 microtome (Leica, Wetzlar, Germany) with Accu-Edge low profile 
microtome blades (Sakura Finetek, Zoeterwoude, Netherlands). The sections were floated 
on distilled water at 36 
oC, and then mounted on poly-L-lysine coated microscope slides 
(Sigma, Poole, UK). The slides were then dried overnight at 36 
oC.  Chapter 3   Results: Identification of Neurotransmitters 
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2.14.3  H&E Staining of Bovine Intraocular LPCA. 
The slides were placed in Tissue-Clear for three two-minute periods and then placed in 
100% ethanol for three two-minute periods, 90% ethanol for three two-minute periods and 
70% ethanol for two minutes. They were then washed in gently running tap water for 
several minutes and placed in haematoxylin (Mayer, 1903) for five minutes and rinsed in 
running tap water for a further five minutes. The slides were then bathed in a 1% aqueous 
eosin solution for two minutes and rinsed briefly in running tap water. They were then 
briefly rinsed in 70% ethanol and then 90% ethanol, before being placed in 90% ethanol 
for two periods of two minutes. The slides were then bathed in 100% ethanol for three two-
minute periods.  The final stage was to place the slides in Tissue-Clear for three two-
minute periods and then mount them with the synthetic mounting media D.P.X. (Sigma, 
Poole, UK). 
2.15  Drugs and Solvents 
α-chymotrypsin, α-β-methyleneATP (α-β-methyleneadenosine-5’triphosphate lithium salt), 
apamin (from bee venom), AAAN (N-[(4S)-4-amino-5-[(2-aminoethyl)amino]pentyl]-N'-
nitroguanidine tris(trifluoroacetate) salt  , ATP (adenosine-5’triphosphate disodium), 
barium chloride dihydrate crystalline, bradykinin triacetate, capsaicin (8-methyl-N-
vanillyl-trans-6-nonenamide), CGRP8-37, DMSO (dimethyl sulfoxide), guanethidine 
sulphate, indomethacin, L-arginine, L-NAME (N
G-nitro-L-arginine methyl ester), L-
NMMA (N
G-monomethyl-L-arginine acetate salt), papaverine hydrochloride, PPADS (4-
[[4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-1,3 
benzenedisulfonic acid tetrasodium salt), reactive blue 2 (1-amino-4-[[4-[[4-chloro-6-[[3 
(or 4)-sulfophenyl]amino]-1,3,5-triazin-2-yl]amino]-3-sulfophenyl]amino]-9,10-dihydro-
9,10-dioxo-2-anthracenesulfonic acid), Rp-8-Br-cAMPS (8-bromoadenosine-3’,5’-cyclic 
monophosphorothioate Rp-isomer), Rp-8-Br-PET-cGMPS (Rp-8-Bromo-β-phenyl-1,N
2-
ethenoguanosine 3’:5’-cyclic monophosphorothioate sodium salt), substance P, suramin, 
tetraethylammonium chloride (TEA), U46619 (9,11-dideoxy-11α,9α-epoxy-
methanoprostaglandinF2α), VIP, VIP antiserum (rabbit anti-vasoactive intestinal peptide) 
and zaprinast (M&B 22948) were all obtained from Sigma (Poole, U.K.). CGRP, H89 
dihydrochloride and KT5823 were all obtained from Merck Biosciences (Nottingham, 
U.K.). Charybdotoxin and iberiotoxin were obtained from Latoxan (Valence, France). 
Ethanol (absolute) was purchased from Fisher Scientific (Loughborough, UK). 
Glibenclamide was purchased from Tocris (Avonmouth, UK). L-733,066 ((2s,3s)-3-[(3,5-
bis(trifluoromethyl)phenyl)methoxy]-2-phenylpiperidine hydrochloride) was purchased Chapter 3   Results: Identification of Neurotransmitters 
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from Sigma (Schnelldorf, Germany). Levcromakalim was a gift from GlaxoSmithKline 
(Harlow, UK). ODQ (1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one) and N
G-propyl-L-
arginine were obtained from Alexis Biochemicals (Nottingham, U.K.). Sildenafil (Viagra) 
was a gift from Pfizer (Sandwich, UK). TTX was purchased from Biomol (Plymouth 
Meeting, U.S.A.).  
All drugs were dissolved and diluted in 0.9% saline, with the following exceptions: 
capsaicin (1 mM), glibenclamide (1 mM) and N
G-propyl-L-arginine (100 mM) in 100% 
ethanol; levcromakalim (10 mM) in 70% ethanol; U46619 (1 mM) in 50% ethanol; 
indomethacin (1 mM) in Na2CO3 (1 M); TTX (1 mM) in 0.1 M acetic acid; CGRP (300 
μM) and CGRP8-37 (300 μM) in 1% acetic acid; ODQ (1 mM), L-733,060 (100 μM), H-89 
(1 mM) and KT5823 (1 mM) in DMSO. 
 
2.16  Statistical Analysis 
Results are expressed as the mean ± s.e.mean of n observations, each from a separate 
vessel from a different eye. Statistical comparisons were made using one-way analysis of 
variance (ANOVA) and the Bonferroni post-hoc test and confirmed using the Kruskal-
Wallis test. When necessary, further statistical analysis was carried out using the repeated 
measures General Linear Model test and the Wilcoxon Signed Ranks test. All statistics 
were performed with the aid of a computer program, Prism (GraphPad, San Diego, 
U.S.A.). A probability (P) less than or equal to 0.05 was considered significant. 
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3  Identification of Neurotransmitters Mediating Neurogenic 
Vasodilatation 
3.1  Determination of Stimulation Parameters 
Preliminary experiments were carried out to determine the stimulation parameters required 
to obtain a neurogenic response in the bovine intraocular LPCA. The following initial 
experiment was carried out using untested parameters, merely to establish if EFS evoked 
dilatation in the bovine LPCA.   
In the presence of submaximal U46619 (0.1 μM)–induced tone and the adrenergic neurone 
blocker, guanethidine (30 μM), EFS (15 V, 16 Hz, 0.3 ms pulse width, 10 s train length) of 
bovine intraocular LPCA rings evoked dilatation that was biphasic in nature (Figure 3.1). 
The optimal times for the first and second components of dilatation to occur were 10 s and 
50 s, respectively. Therefore all subsequent work involved two measurements, made at 10 
s and 50 s, so that pharmacological analysis of each component was possible.  
3.1.1  Voltage-Response Curve 
As EFS in the presence of U46619-induced tone evoked dilatation, the next stage was to 
establish the optimum stimulus strength required to obtain maximum dilatation. A voltage 
response curve (10 - 18 V, 16 Hz, 0.3 ms pulse width, 10 s train length) was constructed in 
the presence of guanethidine (30 μM). Dilatation occurred optimally at 18 V (Figure 3.2), 
with responses of 16 ± 2% and 27 ± 4% (n=16) for the first and second components, 
respectively. Furthermore, to determine that the response to EFS was entirely neurogenic, a 
second voltage response curve (5 – 25 V, 16 Hz, 0.3 ms pulse width, 10 s train length) was 
carried out in the presence of the neurotoxin TTX, (Narahashi et al., 1964; 0.1 μM). Both 
first and second components were completely inhibited in the presence of TTX when the 
stimulus strength was between 5 and 15 V (n=8, Figure 3.3). However, between 15 and 20 
V a non-neurogenic, vasodilator response developed (Figure 3.3) and first (4 ± 5%) and 
second (24 ± 5%) components were observed. Therefore, the maximum stimulus strength 
employed in all subsequent experiments was 15 V and all experimental protocols were 
designed to include a voltage-response curve for each set of tissues. 
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Figure 3.1 The biphasic relaxant response of bovine intraocular LPCA rings to EFS (15 V, 
16 Hz, 0.3 ms pulse width, 10 s train length). The response was generated in the presence 
of U46619 (0.1 μM) and guanethidine (30 μM). The first solid line marker indicates the 
onset of stimulation; the second (at 10 s) represents both the end of the stimulation period 
and the peak of the first component of dilatation. The third line (at 50 s) indicates the peak 
of the second component of relaxation. (a) The control biphasic response. (b) Both 
components of dilatation were abolished by TTX (0.1 μM).   
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Figure 3.2 Voltage - response curves to EFS (10 – 18 V, 16 Hz, 0.3 ms pulse width, 10 s 
train length) in control bovine intraocular LPCA rings. The response was generated in the 
presence of U46619 (0.1 μM) and guanethidine (30 μM). The first (a) and second (b) 
components measured at 10 s and 50 s, respectively, both increased in magnitude in a 
voltage-dependent manner, optimally at 18 V. Data are mean±s.e. mean; n=16.   
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Figure 3.3 Voltage - response curves to EFS (5 – 25V, 16 Hz, 0.3 ms pulse width, 10 s 
train length) in bovine intraocular LPCA rings in the presence of TTX (0.1 μM). The 
response was generated in the presence of U46619 (0.1 μM) and guanethidine (30 μM). 
The first (a) and second (b) components of dilatation measured at 10 s and 50 s 
respectively, were inhibited in the presence of TTX at lower voltages (5 – 15 V). However, 
at voltages above 15 V a non-neurogenic dilatation was observed. For this reason, the 
stimulation strength was never increased above 15 V for the remainder of the EFS 
experiments.  Data are mean±s.e. mean; n=8. 
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3.1.2  Frequency-Response Curve 
A frequency-response curve was generated (10 - 15 V, 0.5 - 32 Hz, 0.3 ms pulse width, 10 
s train length) to determine the optimum frequency for stimulation (n=21, Figures 3.4 and 
3.5). The dilatation was maximally observed for both first (10 s) and second components 
(50 s) at 32 Hz (32 ± 3% and 21 ± 2%, respectively). 
3.1.3  Constrictor Response to EFS in the Absence of Tone 
A frequency-response curve (10 - 15 V, 0.5 - 32 Hz, , 0.3 ms pulse width, 10 s train length) 
was carried out in the absence of tone to determine if a constrictor response could be 
obtained in the bovine LPCA (Figure 3.6). Although control tissues were unresponsive to 
stimulation at any frequency (n=6, response at 32 Hz was 0.02 ± 0.10 mN), incubation 
with the inhibitor of NOS, L-NAME (Hobbs & Gibson, 1990; 100 μM), uncovered a small, 
frequency-dependent constrictor response.  The optimum frequency for contraction was 32 
Hz (0.79 ± 0.12 mN, n=11) and this was significantly different to the control response 
(P<0.001). In the presence of guanethidine (30 μM) this constrictor response was inhibited 
(0.17 ± 0.09 mN, n=9) and was undistinguishable from the control response.  
 
3.1.4  Effect of TTX on Neurogenic Vasodilatation 
To determine if dilator responses to EFS were neurogenic at all frequencies, frequency 
response curves (0.5 – 32 Hz) were generated in the absence and presence of TTX (0.1 
μM,). Both components of dilatation to EFS were abolished at all frequencies. At 32 Hz, 
the first and second components were 25 ± 3% and 19 ± 3% (n=8), respectively in control 
tissues and 1 ± 1 % and 1 ± 1% (n=8) in rings treated with TTX (P<0.001). This confirmed 
that both components of dilatation were neurogenic in origin at all frequencies (Figures 3.1 
and 3.7). 
 
3.1.5  Effect of Removal of the Endothelium on Neurogenic Vasodilatation 
The endothelium-dependent relaxant, bradykinin (1 μM), evoked powerful dilatation in 
control tissues (58 ± 4%, n=8) and this was virtually abolished in endothelium-denuded 
tissues (5 ± 1%, n=8, P<0.001, Figure 3.8). Endothelium denudation had no effect, 
however on the magnitude of the first or second components of dilatation to EFS at any 
frequency (Figure 3.9). The first and second components at the optimal frequency of 32Hz  Chapter 3   Results: Identification of Neurotransmitters 
  68
 
 
 
 
Figure 3.4 Frequency-response curves to EFS (15V, 0.5 - 32 Hz, 0.3 ms pulse width, 10 s 
train length) in control bovine intraocular LPCA rings, generated in the presence of 
U46610 (0.1 μM) and guanethidine (30 μM). Both (a) the first component of dilatation, 
measured at 10 s and (b) the second component, measured at 50 s dilate in a frequency-
dependent manner, optimally at 32 Hz. Data are mean±s.e. mean; n≥20. 
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Figure 3.5 The relaxant response of bovine intraocular LPCA rings to EFS (15 V, 0.3 ms 
pulse width, 10 s train length) over a range of frequencies from 0.5 – 32 Hz, in the 
presence of U46619 (0.1 μM) and guanethidine (30 μM). The dotted markers indicate the 
onset of stimulation and end of the stimulation period. A clear biphasic response can be 
seen at frequencies of 8 Hz and greater. A 5 minute recovery period was observed between 
stimulations. 
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Figure 3.6 Frequency-response curves showing constriction to EFS (0.5 - 32 Hz) in the 
absence of tone, in control bovine intraocular LPCA rings and in those treated with the 
inhibitor of NOS, L-NAME (100 μM) or L-NAME (100 μM) and the adrenergic neurone 
blocker, guanethidine (30 μM). There was little response to stimulation at any frequency in 
control tissues.  In the presence of L-NAME, a small frequency–dependent contraction was 
uncovered. This contraction was inhibited in the presence of guanethidine. The x-axis is 
displayed in a log scale to facilitate interpretation of the data points from 0.5 to 8 Hz.  Data 
are mean±s.e. mean; n≥6; **P<0.01 and ***P<0.001 indicate differences from control. 
 
 
 
 
 
 
 
 
 
 Chapter 3   Results: Identification of Neurotransmitters 
  71
 
 
Figure 3.7 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those treated with the neurotoxin, TTX (0.1 μM). Both (a) the first 
component of dilatation, measured at 10 s, and (b) the second component, measured at 50 
s, were abolished by TTX at all frequencies. Data are mean±s.e. mean; n=8. 
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Figure 3.8 In the presence of U46619, the addition of bradykinin (1 μM) induced powerful 
dilatation of control bovine intraocular LPCA rings. In rings where the endothelium had 
been denuded by rubbing with a human hair, relaxation to bradykinin (1 μM) was virtually 
abolished. +EC and –EC indicate the presence and absence of the endothelium, 
respectively. Data are mean±s.e. mean; n=8; ***P<0.001 indicates a difference from 
endothelium-containing rings. 
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Figure 3.9 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in endothelium denuded tissues. Neither (a) the first component of 
dilatation, measured at 10 s, nor (b) the second component, measured at 50 s, was affected 
by endothelial denudation. +EC and –EC indicate the presence and absence of the 
endothelium, respectively. Data are mean±s.e. mean; n=8. 
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were 25 ± 3% and 19 ± 3% (n=8), respectively, in control tissues and 19 ± 6% and 21 ± 
6% (n=8) in endothelium-denuded tissues. These data suggest that the responses to EFS 
are not influenced by the presence of the endothelium. 
 
3.2  Role of NO in Neurogenic Vasodilatation 
NO has previously been identified as a neurotransmitter that mediates dilatation in 
response to EFS in the bovine intraocular LPCA (Wiencke et al., 1994). Therefore, we 
initially attempted to inhibit the response to EFS using known blockers of the NO-cGMP 
pathway.  
3.2.1  Effect of L-NAME on Neurogenic Vasodilatation 
The first component of dilatation to EFS at all frequencies was abolished and even 
reversed to a small contraction by the NOS inhibitor, L-NAME (100 μM), but the second 
component remained entirely unaffected. Control dilatations at 32 Hz were 36 ± 5% and 24 
± 3% (n=12)  for first and second components, respectively. A contraction of 9 ± 4% 
(P<0.001) and dilatation of 25 ± 3% (n=12) were obtained in L-NAME treated tissues 
(Figures 3.10 and 3.11). These data suggested that the first, but not second, component of 
dilatation was mediated by NO released from nitrergic nerves. 
 
3.2.2  Effect of ODQ on Neurogenic Vasodilatation 
The inhibitor of soluble guanylate cyclase, ODQ (Garthwaite et al., 1995; 0.3 μM), also 
abolished the first component of dilatation at all frequencies (Figure 3.12). At the optimum 
frequency of 32 Hz a contraction of 9 ± 3% was obtained, compared with a dilatation of 26 
± 5% in control tissues (P<0.001, n=7). However, ODQ had no effect on the magnitude of 
the second component which was 31 ± 6% in control tissues and 33 ± 5% in treated rings, 
respectively (n=7). These data suggest that the first, but not the second component of 
dilatation, is mediated via soluble guanylate cyclase. 
 
3.3  Role of CGRP in Neurogenic Vasodilatation 
CGRP has also previously been proposed as a neurotransmitter that mediates dilatation in 
response to EFS in the bovine intraocular LPCA (Wiencke et al., 1994). In order to test  Chapter 3   Results: Identification of Neurotransmitters 
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Figure 3.10 The biphasic dilator response of bovine intraocular LPCA rings to EFS (15 V, 
0.3 ms pulse width, 10 s train length, 16 Hz). The first solid line marker indicates the onset 
of stimulation; the second (at 10 s) represents both the end of the stimulation period and 
the peak of the first component of dilatation. The third line (at 50 s) indicates the peak of 
the second component of dilatation. (a) The control biphasic response. (b) The first 
component is abolished by the NOS inhibitor, L-NAME (100 μM), but the second 
component is unaffected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b Chapter 3   Results: Identification of Neurotransmitters 
  76
 
 
 
Figure 3.11 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA and in those treated with the NOS inhibitor, L-NAME (100 μM). (a) The first 
component of dilatation, measured at 10 s, was abolished by L-NAME at all frequencies. 
(b) The second component, measured at 50 s, was unaffected by L-NAME. Data are 
mean±s.e. mean; n=12; **P<0.01 and ***P<0.001 indicate differences from control. 
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Figure 3.12 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those treated with the inhibitor of soluble guanylate cyclase, ODQ (0.3 
μM). (a) The first component of dilatation, measured at 10 s, was abolished by ODQ at all 
frequencies. (b) The second component, measured at 50s, was unaffected by ODQ. Data 
are mean±s.e. mean; n=7; **P<0.01 and ***P<0.001 indicate differences from control.  
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this hypothesis a number of strategies, including inhibiting release of CGRP from sensory 
nerves and utilising a CGRP1 receptor antagonist, were employed. 
 
3.3.1  Effect of capsaicin and CGRP8-37 on Neurogenic Vasodilatation 
The sensory nerve excitotoxin, capsaicin (Jancsó et al., 1967; 1 μM), induced a transient 
fall in U46619 (0.1 μM)- induced tone of bovine intraocular LPCA rings (15 ± 6%, n=8, 
Figure 3.13a), which recovered to pre-drug levels within 15 min (Figure 3.13b). A second 
addition of capsaicin (1 μM) failed to induce dilatation, but instead promoted a small 
contraction (19 ± 5%, n=8).  
Furthermore, desensitisation with capsaicin (1 μM), as above, for 1 hr prior to EFS had no 
effect on either the first or second component of dilatation at any frequency (Figure 3.14): 
first and second components at 32 Hz were 28 ± 3% and 18 ± 2% (n=12), respectively, in 
control tissues and 25 ± 1 % and 18 ± 3% in rings treated with capsaicin (n=12). From 
these data, it seems unlikely that CGRP mediates either the first or second component of 
neurogenic dilatation in this tissue. 
In the presence of U46619 (0.1 μM)- induced tone in bovine intraocular LPCA, CGRP (0.1 
– 300 nM, n=10) induced concentration-dependent dilatation, with a maximally observed 
dilatation of 90 ± 2% and a pEC50 of 8.90 ± 0.04 (Figure 3.15).  
In the presence of the CGRP1 receptor antagonist, CGRP8-37 (Chiba et al., 1989; 1 and 5 
μM, n≥8), the CGRP concentration-response curve was shifted to the right, with an 
apparent pKB of 6.65, but the maximally observed response was unaffected (Figure 3.15). 
Furthermore, pretreatment of vessels that had not been previously exposed to capsaicin 
with the CGRP1 receptor antagonist, CGRP8-37 (1 μM), abolished the capsaicin (1 μM)-
induced dilatation (reversed to a small contraction of 6 ± 7%, n=15, Figure 3.13). It is 
therefore likely that the capsaicin-induced dilatation is mediated through release of CGRP. 
The first and second components of dilatation to EFS remained unaffected at all 
frequencies in ciliary artery rings pretreated with CGRP8-37 (1 μM, Figure 3.16): control 
dilatations at 32 Hz were 25 ± 4% and 27 ± 4% (n=10) for first and second components, 
respectively, and dilatations of 24 ± 3% and 25 ± 4% (n=10) were obtained in CGRP8-37 
treated tissues. This experiment was repeated using 5 μM CGRP8-37 (n=8). Again CGRP8-37  
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Figure 3.13 The response of bovine intraocular LPCA rings to capsaicin. (a) A first 
addition of capsaicin (1 μM) induced dilatation of bovine intraocular LPCA rings that was 
transient in nature. When the response had completely resolved, a second addition of 
capsaicin (1 μM) failed to elicit relaxation, but produced a slight contraction. Furthermore, 
pretreatment with the CGRP1 receptor antagonist, CGRP8-37 (1 μM), inhibited the relaxant 
response to a first addition of capsaicin. (b) The response to capsaicin (1 μM) was transient 
and resolved within approximately 15 minutes. Data are mean±s.e. mean; n≥8; **P<0.01 
indicates a difference from the first addition of capsaicin. 
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Figure 3.14 Frequency-response curves to EFS (0.5-32 Hz) in control bovine intraocular 
LPCA rings and in those pretreated with capsaicin (1 μM). Neither (a) the first component 
of dilatation, measured at 10 s, nor (b) the second component, measured at 50 s, was 
inhibited in the presence of capsaicin. Data are mean±s.e. mean; n=12. 
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Figure 3.15 CGRP (0.1-300 nM) induced concentration-dependent relaxation of bovine 
intraocular LPCA rings and this was inhibited following pretreatment with the CGRP1 
receptor antagonist, CGRP8-37 (1 and 5 μM). Data are mean±s.e. mean; n≥8. ***P<0.001 
indicates a difference in pEC50 from control. 
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Figure 3.16 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those pretreated with the CGRP1 receptor antagonist, CGRP8-37 (1 μM). 
Neither (a) the first component of dilatation, measured at 10 s, nor (b) the second 
component, measured at 50 s, was affected by CGRP8-37. Data are mean±s.e. mean; n=10.  
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failed to inhibit EFS-induced dilatation, with first and second components at 32 Hz of 28 ± 
4% and 21 ± 3%, respectively, in control tissues and 30 ± 4% and 22 ± 4% in rings treated 
with antagonist (Figure 3.17). These experiments were also repeated in the presence of L-
NAME (100 μM) to remove the first component (Figure 3.18). Once more, CGRP8-37 
(5μM) did not inhibit the second component of dilatation to EFS. In fact, the maximally 
observed response at 32 Hz was slightly potentiated (16 ± 3% in control tissues and 24 ± 
2% in those treated with both L-NAME and CGRP8-37, P<0.01, n=11). 
 
The above data make it improbable that CGRP contributes to either the first or second 
components of neurogenic dilatation in the bovine intraocular LPCA. 
 
3.4  Role of Substance P in Neurogenic Vasodilatation 
Once we determined that the transmitter mediating the second component of dilatation to 
EFS was not CGRP, we sought to establish if it was another neuropeptide, substance P. 
3.4.1  Effect of Substance P Desensitisation on Neurogenic Vasodilatation 
Substance P (0.1 nM - 0.1 μM) induced concentration-dependent dilatation of ciliary artery 
rings, with a maximally observed dilatation of 18 ± 4% (n=8, Figure 3.19). However, rapid 
desensitisation occurred, such that it was difficult to complete a concentration-response 
curve (Figures 3.19 and 3.20).  
Following the development of complete desensitisation to substance P (0.1 μM), the first 
and second components of dilatation to EFS remained unaffected at all frequencies (Figure 
3.21). Control responses of 19 ± 4% and 22 ± 3% (n=11) were obtained for the first and 
second components, respectively, at 32 Hz. In tissues desensitised to substance P, 
responses of 22 ± 4% and 27 ± 3% (n=11), respectively, were obtained. 
3.4.2  Effect of L733,060 on Neurogenic Vasodilatation 
In the presence of the NK1 antagonist, L733,060 (Seabrook et al., 1996; 0.3 μM), the 
relaxant response to exogenous substance P (0.1 μM) was reduced from 16 ± 4% to 3 ± 2% 
(P<0.01, n=10, Figure 3.22), confirming that the antagonist is effective in this tissue. 
Nevertheless, in the presence of L733,060 (0.3 μM), the response to EFS at all frequencies 
was unchanged (n=4, Figure 3.23). At the optimum frequency of 32 Hz, control values of 
of 33 ± 4% and 40 ± 4% (n=8) were obtained for the first and second components, Chapter 3   Results: Identification of Neurotransmitters 
  84
 
 
 
Figure 3.17 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those pretreated with the CGRP1 receptor antagonist, CGRP8-37 (5 μM). 
Neither (a) the first component of dilatation, measured at 10 s, nor (b) the second 
component, measured at 50 s, was inhibited by CGRP8-37. Data are mean±s.e. mean; n=8. 
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Figure 3.18 Frequency-response curves to EFS (0.5 - 32 Hz) in bovine intraocular LPCA 
rings pretreated with the NOS inhibitor, L-NAME (100 μM), or a combination of L-
NAME (100 μM) and the CGRP1 receptor antagonist, CGRP8-37 (5 μM). (a) As expected, 
the first component of dilatation, as measured at 10 s, was abolished by L-NAME alone 
and by the combination of L-NAME and CGRP8-37, at all frequencies. (b) The second 
component, as measured at 50 s, was unaffected by L-NAME or the combination of L-
NAME and CGRP8-37, apart from at 32 Hz, where the response appeared to be potentiated. 
Data are mean±s.e. mean; n=11; **P<0.01 indicates a difference from control. 
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Figure 3.19 Substance P (0.1-100 nM) induced concentration-dependent relaxation of 
bovine intraocular LPCA rings. However, desensitisation occurred very quickly, such that 
further addition of Substance P after a concentration of 1 nM failed to promote relaxation. 
Data are mean±s.e. mean; n=8. 
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Figure 3.20 Substance P (0.1 μM) induced dilatation of bovine intraocular LPCA rings. 
However, desensitisation set in quickly, such that the response was lost within 2 min and a 
second addition of substance P (0.1 μM) failed to promote further relaxation.  
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Figure 3.21 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those desensitised to substance P (0.1 μM). Neither (a) the first 
component of dilatation, measured at 10 s, nor (b) the second component, measured at 50 
s, was inhibited by desensitisation to substance P. Data are mean±s.e. mean; n=11. 
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Figure 3.22 Addition of substance P (0.1 μM) induced dilatation of bovine intraocular 
LPCA rings. Pretreatment with the NK1 antagonist, L733,060 (0.3 μM), inhibited the 
dilator response to substance P (0.1 μM). Data are mean±s.e. mean; n=10; **P<0.01 
indicates a difference from control. 
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Figure 3.23 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those pretreated with NK1 antagonist, L-733,060 (0.3 μM). Neither (a) 
the first component of dilatation, measured at 10 s, nor (b) the second component, 
measured at 50 s, was inhibited by L-733,060. Data are mean±s.e. mean; n=8. 
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respectively. Values of 27 ± 6% and 38 ± 5% (n=8) were obtained for first and second 
components respectively, in rings treated with L733,060. Persistence of dilatation, both in 
the presence of L733,060 and in tissues desensitised to substance P, suggests that this 
neuropeptide does not contribute to either component of neurogenic dilatation. 
3.5  Role of VIP in Neurogenic Vasodilatation 
VIP is another neurotransmitter that is known to promote vasodilatation in response to EFS 
in certain tissues. Consequently, we utilised a desensitisation protocol, a protease, VIP 
antiserum and glibenclamide to determine if VIP contributed to neurogenic vasodilatation 
in the bovine intraocular LPCA. 
3.5.1  Effect of VIP desensitisation on Neurogenic Vasodilatation 
VIP (0.1 nM – 0.3 μM) induced concentration-dependent dilatation, with a maximal 
dilatation of 77 ± 3% and a pEC50 of 8.47 ± 0.11 (Figure 3.24, n=7). Addition of VIP (0.3 
μM) induced dilatation (73 ± 2%, n=12) in control rings (Figure 3.25). Approximately 25 
min later this dilatation had declined to 30 ± 2% (n=12) and a second addition of VIP (0.3 
μM) failed to promote any further dilatation (Toda, 1982; Figure 3.25). In this desensitised 
state, further U46619 (0.2 - 0.5 μM) was added to re-establish tone to the original level, but 
the first and second components of dilatation to EFS remained unaffected at all frequencies 
(Figure 3.26). First and second components at 32 Hz were 30 ± 3% and 17 ± 2%, 
respectively (n=11), in control tissues. In rings partially desensitised to VIP, first and 
second components were 34 ± 3 % and 14 ± 2% (n=11), respectively. These data suggest 
that VIP does not contribute to either component of dilatation to EFS. 
 
3.5.2  Effect of α-chymotrypsin on Neurogenic Vasodilatation 
The protease, α-chymotrypsin, was used in an attempt to degrade endogenous VIP that 
might contribute to the EFS-induced dilatation (Morris, 1993). However, addition of α-
chymotrypsin (10 U ml
-1) to LPCA rings led to a pronounced fall in tone (43 ± 3%, n=7), 
which did not recover spontaneously. Additional U46619 (0.2 μM) was used in an attempt 
to restore tone, but it continued to fall, thus preventing full frequency-response curve from 
being constructed. Nevertheless, in the continued presence of α-chymotrypsin, the first and 
second components of dilatation at a single frequency (16 Hz, Figure 3.27) remained 
unaffected: first component 13 ± 2% and 16 ± 2% for control and treated,  Chapter 3   Results: Identification of Neurotransmitters 
  92
 
 
Figure 3.24 VIP (0.1-300 nM) induced concentration-dependent dilatation of bovine 
intraocular LPCA rings. Data are mean±s.e. mean; n=7. 
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Figure 3.25 VIP (0.3 μM) induced powerful relaxation of bovine intraocular LPCA rings, 
which decayed to a lower but stable level within ~25 min. In this state, a second addition 
of VIP failed to promote further relaxation. Data are mean±s.e. mean; n=12; ***P<0.001 
indicates differences from the maximally observed relaxation induced by VIP. NS 
indicates no significant difference. 
 
 
 
 
 
 
 
 
-80
-70
-60
-50
-40
-30
-20
-10
0
1st 2nd ≥ 25 min
***
NS
V
I
P
-
i
n
d
u
c
e
d
 
d
i
l
a
t
a
t
i
o
n
 
(
%
)
***Chapter 3   Results: Identification of Neurotransmitters 
  94
 
Figure 3.26 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those partially desensitised to VIP (0.6 μM). Desensitisation to VIP did 
not inhibit (a) the first component of dilatation, as measured at 10 s, or (b) the second 
component of dilatation, measured at 50 s. Data are mean±s.e. mean; n=9. 
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Figure 3.27 Response to a single stimulation at 16 Hz in control bovine intraocular LPCA 
rings and in those pretreated with α-chymotrypsin (10 U ml
-1). Incubation with α-
chymotrypsin had no effect on either (a) the first component of dilatation, measured at 10s 
or (b) the second component, measured at 50 s. Both responses appeared to be potentiated, 
but this was not statistically significant.  Data are mean±s.e. mean; n=5. 
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respectively (n=5); and second component 9 ±.2% and 13 ± 4% for control and treated, 
respectively (n=5). The large fall in tone and resultant small responses to stimulation at 16 
Hz meant the outcome of incubation with α-chymotrypsin was unsatisfactory. However, it 
remains unlikely that VIP is involved in EFS-induced vasodilatation in the bovine 
intraocular LPCA. 
 
3.5.3  Effect of VIP antiserum on Neurogenic Vasodilatation 
VIP antiserum (Matthew et  al., 1997; dilution 1:250) failed to block dilatation to 
exogenous VIP (0.1 nM – 0.3 μM) in a satisfactory manner (n=7, Figure 3.28). Although 
the maximum response was significantly reduced from 77 ± 3% in control tissues, to 52 ± 
3% in the presence of VIP antiserum (P<0.01), the respective pEC50 values (8.47 ± 0.11 
and 8.67 ± 0.10) were not significantly different. The lower and upper portions of the VIP 
concentration-response curve were, however, unaffected by it. The addition of VIP 
antiserum also induced a sustained fall in tone of ciliary artery rings (25 ± 6%, n=7), which 
was difficult to restore to the original level with further U46619. The presence of 
antiserum also promoted a great deal of frothing in the myograph chamber making 
responses difficult to discern. In spite of these difficulties, a frequency curve (0.5 – 32 Hz) 
was constructed in the presence of VIP antiserum (Figure 3.29).  The first and second 
components of dilatation remained unaffected, however: at 32 Hz the first components 
were 22 ± 2% and 12 ± 5%, for control and treated tissues, respectively (n=8); and second 
components of 28 ± 5% and 24 ± 6%, for control and treated tissues respectively (n=8). 
3.5.4  Effect of glibenclamide on Neurogenic Vasodilatation 
Results obtained with the desensitisation protocol, α-chymotrypsin and with VIP antiserum 
were somewhat unsatisfactory, so another strategy was employed to determine if VIP 
contributed to the neurogenic relaxation of the bovine intraocular LPCA. As VIP is 
reported to mediate dilatation via KATP channels (Standen et al., 1989), the effects of the 
KATP channel blocker glibenclamide were investigated. Prior to doing this, however, 
experiments were conducted on the bovine intraocular LPCA to determine if glibenclamide 
inhibited dilatation to the KATP channel opener, levcromakalim. Indeed, in this tissue, 
glibenclamide (10 μM) powerfully inhibited dilatation to levcromakalim (0.1 nM - 30 μM, 
Figure 3.30, n=6). Thus glibenclamide was clearly an effective KATP channel blocker in the  Chapter 3   Results: Identification of Neurotransmitters 
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Figure 3.28 VIP (0.1-300 nM) induced concentration-dependent relaxation of bovine 
intraocular LPCA rings. This was slightly inhibited at high concentrations of VIP (30 and 
100 nM only) by incubation with antiVIP (1:250). Data are mean±s.e. mean; n=7; *P<0.01 
and **P<0.001 indicate differences from control. 
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Figure 3.29 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those pretreated with antiVIP (1:250 dilution). Incubation with antiVIP 
had no effect on either (a) the first component of dilatation, measured at 10 s or (b) The 
second component of dilatation, measured at 50 s. Data are mean±s.e. mean; n=8. 
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Figure 3.30 The KATP channel opener, levcromakalim (0.1 nM–30 μM), induced powerful 
relaxation of bovine intraocular LPCA rings. As expected, incubation with glibenclamide 
(1 μM), which blocks KATP channels, shifted the concentration response curve to the right 
and also reduced the maximally observed relaxation. Data are mean±s.e. mean; n=6; 
**P<0.01 and ***P<0.001 indicate differences from control. 
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Figure 3.31 VIP (0.1-300 nM) induced concentration-dependent dilatation of bovine 
intraocular LPCA rings. Incubation with glibenclamide (10 μM), which blocks KATP 
channels, did not affect relaxation to VIP. Data are mean±s.e. mean; n=6. 
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bovine LPCA. Despite this, dilatation to exogenous VIP (0.1 nM – 0.3 μM) was unaffected 
in the presence of glibenclamide (10 μM, Figure 3.31): pEC50 values of 8.47 ± 0.11 and 
8.61 ± 0.06 for control and treated tissues, respectively. Although glibenclamide did not 
block dilatation to exogenous VIP, we assessed whether it could inhibit neurogenic 
relaxation of the bovine intraocular LPCA. Glibenclamide (10 μM) failed to inhibit the 
response to EFS at all frequencies (Figure 3.32) and actually seemed to potentiate the 
second response, although this was not significant: first and second components at 32 Hz 
were 32 ± 4% and 32 ± 5% (n=6), respectively, in control tissues and 34 ± 4 % and 40 ± 
6% (n=6) in rings treated with glibenclamide. 
The above data make it unlikely that VIP contributes to either the first or second 
components of neurogenic dilatation in the bovine intraocular LPCA. 
3.6  Role of ATP in Neurogenic Vasodilatation 
The final neurotransmitter candidate investigated for involvement in neurogenic 
vasodilatation in the bovine intraocular LPCA was ATP. A number of established ATP 
receptor antagonists and other modulators were employed to test this possibility. 
3.6.1  Effect of Suramin  
Exogenous ATP (10 nM – 30 μM) induced concentration-dependent dilatation, with a 
maximally observed dilatation of 71 ± 6% (n=7, Figure 3.33) and a pEC50 of 6.38 ± 0.06. 
 
A concentration-response curve to ATP was performed in the presence of the P2Y 
purinoceptor antagonist, suramin (Dunn & Blakeley, 1998; 500 μM). However, suramin 
did not block dilatation to exogenous ATP (Figure 3.33): pEC50 values in control and 
treated tissues were 6.38 ± 0.06 and 6.14 ± 0.03, respectively (n=8).  
 
Furthermore, suramin (500 μM) did not inhibit neurogenic dilatation in the bovine 
intraocular LPCA (Figure 3.34). If anything, the response was slightly potentiated in the 
presence of suramin, but this was not significant. At 32 Hz, control responses for the first 
and second components were 22 ± 6% and 34 ± 5% (n=8), respectively. In the presence of 
suramin, the equivalent values were 29 ± 9% and 38 ± 4% (n=8). These data suggest that 
ATP does not contribute to either component of neurogenic dilatation. However, as 
suramin did not block dilatation to exogenous ATP in the bovine intraocular LPCA, other  Chapter 3   Results: Identification of Neurotransmitters 
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Figure 3.32 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those pretreated with the KATP channel inhibitor, glibenclamide (10 
μM). Neither (a) the first component of dilatation, measured at 10 s, nor (b) the second 
component, measured at 50 s, was inhibited by glibenclamide. Data are mean±s.e. mean; 
n=6. 
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Figure 3.33 ATP (10 nM-30 μM) induced concentration-dependent dilatation of bovine 
intraocular LPCA rings, which was unaffected following pretreatment with the P2Y 
receptor antagonist, suramin (500 μM). Data are mean±s.e. mean; n=8. 
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Figure 3.34 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those pretreated with the P2Y receptor antagonist, suramin (500 μM). 
Neither (a) the first component of dilatation, measured at 10 s, nor (b) the second 
component, measured at 50 s, was inhibited by suramin. It appeared to potentiate both, 
however this was not statistically significant. Data are mean±s.e. mean; n=8. 
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ATP receptor antagonists were employed to determine the role of ATP. 
 
3.6.2  Effect of PPADS 
A concentration-response curve to ATP (10 nM – 30 μM) was performed in the presence 
and absence of the P2Y receptor antagonist, PPADS (Lambrecht et al., 1992; 100 μM). As 
with suramin, PPADS did not block dilatation to exogenous ATP (Figure 3.35): the pEC50 
values in control and treated tissues were 6.38 ± 0.06 and 6.42 ± 0.05, respectively (n=10). 
These data suggests that PPADS is not an effective antagonist to ATP in the bovine 
intraocular LPCA. Experiments were therefore not conducted to determine the effects of 
this agent on neurogenic vasodilatation in the bovine intraocular LPCA. 
 
3.6.3  Effect of RB2 
Similarly, another P2Y receptor antagonist, reactive blue 2 (Burnstock & Warland, 1987b; 
300 μM) did not inhibit dilatation to exogenous ATP (10 nM – 30 μM, Figure 3.36). 
Although there was a slight rightward shift of the concentration-response curve, the pEC50 
values in control and treated tissues (6.38 ± 0.06 and 5.91 ± 0.06, respectively) were not 
significantly different (n=8). Consequently, we did not investigate effects of reactive blue 
2 on neurogenic vasodilatation in the bovine intraocular LPCA. 
 
3.6.4  Effect of α,β-methyleneATP 
A further concentration-response curve to ATP was performed in the presence of P2X 
receptor agonist, α,β-methyleneATP (Corr & Burnstock, 1994; 30 μM; Figure 3.37). In 
these experiments  α,β-methyleneATP acted as an antagonist at the P2X receptors by 
desensitising the receptor.  On the whole the response to exogenous ATP was unaffected 
by pretreatment with α,β-methyleneATP: the pEC50 values in control and treated tissues 
were 6.38 ± 0.06 and 6.22 ± 0.04, respectively. However, the response to 30 μM ATP 
appears to have been slightly potentiated in the presence of α,β-methyleneATP (n=7, 
P<0.05) 
 
As we were unable to find a suitable blocking agent for ATP in the bovine intraocular 
LPCA, we were unable to fully rule out the involvement of ATP in neurogenic 
vasodilatation in this tissue 
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Figure 3.35 ATP (10 nM-30 μM) induced concentration-dependent relaxation of bovine 
intraocular LPCA rings, which was unaffected following pretreatment with the P2Y 
receptor antagonist, PPADS (100 μM). Data are mean±s.e. mean; n=10. 
 
 
 
 
 
 
 
 
 
 
 
 
-9 -8 -7 -6 -5 -4
-90
-80
-70
-60
-50
-40
-30
-20
-10
0
10
Control
PPADS
Log [ATP] M
C
h
a
n
g
e
 
i
n
 
T
o
n
e
 
(
%
)Chapter 3   Results: Identification of Neurotransmitters 
  107
 
 
 
 
Figure 3.36 ATP (10 nM-30 μM) induced concentration-dependent dilatation of bovine 
intraocular LPCA rings, which was unaffected following pretreatment with the P2Y 
receptor antagonist,  RB2 (300 μM). Data are mean±s.e. mean; n=8.  
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Figure 3.37 ATP (10 nM-30 μM) induced concentration-dependent dilatation of bovine 
intraocular LPCA rings. Generally, this was unaffected by pretreatment with the P2X 
receptor agonist, α,β-methyleneATP (30 μM). However the response to 30 μM ATP 
appears to have been slightly potentiated in the presence of α,β-methyleneATP. Data are 
mean±s.e. mean; n=7; *P<0.05 indicates difference from control. 
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4  Identification of the Mechanism Mediating Neurogenic Vasodilatation 
In the previous chapter, it was established that neurogenic vasodilatation in the bovine 
intraocular LPCA was biphasic in nature and that the first component appeared to be 
mediated by NO released from nitrergic nerves. However, the identity of the transmitter 
that mediated the second component of dilatation remained unclear because it was not 
blocked using conventional neurotransmitter inhibitors and desensitisation protocols. 
Consequently, an attempt was made to determine the mechanism by which the unknown 
transmitter promoted dilatation.  
4.1  Role of K
+ Channels in Neurogenic Vasodilatation 
As has already been discussed, vasodilatation can be facilitated by hyperpolarisation of the 
VSM, through the opening of K
+ channels, or by activation of the cAMP or cGMP 
pathways. Consequently, an attempt was made to inhibit or potentiate these pathways using 
appropriate antagonists and other modulators, to determine if they were responsible for 
mediating the second component of dilatation. The first strategy adopted was to block a 
variety of K
+ channels to determine if they were involved. 
4.1.1  Effect of TEA on Neurogenic Vasodilatation 
The non-specific K
+ channel blocker, TEA (Nelson & Quayle, 1995; 10 mM) increased 
U46619-induced tone of intraocular LPCA rings by 0.82 ± 0.19 mN (Figure 4.1). TEA also 
appeared to potentiate the response to EFS when bovine intraocular LPCA rings were 
stimulated at a single frequency of 16 Hz (Figure 4.2): the magnitude of the first 
component of dilatation increased from 15 ± 3 %  t o  2 2  ± 3% (n=12) and the second 
component from 16 ± 3% to 21 ± 3% (n=12), however neither increase was statistically 
significant. These data suggest that non-specific block of K
+ channels did not inhibit 
neurogenic vasodilatation, therefore a number of specific K
+ channels were blocked using 
selective inhibitors. 
4.1.2  Effect of BaCl2 on Neurogenic Vasodilatation 
The inhibitor of KIR channels, BaCl2 (Quayle et al., 1993; 30 μM), caused an increase in 
U46619-induced tone of 0.39 ± 0.16 mN (Figure 4.1), upon addition to the bath. BaCl2 
failed, however, to affect either component of dilatation in response to stimulation at 16 Hz 
(Figure 4.3). Again, there was a slight, but statistically insignificant, increase in the  Chapter 4    Results: Identification of Mechanism 
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Figure 4.1 A rise in U46619-induced tone was observed upon addition of a number of K
+ 
channel inhibitors: the non-specific K
+ channel blocker, TEA (10 mM), the inhibitor of 
inward rectifier K
+ (KIR) channels, BaCl2 (30 μM), the inhibitor of large conductance KCa 
channels, iberiotoxin (0.1 μM), the inhibitor of large and intermediate KCa channels and KV 
channels, charybdotoxin (0.1 μM), and the small conductance KCa channel inhibitor, 
apamin (0.1 μM). All induced a rise in tone. Only the KATP channel inhibitor, 
glibenclamide (10 μM) did not induce a rise in tone. Data are mean±s.e. mean; n≥6.
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Figure 4.2 Dilatation in response to EFS at a single frequency (16 Hz) in control bovine 
intraocular LPCA rings and in those incubated with the K
+ channel blocker, TEA (10 mM). 
Pretreatment with TEA appeared to potentiate both (a) the first component, measured at 
10s and (b) the second component, measured at 50 s, but neither increase was statistically 
significant. Data are mean±s.e. mean; n=12. 
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Figure 4.3 Dilatation in response to EFS at a single frequency (16 Hz) in control bovine 
intraocular LPCA rings and in those pretreated with the K(IR) channel blocker, BaCl2 (30 
μM). Incubation with BaCl2 appeared to potentiate both (a) the first component, measured 
at 10s and (b) the second component, measured at 50 s, but neither increase was 
statistically significant. Data are mean±s.e. mean; n=6. 
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magnitude of the responses: the magnitude of the first component increased from 11 ± 6% 
to 13 ± 6% (n=6) and the second component from 29 ± 5% to 34 ± 3% (n=6). These data 
suggest that KIR channels do not play a role in neurogenic vasodilatation in the bovine 
intraocular LPCA. 
4.1.3  Effect of Iberiotoxin on Neurogenic Vasodilatation 
A frequency-response curve was generated in the presence of the BKCa channel inhibitor, 
iberiotoxin (Latorre et al., 1992; 0.1 μM). Addition of iberiotoxin to the bath led to an 
increase in U46619-induced tone of 2.53 ± 0.70 mN (Figure 4.1). However, iberiotoxin 
blocked neither the first nor the second component of neurogenic vasodilatation, at any 
frequency (Figure 4.4). Control dilatations at 32 Hz were 25 ± 4% and 18 ± 4% (n=8) for 
first and second components, respectively, and dilatations of 22 ± 4% and 21 ± 4% (n=8), 
respectively, were obtained in iberiotoxin-treated tissues. These data suggest that large 
conductance KCa channels do not play a role in neurogenic vasodilatation in the bovine 
intraocular LPCA. 
4.1.4  Effect of Charybdotoxin on Neurogenic Vasodilatation 
The inhibitor of BKCa, IKCa and KV channels, charybdotoxin (Grissmer et al., 1994; Miller 
et al., 1985; 0.1 μM), also caused an increase in U46619-induced tone when added to the 
bath (1.52 ± 0.29 mN, Figure 4.1). However, charybdotoxin failed to affect neurogenic 
vasodilatation at any frequencies (Figure 4.5). At the optimum frequency of 32 Hz, control 
responses for the first and second components were 25 ± 4% and 24 ± 3% (n=12), 
respectively. In the presence of charybdotoxin, the responses were unaffected and were 22 
± 3% and 19 ± 2% (n=12), respectively. These data suggest that large and intermediate 
conductance KCa and KV channels do not play a role in neurogenic vasodilatation in the 
bovine intraocular LPCA. 
4.1.5   Effect of Apamin on Neurogenic Vasodilatation 
The small conductance KCa channel inhibitor, apamin (Blatz & Magleby, 1986; 0.1 μM), 
caused a small increase in U46619-induced tone when it was added to the bath (0.70 ± 0.13 
mN, Figure 4.1). The first and second components of neurogenic vasodilatation remained 
unaffected at all frequencies in bovine intraocular LPCA rings pretreated with apamin. At  
 Chapter 4    Results: Identification of Mechanism 
  115
 
Figure 4.4 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those incubated with the inhibitor of large conductance KCa channels, 
iberiotoxin (0.1 μM). Neither (a) the first component of dilatation, measured at 10 s, nor 
(b) the second component, measured at 50 s, was inhibited by iberiotoxin. Data are 
mean±s.e. mean; n=8. 
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Figure 4.5 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those incubated with the inhibitor of large and intermediate 
conductance KCa and KV channels, charybdotoxin (0.1 μM). Neither (a) the first 
component of dilatation, measured at 10 s, nor (b) the second component, measured at 50 
s, was inhibited by charybdotoxin. Data are mean±s.e. mean; n=12. 
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Figure 4.6 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those incubated with the small conductance KCa channel inhibitor, 
apamin (0.1 μM). Neither (a) the first component of dilatation, measured at 10 s, nor (b) 
the second component, measured at 50 s, was inhibited by apamin. Data are mean±s.e. 
mean; n=6. 
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32 Hz control responses for the first and second components were 37 ± 4% and 27 ± 5% 
(n=6), respectively (Figure 4.6). In the presence of apamin the responses were 44 ± 3% and  
31 ± 5% (n=6), respectively. These data suggest that small conductance KCa channels do 
not play a role neurogenic vasodilatation in the bovine intraocular LPCA. 
4.1.6  Effect of Glibenclamide on Neurogenic Vasodilatation 
The KATP channel inhibitor, glibenclamide (Schmid-Antomarchi et al., 1987; 10 μM), had 
no affect on U46619-induced tone (0.07 ± 0.15 mN, Figure 4.1). Glibenclamide also failed 
to inhibit neurogenic vasodilatation at all frequencies, as was described in the previous 
chapter (Figure 3.32) and seemed to potentiate the second response, although this was not 
statistically significant. Control dilatations at 32 Hz were 32 ± 4% and 32 ± 5% (n=6) for 
first and second components, respectively, and 34 ± 4 % and 40 ± 6% (n=6) in rings 
treated with glibenclamide.  These data suggest that KATP channels do not play a role in 
neurogenic vasodilatation in the bovine intraocular LPCA. 
4.2  Role of cGMP in Neurogenic Vasodilatation 
As none of the specific or non-specific K
+ channel inhibitors affected either the first or 
second components of neurogenic vasodilatation, the cGMP pathway was investigated for 
its involvement. From earlier observations in the presence of L-NAME and ODQ, it was 
likely that the NO and soluble guanylate cyclase systems mediated the first but not the 
second component of dilatation. 
4.2.1  Effect of PDE5 Inhibition on Neurogenic Vasodilatation 
Addition of the PDE5 inhibitor, zaprinast (Bowman & Drummond, 1984; 10 μM), to the 
bath led to a large drop in U46619-induced tone (3.18 ± 0.66 mN) and additional U46619 
(0.1 – 0.5 μM) was used to restore it. Zaprinast potentiated the first component of 
neurogenic vasodilatation at 16 and 32 Hz (both P<0.05, Figure 4.7). At 32 Hz the 
response increased from 22 ± 8% in control tissues to 31 ± 8% in treated tissues (n=5). The 
second component was, however, unchanged in the presence of zaprinast, with responses 
at 32 Hz of 38 ± 8% in control tissues and 41 ± 10% in treated rings (n=5).  
Another PDE5 inhibitor, sildenafil (Boolell et al., 1996; 1 μM), also produced a fall in tone 
and again additional U46619 (0.1 – 0.5 μM) was used to reinstate it to the previous level. 
However, in contrast to zaprinast, sildenafil did not potentiate the first component of  Chapter 4    Results: Identification of Mechanism 
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Figure 4.7 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those incubated with the PDE5 inhibitor, zaprinast (10 μM). (a) 
Pretreatment with zaprinast significantly potentiated the first component of vasodilatation 
at 16 & 32 Hz, as measured at 10 s. (b) The second component of relaxation, measured at 
50 s, was not affected by treatment with zaprinast. Data are mean±s.e. mean; n=5. *P<0.05 
indicates a difference from control. 
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Figure 4.8 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those incubated with the PDE5 inhibitor, sildenafil (1 μM). (a) 
Incubation with sildenafil did not affect the first component of the relaxation, measured at 
10 s. (b) The second component of relaxation, measured at 50 s, appeared to be potentiated 
at frequencies of 16 and 32 Hz in the presence of sildenafil, but this was not statistically 
significant. Data are mean±s.e. mean; n=7. 
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dilatation (Figure 4.8): the magnitude of the first component in control tissues was 51 ± 
5%, compared with 46 ± 6% in rings incubated with sildenafil (n=7). Furthermore, 
incubation with sildenafil appeared to increase the magnitude of the second component of 
dilatation at 16 and 32 Hz, but this was not statistically significant: at 32 Hz the response 
was 54 ± 6% in control tissues and 65 ± 10% in treated rings (n=7). Thus zaprinast 
potentiated the magnitude of the first component, as expected, but surprisingly this was not 
the case for sildenafil. Furthermore, there is no evidence to suggest that the cGMP pathway 
mediates the second component of dilatation. 
4.2.2  Effect of PKG Inhibition on Neurogenic Vasodilatation 
As the results obtained with the PDE5 inhibitors were inconsistent, another stage of the 
cGMP pathway was blocked by inhibiting PKG. Incubation with the PKG inhibitor, Rp-8-
Br-PET-cGMPS (Butt et al., 1995; 30 μM), caused an increase in U46619-induced tone of 
0.44 ± 0.07 mN. Stimulation at a single frequency of 16 Hz in the presence of Rp-8-Br-
PET-cGMPS reduced the magnitude of the first and second component of dilatation. 
However only the first component was significantly reduced (P<0.05; Figure 4.9). The first 
component of the response was reduced from 26 ± 4% to 17 ± 3% (n=6) and the second 
component from 32 ± 10% to 21 ± 7% (n=6), in the presence of Rp-8-Br-PET-cGMPS.  
 
Although Rp-8-Br-PET-cGMPS did slightly inhibit the first component of dilatation, the 
blockade was fairly poor and so the effects of another PKG inhibitor, KT5823 (Wyatt et 
al., 1991; 10 μM), were examined (Figure 4.10). The addition of KT5823 to the bath, led 
to a decrease in tone of 1.02 ± 0.30 mN, however, this recovered spontaneously and did not 
require further addition of U46619. The first and second components of neurogenic 
vasodilatation remained unaffected at all frequencies in bovine intraocular LPCA rings 
pretreated with KT5823: first and second components were 22 ± 5% and 22 ± 6% (n=6), 
respectively, in control tissues and 21 ± 6 % and 20 ± 6% (n=6) in rings treated with the 
PKG inhibitor.  
 
The PKG inhibitors utilised, like the PDE5 inhibitors, had limited success in inhibiting the 
first and second components of EFS-mediated vasodilatation. 
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Figure 4.9 Dilatation in response to EFS at a single frequency (16 Hz) in control bovine 
intraocular LPCA rings and in those pretreated with the PKG inhibitor, Rp-8-Br-PET-
cGMPS (30 μM). Incubation with Rp-8-Br-PET-cGMPS appeared to reduce the magnitude 
of both (a) the first component, measured at 10 s, and (b) the second component, measured 
at 50 s. However only the reduction measured at 10 s was statistically significant (P<0.05). 
Data are mean±s.e. mean; n=6. 
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Figure 4.10 Dilatation in response to EFS at a single frequency (16 Hz) in control bovine 
intraocular LPCA rings and in those pretreated with the PKG inhibitor, KT5823 (10 μM). 
Neither (a) the first component of dilatation, measured at 10 s, nor (b) the second 
component, measured at 50 s, was inhibited by KT5823. Data are mean±s.e. mean; n=6. 
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4.3  Role of cAMP in Neurogenic Vasodilatation  
As inhibition of PDE and PKG failed to provide information on the mechanisms 
underlying the first and second components of neurogenic dilatation in the bovine 
intraocular LPCA, the possible involvement of the cAMP pathway was investigated.  
 
4.3.1  Effect of PKA Inhibition on Neurogenic Vasodilatation 
The PKA inhibitor, Rp-8-Br-cAMPS (Gjertsen et  al., 1995; 50 μM) caused a rise in 
U46619-induced tone of 0.72 ± 0.24 mN, when added to the bath.  Stimulation at a single 
frequency of 16 Hz in the presence of Rp-8-Br-cAMPS appeared to significantly reduce 
the magnitude of the second (P<0.05), but not the first component of dilatation (Figure 
4.11). The second component was reduced from 29 ± 3% to 17 ± 4% (n=4) in the presence 
of Rp-8-Br-cAMPS. The first component remained unchanged and control responses were 
38 ± 7%, compared with 35 ± 6% (n=4) in treated tissues.  
To determine if the second component could be further inhibited, a second group of tissues 
was incubated with a higher concentration of Rp-8-Br-cAMPS (100 μM, Figure 4.12). 
Incubation with the higher concentration of Rp-8-Br-cAMPS appeared to reduce the 
magnitude of both the first and second components of dilatation, but neither reduction was 
significant. First and second components at 16 Hz were 18 ± 6% and 29 ± 5% (n=7), 
respectively, in control tissues and 9 ± 7% and 17 ± 3% (n=7) in rings treated with the Rp-
8-Br-cAMPS. 
A second PKA inhibitor, H89 (Combest et al., 1988; 10 μM), was also used in an attempt 
to block neurogenic vasodilatation (Figure 4.13). Incubation with H89 resulted in a fall in 
U46619-induced tone of 1.79 ± 0.29 mN and it was difficult to recover this to the original 
level, even with the use of additional U46619. However, H89 had no effect on either the 
first or second components of dilatation after stimulation at a single frequency of 16 Hz.  
First and second components at 16 Hz were 20 ± 8% and 25 ± 7% (n=6), respectively, in 
control tissues and 23 ± 4 % and 23 ± 4% (n=6) in rings treated with H89.  
On the basis of the above experiments, it was not possible to determine if PKA was 
involved in either the first or second components of neurogenic vasodilatation in the 
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Figure 4.11 Dilatation in response to EFS at a single frequency (16 Hz) in control bovine 
intraocular LPCA rings and in those pretreated with the PKA inhibitor, Rp-8-Br-cAMPS 
(50 μM). (a) The first component of dilatation, measured at 10 s, was unaffected by Rp-8-
Br-cAMPS. However, (b) the second component, measured at 50 s, was partially inhibited 
by Rp-8-Br-cAMPS. Data are mean±s.e. mean; n=4; *P<0.05 indicates a difference from 
control. 
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Figure 4.12 Dilatation in response to EFS at a single frequency (16 Hz) in control bovine 
intraocular LPCA rings and in those pretreated with the PKA inhibitor, Rp-8-Br-cAMPS 
(100 μM). Incubation with Rp-8-Br-cAMPS appeared to reduce the magnitude of (a) the 
first component, measured at 10 s and (b) the second component, measured at 50 s, but 
neither reduction was statistically significant. Data are mean±s.e. mean; n=7. 
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Figure 4.13 Dilatation in response to EFS at a single frequency (16 Hz) in control bovine 
intraocular LPCA rings and in those pretreated with the PKA inhibitor, H89 (10 μM). 
Neither (a) the first component of dilatation, measured at 10 s, nor (b) the second 
component, measured at 50 s, was inhibited by H89. Data are mean±s.e. mean; n=6. 
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5  Effect of NOS Inhibitors on Neurogenic and Endothelium-Dependent 
Vasodilatation 
N
G-substituted analogues of L-arginine are routinely used to inhibit the NOS family of 
enzymes (Hobbs et al., 1999). The first of these to be introduced, L-NMMA (Hibbs et al., 
1987), is generally reported to inhibit all three isoforms of NOS in standard enzyme assays 
(Moore et al., 1996). However, there have been a number of anomalous findings regarding 
the specificity of L-NMMA. Although L-NMMA blocks nitrergic nerve mediated-
relaxation in the rat anococcygeus (Gillespie et al., 1989) and mouse anococcygeus 
(Gibson et al., 1990) muscle it does not inhibit nitrergic relaxation in the BRP muscle 
(Martin et al., 1993). Furthermore, in the BRP muscle, L-NMMA actually protects against 
block by the NOS inhibitors L-NOARG and L-NAME (Martin et al., 1993). In the bovine 
penile artery, L-NMMA also fails to inhibit nitrergic transmission but does block 
endothelium-dependent, NO-mediated vasodilatation (Liu et al., 1991). Furthermore, in the 
rat aorta, L-NMMA inhibits basal release, but not agonist-stimulated release of NO from 
the endothelium (Frew et al., 1993). Therefore, the aim of these experiments was to 
determine the effects of L-NMMA, L-NAME and the putative nNOS-specific inhibitors, 
AAAN (Hah et  al., 2001) and N
G-propyl-L-arginine (Zhang et  al., 1997a), on 
endothelium-dependent and nitrergic nerve-mediated dilatation in the bovine intraocular 
LPCA.   
 
5.1  Effect of NOS Inhibitors on Neurogenic Vasodilatation 
5.1.1  L-NAME 
As has been established in chapter 3, the first component of neurogenic vasodilatation, 
measured at 10 s, was abolished at all frequencies by the NOS inhibitor, L-NAME (Hobbs 
& Gibson, 1990; 100 μM), but the second component, measured at 50 s, was unaffected 
(Figure 3.11). Control dilatations at 32 Hz were 36 ± 5% and 24 ± 3% (n=12) for first and 
second components, respectively. In contrast, a contraction of 9 ± 4% (P<0.001) and 
dilatation of 25 ± 3% (n=12) were obtained in L-NAME-treated tissues.  
5.1.2  L-NMMA 
A frequency-response curve (10 - 15 V, 0.5 - 32 Hz, 0.3 ms, 10 s train length) was also 
generated in the presence of the L-arginine analogue, L-NMMA (Hibbs et al., 1987; 100 Chapter 5    Results: Effect of NOS Inhibitors 
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μM). In contrast to L-NAME, L-NMMA did not inhibit either the first or second 
component of neurogenic vasodilatation at any frequency (Figure 5.1): at 32 Hz responses 
of 30 ± 7% and 42 ± 9% (n=8) were obtained for the first and second components in 
control tissues, respectively, and in the presence of L-NMMA the responses were 35 ± 4% 
and 34 ± 5% (n=8), respectively. These data show that L-NMMA does not inhibit nitrergic 
nerve-mediated dilatation in the bovine intraocular LPCA. 
 
5.1.3  Blockade of L-NAME action by L-NMMA and L-arginine  
EFS at a single frequency of 16 Hz in the presence of L-NAME (0.1 – 100 μM) 
demonstrated that inhibition was concentration-dependent (Figure 5.2).  Complete 
inhibition was obtained using 100 μM L-NAME and a pEC50 value of 5.74 ± 0.16 was 
generated (n=13). In comparison, L-NMMA (10 μM – 1 mM) failed to inhibit dilatation at 
any of the concentrations examined (Figure 5.2, n=8). Pre-incubation with L-arginine (1 
mM) protected against blockade by L-NAME at all concentrations but the maximally 
observed response was unaffected. In the presence of L-arginine the new apparent pEC50 
for L-NAME was 4.07 ± 0.11 (n=8), which was significantly different (P<0.001) from that 
of L-NAME alone (Figure 5.2). Furthermore, pre-incubation with L-NMMA (1 mM) also 
protected against blockade by L-NAME, with the maximally observed response again 
unaffected. A new apparent pEC50 of 3.50 ± 0.26 (n=5) for L-NAME was obtained, which 
was significantly different (P<0.001) from that of L-NAME alone (Figure 5.2). L-NMMA 
appeared to protect against blockade by L-NAME with greater potency than L-arginine, 
but a comparison of EC50 values demonstrated that this was not statistically significant. 
These data show that L-NMMA does not inhibit nitrergic vasodilatation in the bovine 
intraocular LPCA at any concentration but instead acts like the endogenous substrate, L-
arginine, in preventing blockade by L-NAME. 
 
5.1.4  AAAN 
Frequency-response curves were generated in the presence of the putative nNOS-specific 
inhibitor AAAN (Hah et al., 2001; 100 μM). AAAN had no effect on either the first or 
second components of dilatation: at 32 Hz dilatations of 30 ± 5% and 38 ± 4% (n=11) were 
obtained, for first and second components in control tissues, respectively, and in the 
presence of AAAN, the responses were 21 ± 4% and 38 ± 6% (n=11), respectively (Figure 
5.3). These data suggest that AAAN does not inhibit nitrergic vasodilatation in the bovine 
intraocular LPCA. Chapter 5    Results: Effect of NOS Inhibitors 
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Figure 5.1 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those treated with the NOS inhibitor, L-NMMA (100 μM). Both (a) the 
first component of dilatation, measured at 10 s, and (b) the second component, measured at 
50 s, were unaffected by L-NMMA. Data are mean±s.e. mean; n=8. 
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Figure 5.2 The NOS inhibitor, L-NAME (0.1-100 μM), blocked, in a concentration-
dependent manner, the first component of dilatation in response to EFS at a single 
frequency (16 Hz) in bovine intraocular LPCA rings. However, another NOS inhibitor, L-
NMMA (10 μM – 1 mM), did not inhibit neurogenic dilatation at any concentration. 
Furthermore, pretreatment with both L-NMMA and L-arginine (both 1 mM), protected 
against blockade by L-NAME at all concentrations. L-NMMA seemed to protect against 
blockade by L-NAME with greater potency than L-arginine, but this was not statistically 
significant. Data are mean±s.e. mean; n≥5; ***P<0.001 indicate a difference in pEC50 from 
L-NAME alone. 
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Figure 5.3 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine LPCA rings 
and in those pretreated with nNOS inhibitor, AAAN (100 μM). Neither (a) the first 
component of dilatation, measured at 10 s, nor (b) the second component, measured at 50 
s, was inhibited by AAAN. Data are mean±s.e. mean; n=11. 
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5.1.5  N
G-Propyl-L-Arginine 
Frequency-response curves were also generated in the presence of another putative nNOS-
specific inhibitor, N
G-propyl-L-arginine (Zhang et al., 1997a). In contrast to AAAN, N
G-
propyl-L-arginine abolished the first component of neurogenic vasodilatation at all 
frequencies. Indeed, at 32 Hz the first component was transformed from a dilatation of 23 
± 3% to a small contraction of 6 ± 4% (n=9, P<0.001). The second component was 
unaffected and was 34 ± 4% in control tissues and 33 ± 3% in treated tissues (n=9, Figure 
5.4). Furthermore, inhibition by N
G-propyl-L-arginine was concentration-dependent, with a 
maximally observed inhibition of 81 ± 9% and a pEC50 value of 4.95 ± 0.42 (n=12, Figure 
5.5). These data show that N
G-propyl-L-arginine is an effective inhibitor of nitrergic 
vasodilatation in the bovine intraocular LPCA. 
 
5.2  Effect of NOS Inhibitors on Endothelium-Dependent, NO-Mediated 
Vasodilatation 
5.2.1  L-NAME 
In the presence of submaximal U46619 (0.1 μM)–induced tone, bradykinin (1 μM) elicited 
a dilatation of 58 ± 4% (n=6) in control rings of bovine intraocular LPCA (Figure 5.6). 
Pre-treatment with L-NAME alone resulted in an apparent small reduction of the 
bradykinin-induced dilatation to 46 ± 5% (n=11, Figure 5.6), but this was not statistically 
significant. In the presence of the EDHF blockers, apamin and charybdotoxin (Waldron & 
Garland, 1994; Zygmunt & Högestätt, 1996; both 0.1 μM), and the COX inhibitor, 
indomethacin (10 μM), dilatation was also reduced slightly to 45 ± 8% (n=6, Figure 5.6), 
but again this was not statistically significant. However, following blockade of EDHF and 
COX, dilatation was significantly reduced by L-NAME to 13 ± 4% (P<0.001, n=6, Figure 
5.6). These data suggest that L-NAME can powerfully block the endothelium-dependent, 
NO-mediated component of vasodilatation in the bovine intraocular LPCA, but that in 
order to observe this clearly, other endothelium-derived vasodilators must first be 
removed. 
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Figure 5.4 Frequency-response curves to EFS (0.5 - 32 Hz) in control bovine intraocular 
LPCA rings and in those treated with the nNOS inhibitor, N
G-propyl-L-arginine (100 μM). 
(a) The first component of dilatation, measured at 10 s, was abolished by N
G-propyl-L-
arginine at all frequencies. (b) The second component, measured at 50 s, was unaffected by 
N
G-propyl-L-arginine. Data are mean±s.e. mean; n=9; ***P<0.001 indicate differences 
from control. 
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Figure 5.5 The nNOS-specific inhibitor, N
G- propyl-L-arginine (0.1-100 μM), inhibited, in 
a concentration-dependent manner, dilatation of bovine intraocular LPCA rings in response 
to EFS at a single frequency (16 Hz). Data are mean±s.e. mean; n≥6. 
 
 
 
 
 
 
 
 
-8 -7 -6 -5 -4 -3
0
10
20
30
40
50
60
70
80
90
100
Log [propyl-L-arginine] M
I
n
h
i
b
i
t
i
o
n
 
(
%
)Chapter 5    Results: Effect of NOS Inhibitors 
  137
 
 Figure 5.6 Bradykinin (1 μM) induced powerful dilatation of bovine intraocular LPCA 
rings. This was inhibited slightly by the NOS inhibitor, L-NAME (100 μM), alone but this 
was not statistically significant. Pre-treatment with the EDHF blockers, apamin and 
charybdotoxin (both 0.1 μM), and the COX inhibitor, indomethacin (10 μM), also 
appeared to cause a small inhibition, but again this was not statistically significant. 
However, in the presence of L-NAME, following blockade of EDHF and COX, the NO-
mediated component of bradykinin-induced dilatation was significantly reduced. Data are 
mean±s.e. mean; n≥6; ***P<0.001 indicates a difference from control. 
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Figure 5.7 Bradykinin (1 μM) induced powerful dilatation of bovine intraocular LPCA 
rings. This was significantly inhibited in the presence of the NOS inhibitor, L-NMMA 
(100 μM) alone. In the presence of the blockers of EDHF, apamin and charybdotoxin (both 
0.1 μM), and the COX inhibitor, indomethacin (10 μM), bradykinin-induced dilatation was 
apparently increased, but this was not statistically significant. However, in the presence of 
L-NMMA, following blockade of EDHF and COX, the NO-mediated component of 
bradykinin-induced  dilatation was further reduced. Data are mean±s.e. mean; n≥6; 
***P<0.001 indicate differences from control. 
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5.2.2  L-NMMA  
In the presence of submaximal U46619 (0.1 μM)–induced tone, bradykinin (1 μM) elicited 
a dilatation of 52 ± 3% (n=10), in control rings of bovine intraocular LPCA (Figure 5.7). 
Pre-treatment with L-NMMA alone reduced the bradykinin-induced dilatation to 33 ± 2%    
(n=10, Figure 5.7) and this was significantly different from the control response (P<0.001). 
In the presence of the blockers of EDHF, apamin and charybdotoxin (both 0.1 μM), and 
the COX inhibitor, indomethacin (10 μM), bradykinin-induced dilatation was apparently 
increased to 59 ± 7% (n=6, Figure 5.7), but this was not statistically significant from the 
control dilatation. However, following blockade of EDHF and COX, dilatation was further 
reduced by L-NMMA to 12 ± 1% (P<0.001, n=10, Figure 5.7). These data show that L-
NMMA powerfully blocks endothelium-dependent, NO-mediated vasodilatation in the 
bovine intraocular LPCA, but as with L-NAME, inhibition of other endothelium-derived 
vasodilators is necessary to observe this clearly. 
5.2.3  AAAN 
In the presence of submaximal U46619 (0.1 μM)–induced tone, bradykinin (1 μM) elicited 
a dilatation of 68 ± 6% (n=8) in control rings of bovine intraocular LPCA (Figure 5.8). In 
the presence of blockers of EDHF, apamin and charybdotoxin (both 0.1 μM), and the COX 
inhibitor, indomethacin (10 μM), dilatation was apparently reduced to 58 ± 5% (n=8), but 
this was not statistically significant. AAAN (100 μM) had no effect on the NO-mediated 
component of bradykinin-induced dilatation (55 ± 5%, n=8) in the presence of inhibitors of 
EDHF and COX. These data suggest that AAAN does not inhibit endothelium-dependent, 
NO-mediated vasodilatation in the bovine intraocular LPCA. 
5.2.4  N
G- Propyl-L-Arginine  
In the presence of submaximal U46619 (0.1 μM)–induced tone, bradykinin (1 μM) elicited 
a dilatation of 68 ± 6% (n=6) in control rings of bovine intraocular LPCA (Figure 5.9). In 
the presence of the blockers of EDHF, apamin and charybdotoxin (both 0.1 μM), and the 
COX inhibitor, indomethacin (10 μM), dilatation was unaffected and was 66 ± 7% (n=6). 
In contrast to AAAN, pretreatment N
G-propyl-L-arginine inhibited the endothelium-
dependent, NO-mediated component of vasodilatation, seen in the presence of inhibitors of 
EDHF and COX: it was reduced to 22 ± 4%, which was  Chapter 5    Results: Effect of NOS Inhibitors 
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Figure 5.8 Bradykinin (1 μM) induced powerful dilatation of bovine intraocular LPCA. In 
the presence of the EDHF blockers, apamin and charybdotoxin (both 0.1 μM), and the 
COX inhibitor, indomethacin (10 μM), the dilatation was reduced but this was not 
statistically significant. AAAN (100 μM) had no effect on the NO-mediated component of 
bradykinin-induced dilatation in the presence of inhibitors of EDHF and COX. Data are 
mean±s.e. mean; n=8. 
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Figure 5.9 nNOS-specific inhibitor, N
G- propyl-L-arginine (0.1-100 μM), inhibited 
bradykinin (1 μM)-induced relaxation of bovine intraocular LPCA rings, in a 
concentration-dependent manner. Data are mean±s.e. mean; n≥4.  
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statistically significant (P<0.001). 
 
N
G-propyl-L-arginine inhibited the endothelial-dependent, NO-mediated component of 
vasodilatation induced by bradykinin in a concentration-dependent manner, with a pEC50 
of 5.03 ± 0.14 (Figure 5.10): a maximum inhibition of 63 ± 4% (n=6) was obtained using 
100 μM N
G-propyl-L-arginine. Consequently, these data show that N
G-propyl-L-arginine 
is not a powerful inhibitor of endothelium-dependent, NO-mediated vasodilatation in the 
bovine intraocular LPCA. Surprisingly, N
G-propyl-L-arginine inhibited the endothelium-
dependent and nitrergic nerve-mediated vasodilatation with equal potency in the bovine 
intraocular LPCA (Figure 5.10), with pEC50 values of 5.03 ± 0.14 and 4.95 ± 0.42, 
respectively. 
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Figure 5.10 The putative nNOS-specific inhibitor, N
G-propyl-L-arginine (0.1-100 μM) 
inhibited dilatation of bovine intraocular LPCA rings in response to EFS at a single 
frequency (16 Hz) in a concentration-dependent  manner. Furthermore, N
G-propyl-L-
arginine inhibited the endothelium-dependent, NO-mediated dilatation induced by 
bradykinin (1 μM) over a similar concentration range. Data are mean±s.e. mean; n≥4.  
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6  Discussion 
6.1  Neurogenic Vasodilatation in the Bovine Intraocular LPCA 
The main aim of this study was to investigate neurogenic vasodilatation in the bovine 
intraocular LPCA. However, before examining this process in detail, it was important to 
determine the optimal stimulation parameters for this tissue and determine if a constrictor 
innervation, which could be observed optimally at low tone, was present in the tissue. 
In the absence of the thromboxane A2-mimetic, U46619-induced tone, control tissues were 
unresponsive to EFS at any frequency. A small, frequency-dependent neurogenic 
vasoconstriction was uncovered only in the presence of the NOS inhibitor, L-NAME 
(Hobbs & Gibson, 1990), and was subsequently blocked by the adrenergic neurone 
blocking drug, guanethidine (Page & Dustan, 1959). This would seem to suggest that a 
small population of adrenergic vasoconstrictor nerves does exist in the bovine intraocular 
LPCA but that constriction is blocked by NO released from nitrergic nerves. Therefore, all 
future experiments were carried out in the presence of guanethidine to ensure that only 
unopposed dilator responses were observed. 
In the presence of U46619-induced tone and blockade of adrenergic vasoconstriction with 
guanethidine, EFS with a train length of 10 s elicited vasodilator responses in the bovine 
intraocular LPCA and these were clearly resolved into two separate components, which 
peaked at 10 s and 50 s, respectively. It is likely that response is biphasic in nature because 
the first component of the compound response decayed rapidly upon termination of EFS 
and the latency of the second (~12 s, observed in the presence of L-NAME to block the 
first component) was sufficiently long to have begun after the first had decayed 
substantially. The two components of the biphasic response to EFS were both voltage- and 
frequency-dependent, with the latter maximally observed at 32 Hz, while the optimal 
voltage for stimulation was specific to individual tissues. Stimulation strength was capped 
at a maximum of 15 V, however, as TTX-resistant, non-neurogenic dilatations were 
observed at voltages greater than 15 V.  
 
Previous research by Wiencke et al. (1994) had concluded that the response to EFS in the 
bovine intraocular LPCA was monophasic dilator response that decayed with either a fast 
or a slow time course and was mediated in part by NO and in part by CGRP. However, 
these authors used an EFS train length of 20 s, in comparison to the train length of 10 s 
used in the current study. The clear temporal separation of the two components, obtained in Chapter 6    Discussion 
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the current study, provided better conditions for pharmacological analysis than when the 
two components were fused together in a single response using a longer train length 
(Wiencke et al., 1994). 
 
The neurogenic nature of the biphasic response was confirmed by the use of the 
neurotoxin, TTX. TTX has been recognised as a poisonous substance from the ovaries and 
liver of the pufferfish, since the time of the early Egyptian and Chinese dynasties. It was 
eventually extracted and named in the early 1900s (Tahara, 1910) and is now known to 
block voltage-gated sodium channels, thus preventing action potential generation and 
therefore inhibiting neurotransmission (Narahashi et al., 1964). Some sodium channels are 
TTX-insensitive (Ritter & Mendell, 1992), however these are mostly found in sensory 
neurons involved in the nociception pathway (Gold, 1999). Both components of relaxation 
following EFS in the bovine intraocular LPCA were inhibited in the presence of TTX, 
confirming they were neurogenic in origin. Furthermore, endothelial denudation, which 
abolished dilatation to bradykinin, did not inhibit neurogenic vasodilatation in this tissue, 
suggesting that endothelial cells are not involved in either inducing or modulating the 
nerve-evoked dilatation. 
 
6.1.1  Role of NO in Neurogenic Vasodilatation in the Bovine Intraocular LPCA 
The NOS inhibitor, L-NAME (Hobbs & Gibson, 1990), abolished the first component of 
neurogenic vasodilatation at all frequencies examined, but had no effect on the second. 
Therefore, the first component of neurogenic vasodilatation appears to be nitrergic, 
supporting the earlier reported involvement of nitric oxide in neurogenic vasodilatation in 
this vessel (Wiencke et al., 1994). Furthermore, the inhibitor of soluble guanylate cyclase, 
ODQ (Garthwaite et al., 1995), also abolished the first component of relaxation, but did 
not affect the second. This would seem to confirm the involvement of the NO-guanylate 
cyclase-cGMP pathway in the first component of neurogenic vasodilatation. As has already 
been discussed in chapter 1, previous reports describe neurogenic vasodilatation mediated 
solely by nitrergic nerves in retinal and ciliary arteries from a range of species, including 
pig, monkey and dog (Toda et al., 1997; Toda et al., 1999; Toda et al., 1994; Toda et al., 
1998). However, in contrast to Toda et  al. (1997), who reported only nitrergic 
vasodilatation in the porcine ciliary artery, Su et  al. (1994) described only a partial 
inhibition of neurogenic vasodilatation by L-NAME and speculated that another 
transmitter, possibly a peptide, was responsible for the L-NAME-insensitive part of the 
response.  Chapter 6    Discussion 
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Thus, as the transmitter responsible for mediating the first component had been identified 
as NO from nitrergic nerves, the search to identify the mediator responsible for the second 
component began. 
 
6.1.2  Role of CGRP in Neurogenic Vasodilatation in the Bovine Intraocular LPCA 
In contrast to the earlier report of Wiencke et al. (1994), this study found no evidence to 
support a role for CGRP in neurogenic vasodilatation of the bovine intraocular LPCA. The 
CGRP1 receptor antagonist, CGRP8-37, inhibited the dilator actions of exogenous CGRP 
with the expected pKB of ~6.7 (Brain et al., 2002), but it had no effect on either component 
of neurogenic dilatation, at any frequency. Furthermore, in the presence of L-NAME, to 
rule out the possibility that the nitrergic component may have inadvertently contributed to 
the second component of neurogenic vasodilatation and masked any effect of CGRP 
inhibition, the second component was again entirely unaffected by CGRP8-37.   
It is, however, likely that CGRP-containing sensory nerves are present in the bovine 
intraocular LPCA, since capsaicin, which activates vanilloid VR1 receptors on C and Aδ 
fibres (Akerman et al., 2003; Joó et al., 1969) induced a small transient dilatation that was 
inhibited by pretreatment with CGRP8-37. Why EFS did not appear to activate these nerves 
in this study is not clear. It is possible that the simulation parameters used in the present 
study did not activate CGRP-containing sensory nerves. Previous findings on dural 
vasculature show that neurogenic (EFS-induced) vasodilatation involves only Aδ fibres, 
whereas neurogenic inflammation, which is associated with prolonged, high intensity 
stimulation, additionally involves C fibres (Akerman et  al., 2003; Williamson et  al.,  
1997a; Williamson et al., 1997b). It is therefore possible in the bovine LPCA that CGRP is 
present exclusively in C fibres that can be activated by capsaicin but not by the EFS 
parameters used in the present study or by those used by Wiencke et al. (1994). Indeed, 
further evidence against a role for CGRP in neurogenic relaxation was obtained when 
complete desensitisation to capsaicin had been obtained through prior exposure to the 
excitotoxin. Under these conditions, where prolonged inhibition of C fibre transmitter 
release occurs (Jancsó et al., 1967; Lynn, 1990), both the first and second components of 
neurogenic vasodilatation remained entirely unaffected at all frequencies. Thus, although 
CGRP-containing sensory fibres sensitive to capsaicin appear to be present, the separation 
of the two components of neurogenic vasodilatation in bovine intraocular LPCA provides 
no evidence of a role for CGRP, in contrast to the report by Wiencke et al. (1994). 
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6.1.3  Role of Substance P in Neurogenic Vasodilatation in the Bovine Intraocular 
LPCA 
The inability of capsaicin desensitisation to affect neurogenic vasodilatation in the bovine 
intraocular LPCA also rules against a role for substance P, since it too is present in sensory 
fibres. Nevertheless, substance P is known to be involved in neurogenic responses in other 
blood vessels, including rat mesenteric veins (Ahluwalia & Vallance, 1997; Claing et al., 
1992). Although substance P was able to promote dilatation of the bovine intraocular 
LPCA, complete desensitisation to this agent occurred within minutes, thus making it an 
unlikely transmitter candidate for the neurogenic vasodilator response, as the latter 
responses are highly reproducible upon successive stimulations. Moreover, when complete 
desensitisation to substance P had been obtained or when the NK1 receptor antagonist, L-
733,060 (Seabrook et al., 1996), was present, neither the first nor the second components 
of neurogenic vasodilatation was affected. Substance P is therefore unlikely to contribute 
to neurogenic vasodilatation in the bovine intraocular LPCA. 
 
6.1.4  Role of VIP in Neurogenic Vasodilatation in the Bovine Intraocular LPCA 
The presence of VIP-containing perivascular nerves has been demonstrated 
histochemically in ciliary arteries from a wide range of species, including pig, rat and 
human (Bergua et  al., 2003; Flügel et  al., 1994; Toda et  al., 1997). Nevertheless, all 
studies to-date agree that VIP has no functional role in the ciliary artery and that 
neurogenic vasodilatation in these tissues is mediated solely by nitrergic nerves. VIP 
powerfully relaxed the bovine intraocular LPCA and high concentrations led to partial 
desensitisation to the peptide. In this partially desensitised state, which has been used 
previously to rule out involvement of VIP in the neurogenic vasodilatation in dog and 
monkey cerebral arteries (Toda, 1982), the first and second components of neurogenic 
vasodilatation were completely unaffected.  
Moreover, treatment with a protease, α-chymotrypsin, a strategy previously employed to 
successfully establish the role of a peptide in the neurogenic vasodilatation in guinea pig 
uterine and bovine mesenteric arteries (Leckström et al., 1993; Morris, 1993), failed to 
inhibit either the first or second components of the neurogenic response in the bovine 
intraocular LPCA. Although VIP is an unlikely candidate to mediate the second 
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chymotrypsin in the intraocular LPCA made it difficult to dismiss it completely. This fall 
in tone may have been mediated by protease-activated receptors (PARs), a class of GPCR 
activated by proteolytic cleavage. Four members of the PAR family have been identified: 
PAR1 (thrombin receptor), PAR2, PAR3 and PAR4. PAR2 (Nystedt et  al., 1994) is 
activated by trypsin and has been identified on endothelial and SMC of a number of 
vascular tissues.   
A role for VIP in neurogenic vasodilatation was previously established in sheep cerebral 
artery with the use of VIP antiserum (Matthew et al., 1997). In the bovine intraocular 
LPCA, however, VIP antiserum failed to convincingly block dilatation to exogenous VIP 
and caused such a profound fall in tone and frothing in the myograph baths, that its effects 
on neurogenic vasodilatation could not be tested. Furthermore, although VIP is reported to 
mediate vasodilatation via activation of KATP channels in the rabbit cerebral artery 
(Standen et al.,  1989), the KATP channel inhibitor, glibenclamide, failed to block relaxation 
to exogenous VIP and had no effect on either the first or second components of neurogenic 
vasodilatation. In addition, as activation of KATP  channels is also reported to mediate 
vasodilatation by CGRP in a number of VSM preparations (Luu et al., 1997; Nelson et al., 
1990), the inability of glibenclamide to block neurogenic vasodilatation further suggests 
that CGRP does not mediate the second component of neurogenic vasodilatation in this 
vessel. Therefore, none of the experimental approaches used in this study provided any 
evidence that VIP contributes to neurogenic vasodilatation in the bovine intraocular LPCA.  
 
6.1.5  Role of ATP in Neurogenic Vasodilatation in the Bovine Intraocular LPCA 
The final transmitter candidate investigated in detail was ATP, since this nucleotide is 
believed to mediate neurogenic vasodilatation together with NO in the rabbit portal vein 
and mesenteric artery (Brizzolara et  al., 1993; Kakuyama et  al., 1998). ATP-induced 
vasodilatation is mediated mainly via P2Y1 receptors and P2Y2 receptors. For example 
P2Y1 receptors mediate vasodilatation in rat middle cerebral arteries (You et al., 1999) and 
rabbit pulmonary artery (Qasabian et  al., 1997), while P2Y2 receptors mediate 
vasodilatation in rat middle cerebral arteries (You et al., 1999) and in the mouse aorta. 
Furthermore, UTP mediates vasodilatation in the rabbit ear artery by activation of P2Y4 
receptors (Saiag et al., 1998) and in the mouse aorta by activation of P2Y6 receptors (Guns 
et al., 2006). Suramin, RB2 and PPADS all block more than one P2Y receptor subtype 
(von Kugelgen, 2006). Suramin inhibits P2Y1 and P2Y2 receptors with PKB values of 5.7 
and 4.3, respectively, but does not inhibit P2Y4 receptors (Charlton et al., 1996) and is a Chapter 6    Discussion 
  150
poor inhibitor of P2Y6 receptors (von Kugelgen, 2006). RB2 generally inhibits agonist-
induced responses at all P2Y receptors, although weakly at P2Y4 receptors (von Kugelgen, 
2006). PPADS is an effective inhibitor of P2Y1 and P2Y6 receptors, but a poor inhibitor of 
P2Y4 receptors and does not inhibit P2Y2 receptors at all (von Kugelgen, 2006).  
ATP did relax the bovine intraocular LPCA, but this was completely unaffected by the 
P2Y receptor antagonists, suramin (Dunn & Blakeley, 1998), PPADS (Lambrecht et al., 
1992) or RB2 (Burnstock & Warland, 1987b), at concentrations that are effective in other 
tissues, or by the desensitising P2X receptor agonist, α,β-methyleneATP (Simonsen et al., 
1997). Thus, lack of a suitable blocking agent prevented further investigation into the 
possible role of ATP in the neurogenic vasodilatation of the bovine intraocular LPCA.  
 
The lack of availability of selective P2Y antagonists has hampered the identification of 
specific receptors within tissues. Recently, a number of subtype-specific antagonists have 
been suggested and these could, in future studies, be of use in determining the receptor 
ATP acts on to produce dilatation in the bovine intraocular LPCA. For example, the 
bisphosphate analogue MRS2179 (Kaiser & Buxton, 2002) has been reported as a P2Y1 
receptor-specific antagonist in the guinea-pig aorta, and the diisothiocyanate derivative of 
1,2-diphenylethane, MRS2567, has been described as a P2Y6 receptor-specific antagonist 
in both human and rat astrocytes (Mamedova et al., 2004). However, until a subtype-
specific inhibitor is available that is also effective at blocking ATP-induced dilatation in 
the bovine intraocular LPCA, it may be difficult to determine whether this nucleotide has 
any role in neurogenic vasodilatation in this tissue. 
 
6.1.6  CO and H2S as Potential NANC Neurotransmitters 
The gasotransmitters, CO and H2S, have been reported to regulate cardiovascular function 
and both were considered as candidate molecules for the unidentified transmitter that 
mediates the second component of neurogenic vasodilatation in the bovine intraocular 
LPCA. However, neither gas was examined directly as part of the current investigation. 
 
6.1.6.1 CO 
CO-induced vasodilatation was originally demonstrated in the rat coronary artery 
(McGrath & Smith, 1984) and has since been observed in a vast number of tissues; rat and 
rabbit thoracic aorta (Furchgott & Jothianandan, 1991; Lin & McGrath, 1988), canine Chapter 6    Discussion 
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carotid, coronary and femoral arteries (Vedernikov et al., 1989), rat tail artery (Wang et al., 
1997) and piglet mesenteric artery (Villamor et al., 2000). However, the response to CO is 
not universal as it does not induce vasodilatation in canine or rabbit basilar or middle 
cerebral arteries (Brian et al., 1994). Furthermore, in the rat gracilis muscle arterioles it 
actually causes vasoconstriction (Kozma et al., 1999). CO-induced vasodilatation can be 
mediated by activation of both specific K
+ channels and the cGMP pathway. For example, 
CO induced a concentration-dependent, endothelium-independent vasodilatation in the rat 
tail artery that appeared to be mediated by both the cGMP pathway and BKCa channels 
(Wang et al., 1997). Inhibitors of BKCa channels have also been found to inhibit CO-
mediated vasodilatation in piglet pial arterioles (Leffler et al., 1999) and hypoxic rat 
mesenteric arterioles (Naik & Walker, 2003). Although CO was not directly examined, the 
suggested mechanisms of CO-mediated vasodilatation have been investigated in the course 
of the present study. Neither L-NAME nor ODQ, which inhibit components of the cGMP 
pathway or iberiotoxin, charybdotoxin or TEA, which inhibit BKCa channels, were capable 
of inhibiting the second component of neurogenic vasodilatation. Therefore, it would seem 
that CO does not appear to be involved in the second component of neurogenic 
vasodilatation in the bovine intraocular LPCA. Further investigation, perhaps using an 
inhibitor of haem oxygenase, the enzyme that generates CO, such as zinc protoporphyrin 
IX (ZnPPIX; Naik et al., 2003) is required to determine if CO does indeed have a role in 
neurogenic vasodilatation in the bovine intraocular LPCA.  
6.1.6.2 H2S 
More recently, H2S has also been reported as a putative gasotransmitter. H2S-induced 
vasodilatation was first observed in the rat aorta (Hosoki et al., 1997). The vascular effects 
of H2S have been shown in vivo and in vitro in the rat, where vasodilatation is reportedly 
mediated via KATP channels as it is blocked by the KATP channel blocker, glibenclamide, 
and mimicked by pinacidil, a KATP channel opener (Zhao et al., 2001). However, in rat, the 
decrease in blood pressure observed upon bolus i.v. injection of H2S was transient and 
lasted approximately 30 s (Zhao et al., 2001), whereas in the present study, the time course 
for the second component of neurogenic relaxation was of much greater duration. In 
addition, although H2S was not investigated directly in the present study, the involvement 
of KATP channels was examined by the use of glibenclamide. As this KATP channel blocker 
was unable to inhibit the second component of vasodilatation, it would seem unlikely that 
H2S mediates neurogenic vasodilatation in the bovine intraocular LPCA. However, as the 
mechanism of H2S-induced vasodilatation has not been fully elucidated, further Chapter 6    Discussion 
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investigation is required to determine if H2S does indeed have a role in neurogenic 
vasodilatation in the bovine intraocular LPCA. One possible strategy for this would be to 
utilise inhibitors of the two enzymes which generate H2S, cystathionine β-synthase (CBS) 
and cystathionine γ-lyase (CSE). Amino-oxyacetic acid (Braunstein et  al., 1971) and 
propargylglycine (Uren et al., 1978) inhibit CBS and CSE, respectively, and may be of use 
in determining the role, if any, of H2S in neurogenic vasodilatation in the bovine 
intraocular LPCA. 
 
6.1.7  Other Putative NANC Neurotransmitters 
 In addition to the gasotransmitters, two neuropeptide NANC transmitters, which could 
potentially mediate the second component of neurogenic vasodilatation in bovine 
intraocular LPCA, but were not investigated in the present study, are PACAP and PHI, 
which are both structurally-related to VIP. PACAP and PHI-containing fibres have been 
identified in the rat cerebral circulation (Ceccatelli et  al., 1991) using 
immunohistochemistry. Functionally, they have been described as NANC inhibitory 
transmitters in the rat and guinea-pig gastric fundus (Curro et al., 2002; Katsoulis et al., 
1996). Although in theory, the treatment with α-chymotrypsin in this study should have 
inhibited any vasodilatation mediated by a peptide such as PACAP or PHI, the large fall in 
tone generated by the protease in the bovine intraocular LPCA made investigation difficult. 
It is therefore not possible to rule out PACAP or PHI as a neurotransmitter in this vessel. 
The PACAP receptor antagonist, PACAP6-38 and anti-PHI serum have both been used 
successfully to inhibit EFS-induced relaxant responses in the mouse (Baccari & Calami, 
2001) and rat (Curro et al., 2002) gastric fundus, respectively, and are potential tools for 
further study in the bovine intraocular LPCA. 
 
6.2  Identification of the Mechanisms of the Second Component of Neurogenic 
Vasodilatation in the Bovine Intraocular LPCA 
Although it had been established that neurogenic vasodilatation in the bovine intraocular 
LPCA was biphasic in nature and that the first component appeared to be mediated by NO 
released from nitrergic nerves and acting via soluble guanylate cyclase, the identity of the 
transmitter that mediated the second component of dilatation remained unclear. As this 
vasodilatation could not be blocked using conventional neurotransmitter inhibitors or 
desensitisation protocols, an attempt was made to determine the mechanism by which the Chapter 6    Discussion 
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unknown transmitter promoted dilatation. Three potential mechanisms of vasodilatation; 
hyperpolarisation-induced, cGMP-induced and cAMP-induced were investigated. 
 
6.2.1  Hyperpolarisation-Induced, Neurogenic Vasodilatation in the Bovine Intraocular 
LPCA 
The membrane potential of VSM cells, which is highly influenced by K
+ channels, plays an 
important role in arterial tone. The opening of K
+ channels in the cell membrane leads to 
increased K
+ efflux and this, in turn, causes membrane hyperpolarisation. The resultant 
hyperpolarisation closes voltage-dependent Ca
2+ channels, decreasing Ca
2+ entry and this 
leads to vasodilatation. Conversely, inhibition of K
+ channels causes membrane potential 
depolarisation and vasoconstriction (Nelson & Quayle, 1995). Four types of K
+ channel 
have been identified in VSM; KIR, KV, KATP and KCa (of which there are 3 subtypes; BKCa, 
IKCa and SKCa). NO (Bolotina et al., 1994), CGRP (Nelson et al., 1990), VIP (Standen et 
al., 1989), substance P (Frieden et al., 1999) and PACAP (Kishi et al., 1996), have all been 
shown to mediate vasodilatation via activation of a variety of K
+ channels, resulting in the 
hyperpolarisation of the SMC.  
 
Addition of the non-specific K
+ channel blocker, TEA (Nelson & Quayle, 1995), the 
inhibitor of KIR channels, BaCl2  (Quayle  et  al., 1993), the BKCa channel inhibitor, 
iberiotoxin (Latorre et  al., 1992), the inhibitor of BKCa, IKCa and KV channels, 
charybdotoxin (Grissmer et al., 1994; Miller et al., 1985; Desai et al., 2006) and the small 
conductance KCa channel inhibitor, apamin (Blatz & Magleby, 1986), but not the KATP 
channel inhibitor, glibenclamide (Schmid-Antomarchi et al., 1987), to the myograph bath 
caused an increase in U46619-induced tone, suggesting that KIR, BKCa, IKCa, SKCa and KV 
channels but not KATP channels are tonically active in the membrane of VSM cells in the 
bovine intraocular LPCA. 
 
6.2.1.1 Effect of Non-Specific Inhibition of K
+ Channels on Neurogenic Vasodilatation in 
the Bovine Intraocular LPCA 
The non-specific K
+ channel blocker, TEA (Nelson & Quayle, 1995), has previously been 
shown to inhibit NANC-mediated relaxations in the smooth muscle of the human colon 
(Sahin et al., 2001). However, incubation with TEA appeared to potentiate the magnitude 
of neurogenic vasodilatation in bovine intraocular LPCA rings stimulated at a single 
frequency of 16 Hz. TEA has also been shown to potentiate EFS-elicited vasodilatation in 
the rabbit facial vein (Tanaka et al., 2003). In the facial vein the potentiated response was Chapter 6    Discussion 
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attributed to enhanced transmitter release from the nerve terminals, linked to functional 
coupling between prejunctional TEA-sensitive K
+ channels and Q-type Ca
2+ channels. 
Furthermore, there is evidence showing that K
+ channel inhibitors, such as TEA and 4-
aminopyridine, can enhance transmitter output from a variety of nerves by prolonging the 
nerve action potential. In the bullfrog sympathetic ganglia (Kumamoto & Kuba, 1985) and 
the guinea-pig inferior mesenteric ganglia (King & Szurszewski, 1988) enhanced ACh 
released was noted in the presence of TEA. Therefore, it is possible that in bovine 
intraocular LPCA, interaction between prejunctional TEA-sensitive K
+  channels and 
unidentified Ca
2+ channels or a TEA-mediated increase in action potential duration 
contributes to an enhanced level of transmitter output and subsequently an increase in the 
magnitude of neurogenic vasodilatation. 
6.2.1.2 Effect of Inhibition of KIR Channels on Neurogenic Vasodilatation in the Bovine 
Intraocular LPCA  
Low concentrations of the inhibitor of KIR channels, BaCl2 (Quayle et al., 1993), were 
found to block the inhibitory action of CGRP in the guinea-pig ureter SMC (Maggi et al., 
1995). Furthermore, KIR channels are important in K
+-induced dilatations in cerebral 
(Edwards & Hirst, 1988) and coronary (Knot et al., 1996) arteries. Indeed, it has been 
suggested that K
+
 may be the elusive vasodilator agent EDHF (Edwards et al., 1998). 
Edwards  et al. (1998) suggested that K
+  efflux through charybdotoxin and apamin-
sensitive K
+ channels on endothelial cells resulted in an increase in myoendothelial K
+ 
concentration, which hyperpolarised adjacent SMC by activating KIR channels and Na
+/K
+ 
ATPase, resulting in vasodilatation. Therefore, the role of these channels in EFS-induced 
vasodilatation in the bovine intraocular LPCA was examined. However, BaCl2 failed to 
affect either component of dilatation in response to stimulation at16 Hz, suggesting that 
KIR channels do not play a role in neurogenic vasodilatation in the bovine intraocular 
LPCA. 
6.2.1.3 Effect of Inhibition of KCa and KV Channels on Neurogenic Vasodilatation in the 
Bovine Intraocular LPCA  
It is known that in the bovine isolated perfused eye, charybdotoxin alone, which blocks 
BKCa, IKCa and KV channels (Grissmer et  al., 1994; Miller et  al., 1985), and the 
combination of charybdotoxin and apamin, which blocks SKCa channels (Blatz & Magleby, 
1986), can be used to block ACh-mediated vasodilatation (McNeish et al.,  2001). These 
findings suggested that this vasodilatation was mediated by an EDHF. Therefore, as these Chapter 6    Discussion 
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channels are present within the vasculature of the bovine eye, it is plausible that these same 
channels could be involved in the mechanism of neurogenic vasodilatation in the bovine 
intraocular LPCA. In addition to this: CGRP relaxes precontracted rat coronary arteries via 
activation of BKCa channels (Sheykhzade & Berg Nyborg, 2001); VIP and PACAP are 
involved in NANC inhibitory responses of longitudinal muscle of the rat distal colon via 
activation of charybdotoxin and apamin-sensitive K
+ channels, respectively (Kishi et al., 
1996); VIP dilates the porcine coronary by activation of both BKCa and KV channels 
(Kawasaki et al., 1997), while in the same tissue, substance P is reported to activate SKCa 
channels (Frieden et al., 1999) and  finally, NO activates charybdotoxin-sensitive channels 
in the rabbit aorta (Bolotina et  al., 1994). However, in the bovine intraocular LPCA, 
charybdotoxin, apamin and the inhibitor of BKCa channels, iberiotoxin (Latorre et  al., 
1992), do not affect either the first or the second components of neurogenic vasodilatation, 
suggesting that BKCa, IKCa, SKCa and KV channels play no role in neurogenic vasodilatation 
in this vessel. 
6.2.1.4 Effect of Inhibition of KATP Channels on Neurogenic Vasodilatation in the Bovine 
Intraocular LPCA Inhibition  
KATP channel activation has previously been suggested as the mechanism by which a 
number of endogenous vasodilators, especially CGRP, mediate vasodilatation. CGRP has 
been shown to activate KATP channels in the rabbit mesenteric (Nelson et al., 1990) and 
porcine coronary arteries (Miyoshi & Nakaya, 1995). In addition, the KATP channel 
inhibitor, glibenclamide, has been used to inhibit CGRP-mediated vasodilatations in the rat 
cerebral (Hong et al., 1994), rabbit mesenteric (Nelson et al., 1990) and human uterine 
arteries (Nelson et al., 1993). However in a number of cases, glibenclamide only partially 
inhibited the CGRP-mediated dilatation (Kitazono et al., 1993; Maggi et al., 1994) and in 
the porcine coronary artery, it failed completely (Kageyama et  al., 1993). This would 
suggest that additional mechanisms, such as activation of KCa channels, are in operation at 
the same time. Another neuropeptide, VIP, has been show to elicit glibenclamide-sensitive 
hyperpolarisation of the membrane potential of rabbit cerebral arteries (Standen et al., 
1989). In addition, KATP channels have been found to play a role in adenosine-mediated 
vasodilatation in the pig coronary artery (Dart & Standen, 1993), as well as vasodilatation 
mediated by NO in the rabbit mesenteric artery (Murphy & Brayden, 1995). Although the 
KATP channel inhibitor, glibenclamide, was able to block dilatation in response to the KATP 
channel opener, levcromakalim, in the bovine intraocular LPCA, it failed to inhibit 
neurogenic vasodilatation at all frequencies. Furthermore, it did not inhibit relaxation 
induced by exogenous VIP. This would suggest that KATP channels do not play a role in Chapter 6    Discussion 
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either the first or second components of neurogenic vasodilatation in the bovine intraocular 
LPCA. 
 
As inhibition of K
+ channels had no effect on neurogenic vasodilatation in the bovine 
intraocular LPCA, the cGMP/PKG pathway was investigated. 
 
6.2.2  Effect of PDE5 Inhibition on Neurogenic Vasodilatation in the Bovine 
Intraocular LPCA  
Prior to the discovery of nitrergic transmission, the PDE5 inhibitor, zaprinast, was used to 
demonstrate that guanylate cyclase/cGMP pathway played a role in neurogenic relaxation 
in the BRP muscle (Bowman & Drummond, 1984) and the mouse anococcygeus muscle 
(Gibson & Mirzazadeh, 1989). In the BRP, zaprinast elevated the basal cGMP content and 
also potentiated both the magnitude of the relaxation and the rise in cGMP produced by 
NANC nerve stimulation. Similarly, in the mouse anococcygeus muscle, zaprinast was 
shown to increase relaxations induced by NANC nerve stimulation and NO donors, but to 
have no effect on relaxations to VIP, papaverine or 3-isobutyl-1-methylxanthine. 
Following the identification of NO as a NANC transmitter, zaprinast has been shown to 
potentiate nitrergic neurotransmission in a variety of tissues such as the corpus cavernosum 
of man (Bush et al., 1992; Rajfer et al., 1992) and rabbit (Bush et al., 1992) and the gastric 
fundus of the cat (Barbier & Lefebvre, 1995), pig (Lefebvre et al., 1995) and rat (Williams 
& Parsons, 1995). In addition, another PDE5 inhibitor, sildenafil, has been shown to 
enhance neurogenic NO-mediated and soluble guanylate cyclase-dependent vasodilatation 
in the bovine penile small arteries (Simonsen et al., 2001) and relaxation of the human 
corpus cavernosum (Ballard et  al., 1998). In the bovine intraocular LPCA zaprinast 
potentiated the first component of neurogenic vasodilatation but not the second. This 
would seem to confirm that the first, but not the second component is mediated by cGMP. 
However, in contrast to zaprinast, sildenafil did not potentiate the first component of 
dilatation and instead appeared to increase the magnitude of the second component, 
although this was not statistically significant. It is unclear why zaprinast, but not sildenafil 
was able to potentiate the magnitude of the first component, as sildenafil is a highly potent 
inhibitor of PDE5, with an IC50 of 3.5 nM against PDE5 extracted from the human corpus 
cavernosum (Ballard et al., 1998). Furthermore, in the same series of experiments, Ballard 
et al. (1998)  were able to determine that sildenafil was >200 times more potent than 
zaprinast as an inhibitor of PDE5 from the human corpus cavernosum. It is possible that 
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LPCA. However, the data capture method utilised in this study did not allow changes in 
duration of the respose to EFS to be captured. It is therefore possible that if sildenafil 
potentiated the duration of the relaxation but did not potentiate the magnitude of it, as has 
been shown by Hallen et al. (2007), this would not have been recorded. Experimental 
design should take this factor into account when using PDE5 inhibitors to investigate the 
guanylate cyclase/cGMP pathway in the future. Another method which could be used to 
confirm the participation of the guanylate cyclase/cGMP pathway in the first, but not 
second component of neurogenic dilatation in the bovine LPCA, would be to utilise the 
PDE5 inhibitors vardenafil and tadalafil, which were not examined in the present study. 
Both vardenafil and tadalafil have been found to prolong nerve-induced relaxation in the 
rabbit corpus cavernosum (Hallen et al., 2007) and pig urethra (Werkstrom et al., 2006) 
and may be useful tools for clarifying the situation in the bovine intraocular LPCA. 
 
6.2.3  Effect of PKG Inhibition on Neurogenic Vasodilatation in the Bovine 
Intraocular LPCA  
As the results obtained with the PDE5 inhibitors were inconsistent, another stage of the 
cGMP-mediated vasodilatation pathway was blocked by inhibiting PKG. PKG is reported 
to facilitate vasodilatation by reducing the cytosolic [Ca
2+] in a number of ways, including: 
inhibition of Ca
2+ mobilisation through voltage gated Ca
2+ channels (Clapp & Gurney, 
1991) and activation of both the Na
+/Ca
2+ exchanger (Furukawa et  al., 1991) and the 
plasma membrane Ca
2+-ATPase (Yoshida et al., 1991). Therefore, in theory, inhibition of 
PKG should block cGMP-mediated vasodilatation. Incubation with the PKG inhibitor, Rp-
8-Br-PET-cGMPS (Butt et al., 1995) did significantly inhibit the first but not the second 
component of neurogenic vasodilatation. However, although Rp-8-Br-PET-cGMPS is 
described as a potent and selective competitive inhibitor of PKG, with an apparent Ki of 
0.03 μM (Butt et al.,  1995) and competitively suppressed the cGMP-induced current in 
xenopus rod photoreceptors with an IC50 of 25 μM (Wei et al., 1996), the level of blockade 
observed in the bovine intraocular LPCA was only marginally significant. 
As neurogenic vasodilatation was not fully inhibited by Rp-8-Br-PET-cGMPS, the effects 
of another PKG inhibitor, KT5823 (Wyatt et al., 1991), was examined on the response to 
EFS. Although this compound has a Ki of 234 nM in vitro, the first and second 
components of neurogenic vasodilatation remained unaffected in the presence of KT5823. 
While this compound has been used extensively to determine the role of PKG in numerous 
cell signalling processes, such as proliferation of SMC (Chiche et al., 1998), proliferation 
of neuronal cells (Firestein & Bredt, 1998) and in regulation of ion channels (Darvish et Chapter 6    Discussion 
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al., 1995), it has also been reported that it is an ineffective inhibitor in intact cells 
(Burkhardt et al., 2000). Burkhardt et al. (2000) suggested a number of reasons, such as 
compartmentalisation of the drug and insufficient incubation time for the drug to pass 
through the cell membrane, for the disparity in efficacy between in vitro experiments 
utilising KT5823 and those involving intact cells. It is possible that this may be the reason 
why KT5823 does not inhibit the first component of neurogenic vasodilatation in the 
bovine intraocular LPCA, and suggests that KT5823 should not be used in isolation to 
determine the role of PKG in cell signalling pathways. 
Therefore, although results with L-NAME and ODQ, demonstrate the involvement of the 
cGMP-mediated pathway in neurogenic vasodilatation in the bovine intraocular LPCA, 
this could not be confirmed convincingly by either the use of inhibitors of PDE5 or PKG. 
6.2.4  cAMP-Induced, Neurogenic Vasodilatation in the Bovine Intraocular LPCA 
As inhibition of PDE5 and PKG failed to assist with characterisation of the mechanisms 
underlying the first and second components of neurogenic dilatation in the bovine 
intraocular LPCA, the cAMP-mediated vasodilatation pathway was investigated by 
inhibiting PKA.  
6.2.4.1 Effect of PKA Inhibition on Neurogenic Vasodilatation in the Bovine Intraocular 
LPCA  
PKA is reported to mediate vasodilatation in a number of ways, including: decreasing the 
sensitivity of myosin light chain kinase to the Ca
2+-calmodulin complex (de Lanerolle et 
al., 1984), reducing cytosolic [Ca
2+] by stimulating the Ca
2+-ATPase in the plasma 
membrane and sarcoplasminc reticulum (Kimura et al., 1982) and phosphorylation of KCa
 
channels, resulting in hyperpolarisation (Price et  al., 1996; Taguchi et  al., 1995). 
Promisingly, blockade of this kinase with the PKA inhibitor, Rp-8-Br-cAMPS (Gjertsen et 
al., 1995; 50 μM), appeared to significantly reduce the magnitude of the second, but not 
the first component of neurogenic dilatation in the bovine intraocular LPCA. However, 
when a second group of tissues was incubated with a higher concentration of Rp-8-Br-
cAMPS (100 μM) to determine if the second component could be further inhibited, the 
magnitude of both the first and second components of dilatation was reduced, but neither 
reduction was significant.  Chapter 6    Discussion 
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In an attempt to determine if neurogenic vasodilatation could indeed be blocked by 
inhibition of PKA, a second PKA inhibitor, H89 (Combest et al., 1988), was also utilised. 
H89, which has an IC50 of 135 nM against PKA (Davies et al., 2000), had no effect on the 
magnitude of either the first or second component of neurogenic dilatation in the bovine 
intraocular LPCA. 
Although initial results indicated that the second component of neurogenic relaxation in the 
bovine intraocular LPCA could be blocked by inhibition of PKA by Rp-8-Br-cAMPS, this 
could not be confirmed using a higher concentration of Rp-8-Br-cAMPS or a second 
inhibitor, H89. Again, it is difficult to conclude whether the cAMP/PKA pathway is or is 
not involved in either component of neurogenic vasodilatation in the bovine intraocular 
LPCA, or whether both Rp-8-Br-cAMPS and H89 are unsuitable for use in this tissue and 
another inhibitor of the cAMP pathway should be examined in this vessel. Although Rp-8-
Br-cAMPS was selected from a panel of other Rp-cAMPS analogues, as it was more 
resistant to breakdown by PDEs and also penetrated into cells because of its lipophilic 
nature (Gjertsen et al., 1995), the strong ionic nature of the cyclic nucleotide phosphate 
group still limits membrane permeability (Kruppa et al., 1997). Perhaps poor tissue 
permeability or a lack of specificity of both Rp-8-Br-cAMPS and H89, for the isoform of 
PKA found within the bovine intraocular LPCA was the problem.  
Therefore, both the identification and the mechanism of action of the second component of 
neurogenic relaxation in the bovine intraocular LPCA remain unidentified. 
6.2.5  Interaction of NO and the Rho Kinase Pathway 
Although it has been clearly established that NO induces vasodilatation via cGMP/PKG-
dependent mechanisms already discussed, it has also been suggested recently that NO can 
promote vasodilatation via a second signalling pathway, known as the RhoA/Rho kinase 
pathway. As has been discussed in chapter 1, contraction of VSM is initiated by an 
increase in the concentration of intracellular Ca
2+, which in turn, combines with 
calmodulin. The Ca
2+-calmodulin complex activates MLCK to phosphorylate MLC, 
enabling the cycling of myosin cross bridges with actin and smooth muscle contraction. 
Therefore, the contractile state of the smooth muscle is determined by the level of MLC 
phosphorylation (for review see  Somlyo & Somlyo, 2000). Although this pathway is 
activated by receptor-mediated or mechanical (stretch) stimulation, a low level of MLC 
phosphorylation is maintained in the absence of stimuli in some tissues and this is known Chapter 6    Discussion 
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as myogenic tone. The level of MLC phosphorylation is also regulated by MLC 
phosphatase, which dephosphorylates MLC and results in relaxation of the smooth muscle. 
MLC phosphatase consists of three subunits, the largest of which is the myosin binding 
subunit. If this subunit becomes phosphorylated, MLC phosphatase is inhibited, MLC 
remains phosphorylated and smooth muscle contraction persists (Somlyo & Somlyo, 
2000). Rho kinase, which is activated by a G-protein known as Rho A, phosphorylates 
MLC phosphatase and therefore plays a major role in maintaining contraction. As there are 
data in the literature that suggests inhibition of RhoA/Rho kinase induces vasodilatation, it 
is possible to speculate that NO and other endogenous vasodilators may induce 
vasodilatation by inhibiting the Rho kinase pathway. Although this has not been fully 
investigated, there is some initial evidence to support this theory. Sauzeau et al. (2000) 
reported that PKG can phosphorylate and therefore inhibit RhoA and that the NO donor, 
sodium nitroprusside, caused the inactivation of RhoA by uncoupling it from the cell 
membrane, concluding that the inactivation of RhoA contributes to the vasodilator action 
of NO. Chitaley & Webb (2002) utilised the Rho kinase inhibitor, Y-27632, in rings of rat 
aorta and found that in tissues where NO was inhibited using L-NNA or ODQ, the Y-
27632 was markedly less effective at inhibiting phenylephrine-induced contraction. 
Furthermore, addition of sodium nitroprusside restored the effect of Y-27632 and allowed 
the blockade of phenylephrine-induced contraction.  They concluded that reduction in 
efficacy of Y-27632 was due to increased Rho kinase activity in the absence of NO.  
Therefore, although at the moment evidence is limited, it is a possibility that NO could 
mediate, at least in part, the first component of vasodilatation in the bovine intraocular 
LPCA via the RhoA/Rho kinase pathway. It remains unlikely that the second component of 
neurogenic vasodilatation is mediated in this way, as both NOS inhibitors and ODQ fail to 
inhibit the vasodilatation. However, as the ability to inhibit neurogenic vasodilatation in 
the bovine intraocular LPCA using PDE, PKG and PKA inhibitors was very limited, the 
next step, not attempted in the present study, may be to utilise inhibitors of the RhoA/Rho 
kinase pathway. 
6.3  Comparison of the Effect of NOS inhibitors on Neurogenic and Endothelium- 
Dependent Vasodilatation in the Bovine Intraocular LPCA 
The final aim of this investigation was to determine the differential effects of a series of 
non-specific NOS inhibitors (L-NAME and L-NMMA) and putative nNOS-specific 
(AAAN and N
G-propyl-L-arginine) inhibitors on both nitrergic nerve-mediated and 
endothelium-dependent vasodilatation of the bovine intraocular LPCA.     Chapter 6    Discussion 
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6.3.1  Effects of L-NAME and L-NMMA on Neurogenic Vasodilatation in the Bovine 
Intraocular LPCA 
As has already been discussed, L-NAME (Hobbs & Gibson, 1990), abolished the first 
component of neurogenic vasodilatation at all frequencies examined, but had no effect on 
the second. In the present study, L-NMMA (Hibbs et al., 1987) failed to block nitrergic 
transmission in the bovine intraocular LPCA, but acted like L-arginine in inhibiting 
blockade by L-NAME. Both L-NAME and L-NMMA, along with a third N
G-substituted 
analogue of L-arginine, L-NOARG (Moore et al., 1990), are routinely used experimentally 
as non-isoform selective inhibitors of NOS. Although L-NMMA inhibits all three isoforms 
of NOS in standard enzyme assays (Moore et  al., 1996), many reports demonstrate 
anomalous findings with this agent, especially in bovine tissue. For example, in the bovine 
penile artery, L-NMMA fails to block nitrergic transmission, despite being able to inhibit 
the endothelium-dependent, NO-mediated dilatation induced by ACh (Liu et al.,  1991). 
Furthermore, L-NMMA does not block nitrergic transmission in the BRP muscle, but acts 
like the endogenous substrate, L-arginine, to inhibit blockade by L-NOARG or L-NAME 
(Liu et al., 1991; Martin et al., 1993). In addition, in the rat aorta and pulmonary artery, L-
NMMA, enhances rather than inhibits the production of NO, assessed by 
chemiluminescence detection, and inhibits the basal but not agonist-stimulated, 
endothelium-dependent dilatation produced by NO (Archer & Hampl, 1992; Frew et al., 
1993). In addition to the evidence provided by Liu et al. (1991), who suggested that in the 
BRP muscle L-NMMA acts like the endogenous substrate, L-arginine, biochemical 
analysis of murine macrophage iNOS has revealed that L-NMMA does not behave as a 
simple competitive inhibitor. Instead, it acts as an alternative substrate and mechanism-
based inhibitor of the enzyme (Olken & Marletta, 1993). According to this scheme, L-
NMMA is metabolised initially to N
G-hydroxy-N
G-methyl-L-arginine, and finally to NO 
and L-citrulline, but with the intermediate production of a “suicide inhibitor” that slowly 
and irreversibly blocks the enzyme. These findings can therefore account for the seemingly 
anomalous ability of L-NMMA to augment NO production at some sites while blocking it 
at others. 
 
6.3.2  Effects of L-NAME and L-NMMA on Endothelium-Dependent Vasodilatation in 
the Bovine Intraocular LPCA 
The examination of the actions of L-NMMA and L-NAME on endothelium-dependent, 
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the simultaneous activation of other endothelium-derived factors. The application of L-
NAME alone did not inhibit NO-mediated, bradykinin-induced vasodilatation, although L-
NMMA did partially inhibit this response. In addition, inhibition of other endothelium-
derived factors that can mediate vasodilatation, EDHF and COX (not in the presence of L-
NAME or L-NMMA), did not inhibit NO-mediated, bradykinin-induced vasodilatation 
either. A compensatory mechanism seemed to be operating, whereby if one mediator of 
endothelium-dependent vasodilatation was inhibited, the other ensured that the 
vasodilatory capability of the vessel was maintained. This has been reported in the 
mesenteric resistance arteries of eNOS knockout mice (Scotland et al., 2001) and in vivo in 
rats who were subjected to chronic inhibition of NOS (Desai et  al., 2006). Following 
blockade of EDHF with apamin and charybdotoxin (Waldron & Garland, 1994; Zygmunt 
& Högestätt, 1996) and COX with indomethacin, vasodilator responses mediated solely by 
endothelium-derived NO could be elicited with bradykinin. These dilator responses, unlike 
those produced by the nitrergic nerves, were blocked by L-NMMA. They were also 
blocked by L-NAME. Thus, in the bovine ciliary artery L-NMMA blocks endothelium-
dependent, NO-mediated dilatation but not that produced by nitrergic nerves, and this is in 
keeping with earlier findings on the bovine penile artery (Liu et al., 1991). 
 
6.3.3  Selective Inhibition of nNOS 
Since the discovery of NO, great effort has been expended in developing isoform-selective 
inhibitors of NOS, both as investigational tools and potential therapeutic agents. Excess 
NO, usually produced by either iNOS or nNOS, is thought to play a detrimental role in a 
wide range of conditions such as septic shock (Feihl et al., 2001), schizophrenia (Das et 
al., 1995), Alzheimer’s disease (Dorheim et  al., 1994) and in the over-production of 
osteoclasts, leading to disorders of the bone and joints, such as osteoporosis and 
rheumatoid arthritis (MacIntyre et al., 1991). However, although inhibiting excess NO 
production may be therapeutically beneficial in patients suffering from these diseases, it is 
important that the inhibitory action does not effect eNOS activity and its role in 
maintaining blood pressure and flow.  
 
Two nNOS-specific inhibitors have recently been identified: AAAN, which has a ~2,500-
fold greater selectivity for rat nNOS over bovine eNOS (Hah et al.,  2001), and N
G-propyl-
L-arginine, which is ~150-fold more selective for bovine nNOS than eNOS (Zhang et al., 
1997a; Zhang et al., 1997b). The effects of these were examined against neurogenic and 
endothelium-dependent vasodilatation in the bovine intraocular LPCA. Chapter 6    Discussion 
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6.3.4  Effects of AAAN and N
G-propyl-L-arginine on Neurogenic and Endothelium-
Dependent Vasodilatation in the Bovine Intraocular LPCA 
In the bovine intraocular LPCA, AAAN at concentrations up to 100 μM, failed to affect 
vasodilatation induced either by nitrergic nerves or by bradykinin-induced endothelium-
derived NO. A lack of effect on endothelium-dependent vasodilatation might have been 
expected, given its poor Ki for bovine eNOS (314 μM; Hah et al., 2001). Nevertheless, the 
failure to block nitrergic transmission was surprising, in view of its Ki of 0.12 μM for rat 
nNOS. Whether the failure of AAAN to block nitrergic transmission in the bovine 
intraocular LPCA results from poor tissue penetration, a major difference in Ki values for 
bovine and rat nNOS, or some other factor, remains to be established. Equally 
disappointing were the actions of N
G-propyl-L-arginine (Zhang et al., 1997a; Zhang et al., 
1997b) on the bovine intraocular LPCA. Although N
G-propyl-L-arginine did inhibit 
nitrergic vasodilatation, it failed to exhibit the ~150-fold selectivity for nNOS over eNOS 
seen in enzyme assays (Zhang et  al., 1997a). Indeed, N
G-propyl-L-arginine blocked 
endothelium-dependent, NO-mediated vasodilatation over the same concentration range as 
for blockade of nitrergic transmission. These findings with AAAN and N
G-propyl-L-
arginine therefore serve as a reminder that it is not always possible to extrapolate findings 
in biochemical assays to functional responses in intact tissues.  
 
Debate over the reported specificity of a NOS inhibitor is not uncommon. Another 
example of a discrepancy between biochemical assays and studies in an intact system 
involves a member of the indazole family of NOS inhibitors, 7-NI. In isolated enzyme 
studies 7-NI is an equipotent inhibitor of all three enzymes; with IC50 values of 9.7 μM, 8.3 
μM and 11.8 μM for iNOS, nNOS and eNOS, respectively (Alderton et  al., 2001). 
However, it is described as an nNOS specific inhibitor in vivo in models of brain injury 
(Yoshida et al., 1994), where application of 7-NI did not alter the systemic arterial blood 
pressure or inhibit the dilation of pial arterioles in response to ACh, but did greatly reduce 
NOS activity within the cerebral cortex and reduced the size of the infarct in response to 
cerebral artery occlusion. Selectivity for nNOS in vivo may be due to different uptake rates 
of the drug into endothelial cells and neurons (Southan & Szabo, 1996). However, 
Zagvazdin et al. (1996) suggest that 7-NI does suppress basal endothelial NO formation in 
vivo in rats and that this effect is masked by the use of anaesthetics in other studies. Chapter 6    Discussion 
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6.4  Conclusions 
Although this investigation into neurogenic vasodilatation in the bovine intraocular LPCA 
has led to some interesting discoveries about the innervation of the vessel, many questions 
remain unanswered. It is quite clear that in the presence of U46619-induced tone and 
blockade of adrenergic vasoconstriction with guanethidine, EFS elicits a biphasic 
vasodilator response and it is likely that the first component is mediated by the 
neurotransmitter, NO. However in contrast to previous findings by Wiencke et al. (1994), 
the current report could find no evidence that the neuropeptide, CGRP, mediates the 
second component of neurogenic vasodilatation. In addition to this, substance P and VIP 
are unlikely to play a role. The involvement of ATP has not been discounted, due to lack of 
suitable antagonists, but the identity of the neurotransmitter that mediates the second 
component of neurogenic vasodilatation remains a mystery. 
Furthermore, an extensive investigation into the mechanism of vasodilatation employed by 
the mediator of the second component, also failed to provide conclusive answers as to how 
the transmitter operates. It is likely that the first component is mediated via the 
NO/cGMP/PKG pathway, although promising results with the PDE5 inhibitor zaprinast 
were not confirmed by the use of another PDE5 inhibitor, sildenafil, or a number of PKG 
inhibitors. Inhibiting various K
+ channels to prevent hyperpolarisation of the cell 
membrane potential or the cAMP/PKA pathway did not yield any clues as to the possible 
mechanism of the mediator of the second component of neurogenic vasodilatation. 
Therefore the mechanism responsible for the second pathway remains unconfirmed. 
Interestingly, nitrergic vasodilatation in the bovine intraocular LPCA, like many other 
bovine tissues, is not inhibited by the NOS inhibitor L-NMMA. Instead L-NMMA acts like 
L-arginine in inhibiting neurogenic blockade by L-NAME. L-NMMA and L-NAME are 
both successful in blocking endothelium-derived NO, serving as a warning that although 
generally mooted as a non-specific NOS inhibitor, L-NMMA should not be used as the 
sole tool when defining nitrergic neurotransmission. Further care should be taken with 
compounds such as AAAN and N
G-propyl-L-arginine, which are portrayed as putative 
nNOS-specific inhibitors. In the bovine intraocular LPCA, AAAN was found to inhibit 
neither nitrergic transmission nor endothelium-derived NO. N
G-propyl-L-arginine did 
appear to inhibit nNOS, but with the same potency as for eNOS, rendering it a non-specific 
NOS inhibitor in this tissue. Again, care should be taken when utilising these compounds. Chapter 6    Discussion 
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In conclusion, although many aspects of this study have not been fully resolved, it has 
thrown up some interesting questions: what is the identity of the second neurotransmitter? 
What is the mechanism of neurotransmission employed? Why does L-NMMA not inhibit 
nitrergic neurotransmission in bovine tissues?  There is certainly scope for future research 
in this tissue, should anyone wish to continue it. 
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